



Healing Roots: Integrative Herbal Approaches to Chronic Illness

EDITOR
REETU KUMARI





WISELEAF SCIENTIFIC VENTURES

Healing Roots: Integrative Herbal Approaches to Chronic Illness

Reetu Kumari

Assistant Professor, School of Pharmacy, YBN University, Ranchi,
Jharkhand, 834010, India



WiseLeaf
Scientific Ventures





WISELEAF SCIENTIFIC VENTURES

Published by:
Wiseleaf Scientific Ventures Pvt. Ltd.
USA | UK | India
www.wiseleafscientific.com
editor@wiseleafscientific.com

E-ISBN:
BOOK DOI:
Copyright © Reetu Kumari
Citation: [Kumari, R., \(2025\). *Healing Roots: Integrative Herbal Approaches to Chronic Illness*. Wiseleaf Scientific Ventures.](#)

This book is published online under a fully open-access program and is licensed under the Creative Commons Attribution–NonCommercial (CC BY-NC) License. This license permits others to copy, distribute, and adapt the material in any medium or format for non-commercial purposes, provided appropriate credit is given to the author(s) and the original source.

The publisher, authors, and editors disclaim responsibility for any errors, omissions, or consequences resulting from the use or interpretation of the information contained in this book. No warranty, either expressed or implied, is made regarding the accuracy or completeness of the content. Although every effort has been taken to ensure the reliability and factual integrity of the material, verification by third parties has not been independently confirmed.

The publisher remains neutral with respect to jurisdictional claims in published maps and institutional affiliations. Every effort has been made to identify and credit all copyright holders of reproduced material. We sincerely apologize to any rights holders who could not be reached and encourage them to contact us so that proper acknowledgment can be made in future editions or reprints.





WISELEAF SCIENTIFIC VENTURES

Preface

Herbal medicine offers valuable support for people living with chronic diseases, providing natural options alongside conventional care. Over many years, herbs have been used to help manage health and improve quality of life.

This book, *Healing Roots: Integrative Herbal Approaches to Chronic Illness*, covers practical and trustworthy information about many common herbs and their benefits for diabetes, heart and respiratory problems, immune strength, digestion, and brain health, along with important safety and quality guidelines. Each chapter is designed to help readers make informed choices about using herbal remedies safely and effectively.

As the editor, my hope is that readers from all backgrounds—patients, caregivers, and health professionals—will find useful knowledge and encouragement to explore herbal options with confidence.

Editor
Reetu Kumari
November, 2025





WISELEAF SCIENTIFIC VENTURES

Table of contents

1. Introduction to Herbal Medicine and Chronic Diseases.....

Tharun M*, Tejus B R

2. Herbs for Diabetes Management.....

Aditya Shishodia*, Devashish Pal, Manvi Jha, Ashok Kumar

3. Cardiovascular Health and Herbal Remedies.....

Shailendra Kumar, Shivani Sharma*, Himanshu Singh

4. Respiratory Diseases and Herbal Support.....

Anchal Goel*, Manvi Jha, Punit Kumar Mishra, Nilesh Sharma

5. Herbal Approaches to Immune System Enhancement.....

Manvi Jha*, Devashish Pal, Annu Yadav, Anchal Goel

6. Herbal Treatments for Digestive Disorders.....

Aditya Raj*, Harsh Pratap Singh, Aditya Kumar, Devashish Pal

7. Neuroprotective and Cognitive-enhancing Herbs.....

Tejus B R*, Tharun M

8. Safety, Quality Control, and Regulatory Aspects of Herbal
Medicine.....

**Harsh Pratap Singh*, Aditya Raj, Aditya Kumar, Nitin Pratap
Singh**





WISELEAF SCIENTIFIC VENTURES

HEALING ROOTS: INTEGRATIVE HERBAL APPROACHES TO CHRONIC ILLNESS

CHAPTER 1- INTRODUCTION TO HERBAL MEDICINE AND CHRONIC DISEASES

Tharun M^{1*}, Tejus B R²

¹Student, Department of Biochemistry, JSS academy of Higher education and research, JSS university, Mysuru, Karnataka, India

²Student, School of Bio Sciences and Technology, Vellore Institute of Technology, Katpadi, Vellore, Tamil Nadu 632014, India

Email: tharunm542@gmail.com

ABSTRACT

Chronic diseases including cardiovascular disorders, diabetes mellitus, cancer, and neurodegenerative conditions represent escalating global health challenges responsible for substantial morbidity and mortality rates, with conventional pharmacological approaches often producing variable efficacy and considerable adverse effects requiring long-term management. Traditional medicine systems spanning multiple cultural frameworks have accumulated empirical therapeutic strategies for chronic disease management across centuries of clinical application, establishing herbal medicines as increasingly recognized complementary approaches in contemporary healthcare. Bioactive plant constituents including alkaloids, flavonoids, and terpenoid compounds demonstrate sophisticated molecular mechanisms intervening in pathogenic pathways characteristic of chronic diseases through antioxidant, anti-inflammatory, and immunomodulatory activities. Contemporary research reveals that phytochemical compounds suppress critical signaling cascades including nuclear factor-kappa B (NF- κ B) pathway activation, modulate cellular gene expression patterns, and enhance regulatory immune responses essential for disease prevention and management. Clinical investigation demonstrates that medicinal herbs including *Allium sativum* (garlic), *Curcuma longa* (turmeric), and *Panax ginseng* significantly improve metabolic parameters, reduce systemic inflammation markers, and enhance cardiovascular function with substantially fewer adverse effects compared to conventional therapeutic agents. This chapter synthesizes contemporary evidence establishing herbal medicine as a viable integrative approach for chronic disease management, exploring ethnopharmacological foundations, molecular mechanisms of action, clinical efficacy data, safety considerations, and optimal standardization protocols essential for translation into evidence-based clinical practice frameworks.

Keywords: Herbs; Medicine; Chronic Diseases; Plants; Treatment





WISELEAF SCIENTIFIC VENTURES

1. Introduction

1.1 Historical Perspective of Herbal Medicine Use

One of the oldest therapeutic practices in human history is the use of medicinal plants, archaeological evidence indicates that herbal remedies may have evolved from Neanderthal burial sites in modern-day Iraq some 60,000 years ago [1]. Many different civilizations have developed intricate systems of herbal medicine that still have an impact on modern healthcare. Ancient Mesopotamian clay tablets from around 2600 BCE record that more than 1,000 plant species, such as licorice (*Glycyrrhiza glabra*) and the opium poppy (*Papaver somniferum*), were used as medicine [2]. The Egyptian Ebers Papyrus (1550 BCE) listed about 700 medicines made from plants like garlic (*Allium sativum*), juniper (*Juniperus* spp.), and aloe (*Aloe vera*) [3]. This shows that the people who wrote it had a lot of knowledge about drugs.

Traditional Chinese Medicine (TCM), which has existed in practice for more than 5,000 years, has a lot of theories that incorporate herbal medicine with concepts about balance and energetic harmony (4). The *Shennong Ben Cao Jing* or Divine Farmer's Materia Medica, was composed around 200 CE and classified 365 medicines into groups based on therapeutic properties and toxicity profiles [5,6].

Ayurvedic medicine is one of the most holistic and ancient forms of treatment. Originally from the Indian subcontinent, it has a roughly 5,000-year history. The health-care records from the "Rigveda," written between 1700 and 1100 BCE, the "Yajurveda," written between 1400 and 1000 BCE, and the "Atharva Veda," written between 1200 and 1200 BCE, all date back to 5000 BCE. Later writings like the "Charaka Samhita" (990 BCE), "Sushruta Samhita" (660 BCE), and "Dhanwantari Nighantu" (1700 CE) put a strong emphasis on and made extensive use of plant and polyherbal compositions [7,8].

Indigenous healing traditions in Africa, and Americas developed extensive pharmacopoeias designed to their respective ecosystems, significantly enhancing global medicinal plant diversity. The transmission of this ethnobotanical knowledge through oral traditions has preserved therapeutic applications for countless plant species [9]

The modern pharmaceutical industry owes considerable debt to traditional herbal medicine, with approximately 25% of currently prescribed medications derived directly or indirectly from plant sources [10]. Notable examples include aspirin from willow bark (*Salix* spp.), digoxin from foxglove (*Digitalis* spp.), and quinine from cinchona bark [11].

1.2 Overview of Chronic Diseases: Definitions and Global Impact

Non-communicable diseases (NCDs), a different term for chronic diseases, are characterized by their long duration, usually slow progression, and generally symptoms can be effectively managed [12]. The burden of chronic diseases across the globe has hit epidemic levels, representing the leading cause of mortality and morbidity worldwide. According to World





WISELEAF SCIENTIFIC VENTURES

Health Organization NCDs causing around 71 percent of all deaths globally. These conditions claim about 41 million lives each year [13]. Cardiovascular diseases make up the largest proportion with 19 million deaths. Cancers follow right behind at 10 million. Respiratory diseases account for 4 million and diabetes takes over 2 million lives [14].

The epidemiological evolution from infectious to chronic diseases is a result of complicated relationships between environmental factors, sedentary lifestyles, urbanization, aging populations, and dietary changes [15]. About 73% of chronic disease deaths occur in low- and middle-income countries, resulting in disproportionate NCD burdens and significant socioeconomic challenges [14].

In addition to mortality rates, chronic illnesses have significant economic consequences due to medical expenses, productivity losses, and a reduced quality of living. Between 2011 and 2030, NCDs are expected to cause \$47 trillion in global economic losses, posing a serious threat to advancements in development [16]. Individual patients frequently face financial ruin as a result of extended medical needs, prescription drug expenses, and reduced earning potential.

Several chronic conditions are caused by common risk factors, such as tobacco use, physical inactivity, poor diet, and excessive alcohol use [17]. The global disease burden could be significantly decreased by preventive interventions, as these modifiable behavioral factors play a significant role in the development of disease. Furthermore, metabolic risk factors like hypertension, obesity, dyslipidemia, and hyperglycemia are important mediators that connect lifestyle behaviors to disease manifestation [18].

Since chronic diseases are multifactorial, comprehensive management strategies that address underlying pathophysiology, symptom control, complication prevention, and quality of life enhancement are required. The growing recognition of the limitations of traditional medicine in treating chronic illnesses, such as side effects, resistance to treatment, and insufficient symptom control, has led to an increase of interest in complementary therapeutic approaches, especially herbal medicine [19].

1.3 Key Concepts in Herbal Medicine

1.3.1 Phytotherapy

The evidence-based medical practice which employs standardized plant extracts to prevent and treat disease is known as phytotherapy (20). The focus on evidence-based methods sets phytotherapy ahead of traditional herbal medicine. It integrates botanical remedies into modern healthcare systems while maintaining high quality, safety, and efficacy standards [21].

Phytotherapeutic preparations typically use whole plant extracts or defined fractions rather than isolated compounds since many components work together to deliver therapeutic benefits and may reduce adverse reactions [22]. This "entourage effect" sets phytotherapy apart from pharmaceutical methods that focus on single-molecule drugs.





WISELEAF SCIENTIFIC VENTURES

For modern phytotherapy to ensure batch-to-batch uniformity and reproducible therapeutic benefits, standardization to specific identifying ingredients or bioactive compounds is required. Standardized extracts specify minimum concentrations of therapeutically relevant phytochemicals, facilitating quality control and enabling meaningful clinical research [23].

1.3.2 Ethnomedicine

The systematic study of medical systems within particular cultural contexts, including how various societies consider health, the causes of disease, and therapeutic interventions, is referred to as ethnomedicine [24]. This interdisciplinary field integrates anthropological, botanical, pharmacological, and medical perspectives to document traditional healing practices and associated botanical knowledge

Ethnopharmacological study investigates indigenous therapeutic practices to identify potentially beneficial medicinal plants and validate traditional applications using scientific methodology [25]. This approach has proven remarkably productive, with ethnobotanical information guiding the discovery of numerous important pharmaceuticals, including the antimalarial artemisinin and the anticancer agents vincristine and vinblastine [26].

The preservation of ethnomedicinal knowledge represents an urgent priority, as traditional healing systems face erosion through globalization, cultural disruption, and loss of biodiversity [27]. When traditional knowledge is integrated into the development of commercial drugs, documentation efforts must adhere to indigenous intellectual property rights while enabling benefit-sharing arrangements.

1.3.3 Holistic Health

According to the holistic health philosophy, human wellbeing results from the dynamic interplay of the physical, mental, emotional, social, and spiritual realms. Restoring balance, enhancing innate healing abilities, and addressing the root causes of illness are all more important in holistic methods than merely suppressing symptoms [28].

Traditional herbal medicine systems naturally follow holistic concepts, considering the complete person within their social and environmental context, rather than concentrating on treating specific illnesses or organ systems. This perspective aligns with emerging concepts in systems biology and network pharmacology, which recognize disease as arising from complex perturbations in biological networks rather than single molecular defects [29].

Holistic herbal medicine typically combines botanical therapeutics with dietary modifications, stress management, lifestyle modifications, and other complementary modalities to attain optimal health. This comprehensive approach is particularly relevant in the management of chronic diseases [30].





WISELEAF SCIENTIFIC VENTURES

1.4 Common Chronic Diseases Addressed by Herbs

1.4.1 Diabetes Mellitus

Diabetes mellitus is a complex metabolic disorder characterized by chronic hyperglycemia caused by reduced insulin secretion, action, or both [31]. Diabetes affects over 537 million adults globally, with projections suggesting 643 million cases by 2030, increasing to 785 million by 2045 [32]. Herbal medicine is an alternative method of managing diabetes by employing bioactive phytochemicals with antihyperglycemic, antioxidant, anti-inflammatory, and insulin-sensitive [33]. Several plants like *Momordica charantia* (bitter melon), *Trigonella foenum-graecum* (fenugreek), *Gymnema sylvestre*, *Curcuma longa* (turmeric), Berberine and *Cinnamomum verum* (cinnamon), have been extensively studied for their hypoglycemic effect. Phytochemicals such as curcumin, trigonelline, gymnemic acids, etc. have been shown to affect glucose metabolism by improving insulin receptor sensitivity, promoting pancreatic β -cell regeneration, and regulating the enzymes that break down carbohydrates (α -amylase and α -glucosidase). By inhibiting inflammatory mediators like TNF- α and IL-6, these medications help reduce insulin resistance [34,35].

1.4.2. Cardiovascular disease

Cardiovascular diseases (CVDs) comprise heart failure, stroke, hypertension, coronary artery disease, and other disorders of the heart and blood vessels [36]. CVD remain the leading cause of global mortality, accounting for approximately 20.5 million deaths in 2021[37]. The pathophysiology of CVDs includes oxidative stress, inflammation, lipid peroxidation, and endothelial dysfunction, which contribute to atherosclerosis and vascular weakness. Systemic inflammation and persistent dyslipidemia are key factors in the development of plaque and thrombosis, which can result in myocardial infarction and stroke [38,39].

Herbal medicine has shown significant potential in reducing the progression of CVD through a number of pathways, including lipid-lowering, antioxidant, vasodilatory, anti-inflammatory, and antiplatelet activities [40]. Commonly studied botanicals like *Terminalia arjuna*, *Camellia sinensis* (green tea), *Allium sativum* (garlic) contain potent phytochemicals such as allicin, catechins, curcumin, arjunolic acid, and ginsenosides. Additionally, these phytochemicals reduce lipid metabolism, enhance endothelial function, and decrease platelet aggregation [41,42,43].

1.4.3.Cancer

Cancer represents a multifactorial and heterogeneous disease characterized by uncontrolled cellular proliferation, impaired apoptosis, and chronic inflammation driven by dysregulated molecular pathways such as NF- κ B, PI3K/Akt, and MAPK [44]. According to GLOBOCAN 2020, approximately 19.3 million new cases and 10 million deaths were reported globally, underscoring its critical public health burden [45]. Phytochemicals like curcumin (*Curcuma longa*), epigallocatechin-3-gallate (EGCG) (*Camellia sinensis*), and boswellic acids (*Boswellia*





WISELEAF SCIENTIFIC VENTURES

serrata) have shown multi-targeted anticancer effects through antioxidant, anti-inflammatory, pro-apoptotic, and anti-angiogenic mechanisms [46,47,48].

1.4.4. OsteoArthritis

Osteoarthritis (OA) is a chronic degenerative and inflammatory disorder of the synovial joints characterized by progressive degradation of articular cartilage, subchondral bone remodeling, synovitis, and loss of joint function. Pain, stiffness, and reduced mobility are the principal clinical manifestations driven by biomechanical stress, chronic low-grade inflammation, oxidative stress, and matrix metalloproteinase activation [49]. Globally, OA represents a major cause of disability: approximately 595 million individuals were living with OA in 2020, with knee OA being the most prevalent form [50].

A growing body of mechanistic and clinical evidence supports the role of herbal medicines in OA management through anti-inflammatory, antioxidant, and chondroprotective mechanisms [51]. Key botanicals such as *Boswellia serrata* (boswellic acids), *Curcuma longa* (curcuminoids), and *Zingiber officinale* (gingerols, shogaols) modulate central inflammatory pathways suppressing NF- κ B activation, inhibiting 5-lipoxygenase and cyclooxygenase (COX) enzymes, reducing cytokines (IL-1 β , TNF- α), and preventing cartilage matrix breakdown [52,53].

1.4.5. Neurodegenerative

Neurodegenerative disorders such as Alzheimer's disease (AD) and Parkinson's disease (PD) are chronic, progressive conditions marked by neuronal loss, protein misfolding, mitochondrial dysfunction, and neuroinflammation, leading to cognitive and motor decline. Globally, approximately 56 million people were living with neurodegenerative disorder [54]. Phytochemicals from *Withania somnifera* (withanolides), *Bacopa monnieri* (bacosides), and *Ginkgo biloba* (flavone glycosides, ginkgolides) exhibit antioxidant, anti-inflammatory, and neurotrophic effects by modulating NF- κ B, AMPK, and neurotrophic signalling pathways, while also preventing amyloid aggregation and excitotoxicity [55,56].

2. Mechanisms of action of Herbal Medicine in Chronic diseases

The primary source of herbal remedies' therapeutic efficacy in chronic illnesses is their multifactorial modes of action, that rely on interconnected molecular and cellular pathways that explain inflammation, oxidative stress, immunological dysregulation, and metabolic imbalance. Phytochemicals have pleiotropic and synergistic effects, restoring physiological homeostasis by modulating multiple signaling cascades at once, in contrast to single-target synthetic drugs.

A. Anti-inflammatory Mechanisms

Inflammation is a key pathological driver in conditions such as diabetes, cardiovascular diseases, arthritis, and neurodegeneration. Numerous herbal bioactives reduce inflammation by inhibiting cytokines and transcription factors that promote inflammation [57]. Compounds like curcumin (from *Curcuma longa*), boswellic acids (from *Boswellia serrata*), and gingerols





WISELEAF SCIENTIFIC VENTURES

(from *Zingiber officinale*) inhibit NF- κ B, AP-1, and COX/LOX enzymes, thereby reducing the synthesis of TNF- α , IL-1 β , IL-6, and prostaglandins [58,59]. Furthermore, flavonoids like quercetin and catechins reduce inflammatory signaling in both vascular and neural tissues by stabilizing cellular redox status and inhibiting the activation of macrophages and microglia [60,61,62].

B. Antioxidant Mechanisms

In chronic disorders, oxidative stress brought on by an excess of reactive oxygen species (ROS) results in lipid peroxidation, endothelial damage, and neuronal death. Herbal antioxidants act by both direct scavenging of ROS and upregulation of endogenous defense systems [63,64]. Polyphenols such as resveratrol, epigallocatechin gallate (EGCG), and curcumin activate Nrf2 (nuclear factor erythroid 2-related factor 2), which in turn induces superoxide dismutase (SOD), catalase, and glutathione peroxidase expression [65,66,67]. Triterpenoids like withanolides and ginsenosides further stabilize mitochondrial integrity, preventing oxidative damage and apoptosis [68]. This antioxidant network not only prevents cellular injury but also slows disease progression by modulating redox-sensitive signaling pathways such as MAPK and PI3K/Akt [69].

C. Immunomodulatory Mechanisms

Chronic disorders frequently include dysregulated immune activity, which exacerbates tissue damage and prolongs the course of the disease. Immunomodulatory phytochemicals restore immunological equilibrium by enhancing protective immune responses and preventing pathogenic overactivation through dual regulatory effects. For example, withanolides (*Withania somnifera*) and polysaccharides from *Ganoderma lucidum* boost natural killer (NK) cell activity and macrophage phagocytosis, but curcumin and berberine suppress Th17 differentiation and NF- κ B-mediated cytokine storms [70,71,72]. Adaptogenic plants such as *Panax ginseng* and *Astragalus membranaceus* modulate cytokine balance (\uparrow IL-10, \downarrow IL-6, TNF- α) and promote immunological tolerance, beneficial in autoimmune and inflammatory disorders [73].

D. Metabolic Regulation Mechanisms

Phytochemicals exert metabolic effects by modulating glucose and lipid homeostasis, improving insulin sensitivity, and regulating energy metabolism [74]. Compounds like charantin (*Momordica charantia*), gymnemic acids (from *Gymnema sylvestre*), and trigonelline (from *Trigonella foenum-graecum*) act on AMP-activated protein kinase (AMPK) and peroxisome proliferator-activated receptors (PPARs), enhancing glucose uptake and lipid oxidation [75,76,77]. Polyphenols such as catechins and curcumin inhibit α -glucosidase and α -amylase, reducing postprandial glucose spikes, while resveratrol activates SIRT1, improving mitochondrial biogenesis and insulin signaling [78,79]. These molecular actions collectively contribute to improved glycemic control, lipid balance, and energy efficiency, particularly relevant in metabolic syndromes and diabetes [80].





WISELEAF SCIENTIFIC VENTURES

Pytochemicals	Source plant (Common)	Primary Pathway	Disease relevance	Reference
Curcumin	<i>Curcuma longa</i> (turmeric)	Inhibits NF- κ B, activates AMPK, Nrf2	Diabetes, CVD, arthritis, cancer supportive care, neuroprotection	[81,82,83]
EGCG (Epigallocatechin-3-gallate)	<i>Camellia sinensis</i> (green tea)	Antioxidant, inhibits LDL oxidation, modulates MAPK/PI3K-Akt	CVD, cancer chemoprevention/supportive	[84,85]
Boswellic acids (AKBA)	<i>Boswellia serrata</i> (frankincense)	5-LOX inhibition, reduces leukotriene synthesis; NF- κ B modulation	Arthritis, anti-inflammatory	[86,87]
Withanolides	<i>Withania somnifera</i> (ashwagandha)	Modulate NF- κ B, promote neurotrophic signalling, antioxidant, adaptogenic immune modulation	Neurodegenerative disorders, stress-linked metabolic effects, immunomodulation	[88,89]
Bacosides	<i>Bacopa monnieri</i>	Enhance synaptic plasticity, antioxidant, reduce oxidative stress	Cognitive impairment, neuroprotection (MCI, ageing)	[90,91]
Berberine	<i>Berberis</i> spp.,	Activates AMPK, improves insulin signalling, lipid lowering	T2DM (glycemic control), dyslipidaemia, metabolic syndrome	[92,93]
Gymnemic acids	<i>Gymnema sylvestre</i>	Inhibit intestinal glucose absorption, stimulate β -cell regeneration, insulin secretion	T2DM adjunct therapy; reduces sweet taste/absorption	[94,95]
Allicin, Organosulfur compounds	<i>Allium sativum</i> (garlic)	Enhances NO bioavailability, antioxidant;	Hypertension, atherogenesis, dyslipidaemia	[96,97,98]





WISELEAF SCIENTIFIC VENTURES

		inhibits platelet aggregation; modulates lipid metabolism		
Silymarin (Silibinin)	<i>Silybum marianum</i> (milk thistle)	Antioxidant, hepatoprotective, modulates NF- κ B and mitochondrial function	Liver protection in metabolic syndrome/diabetes, adjunct in chemoprotection	[99,100]
Charantin	<i>Momordica charantia</i> (bitter melon)	Insulin-mimetic effects, increase GLUT4 translocation, improve glucose uptake	Glycemic control in T2DM, prediabetes	[101,102]

3. Integration of traditional and modern medical approaches

Integrating traditional herbal treatment with modern biomedical concepts can result in a synergistic approach to controlling chronic conditions. Ayurveda, Traditional Chinese Medicine (TCM), and Unani stress the comprehensive restoration of homeostasis through tailored herbal formulations, nutritional, and lifestyle treatments, whereas modern medicine focuses on molecular targets and evidence-based pharmacotherapy [103].

Bridging these paradigms requires a bidirectional approach—scientific validation of traditional knowledge and inclusion of systems biology to understand complex herb–target networks. For example, the polyphenolic components of the Ayurvedic medicine Triphala, which consists of *Terminalia bellirica*, *Terminalia chebula*, and *Emblica officinalis*, are currently being identified using metabolomics and network pharmacology [104]. A recent clinical audit from Isha Integrative Oncology Clinic (2016–2024) demonstrated that combining Ayurveda, Siddha, yoga, and dietary interventions with standard oncology care resulted in symptomatic improvement in 90% of cancer patients and high compliance (73%), highlighting the real-world potential of integrative models that merge traditional and modern medical systems for enhanced therapeutic outcomes [105].

4. Safety, standardization, and quality control challenges

Despite the therapeutic potential of phytotherapy, maintaining safety and consistency is a significant challenge. The pharmacological activity of herbal preparations is affected by a variety of parameters, such as botanical identity, phytochemical diversity, geographic origin, harvesting time, processing methods, and storage conditions [106]. In unregulated herbal





WISELEAF SCIENTIFIC VENTURES

marketplaces, there have been instances of adulteration with synthetic drugs, misidentification of plant species, and heavy metal contamination [107,108]. Standardization requires quantification of bioactive markers using analytical techniques such as HPLC, LC-MS/MS, and NMR spectroscopy. Moreover, Good Manufacturing Practice (GMP) and pharmacopeial standards (e.g., Indian Herbal Pharmacopoeia, WHO monographs) are being implemented to ensure purity and reproducibility [109,110]

Toxicological evaluation is crucial as several herbs have been demonstrated to display dose-dependent nephrotoxicity, hepatotoxicity, or herb-drug interactions [111]. Thus, integration of pharmacovigilance systems for herbal products, along with the use of validated biomarkers for safety monitoring, is essential for risk mitigation.

5. Regulatory issues and global acceptance

Herbal medicine regulations vary widely throughout the world. Although they all offer frameworks for regulating herbal products, the European Medicines Agency (EMA), the Food and Drug Administration (FDA), and India's Ministry of AYUSH have different classification schemes, ranging from traditional herbal medicinal products (EU) to dietary supplements (U.S.). While WHO's *Traditional Medicine Strategy (2014–2023)* encourages member states to integrate traditional practices into national health systems, lack of uniform international standards complicates approval and trade of herbal formulations [112,113].

Regulatory approval typically requires documentation of traditional use, safety evidence, quality control data, and sometimes clinical efficacy [114]. China and India have developed hybrid regulatory pathways, where traditional evidence supports early approval followed by confirmatory trials. However, challenges persist: discrepancies in phytochemical standardization, intellectual property rights for traditional knowledge, and ethical issues in bioprospecting [115]. Data-driven herb-drug interaction databases, digital pharmacovigilance, and evidence-based research are all contributing to the growing global acceptance. In order to facilitate safer international trade and clinical application, harmonization initiatives like the WHO's International Regulatory Cooperation for Herbal Medicines (IRCH) seek to align testing and labeling requirements [116].

6. Future prospects in herbal medicine research and application

The future of herbal medicine lies in its scientific modernization through advanced technologies and multidisciplinary integration. Emerging research trends include network pharmacology, artificial intelligence-guided compound discovery, multi-omics integration (genomics, metabolomics, and microbiomics), and nanotechnology-based delivery systems for enhanced bioavailability [117,118]. For example, curcumin-loaded nanoparticles nanoemulsions have demonstrated improved pharmacokinetics and targeted tissue delivery [119]. Furthermore, CRISPR-based functional genomics allows for the clarification of biosynthetic pathways for phytochemical optimization, while plant tissue culture and synthetic





WISELEAF SCIENTIFIC VENTURES

biology allow for the sustainable manufacture of rare chemicals like paclitaxel and artemisinin [120].

Clinical translation will benefit from adaptive trial designs and real-world data analytics, enabling personalized phytotherapy based on metabolomic and genetic profiles. The integration of *evidence-based traditional knowledge* into modern precision medicine frameworks could transform chronic disease management [121].

As global demand grows, future priorities include the creation of open-access herbal databases, strengthened regulatory harmonization, and ethical benefit-sharing with indigenous communities. With rigorous validation, sustainability, and innovation, herbal medicine can evolve from an alternative system to a scientifically grounded pillar of integrative global healthcare.

7. Summary

Herbal medicine, rooted in ancient traditions across civilizations, continues to play a vital role in modern healthcare, particularly in the management of chronic diseases. Its therapeutic potential stems from the synergistic actions of diverse phytochemicals that modulate inflammatory, oxidative, immune, and metabolic pathways. By addressing the root causes of diseases rather than isolated symptoms, herbal systems such as Ayurveda and Traditional Chinese Medicine offer a holistic approach that complements evidence-based biomedical practices. Despite challenges in standardization, safety, and regulation, advancements in analytical chemistry, biotechnology, and systems pharmacology are bridging traditional wisdom with modern science. The integration of phytotherapy into contemporary medical frameworks not only enhances therapeutic outcomes but also paves the way for sustainable, patient-centered, and globally harmonized healthcare in the future.

REFERENCES

1. Solecki, R. S. (1975). Shanidar IV, a Neanderthal flower burial in northern Iraq. *Science*, 190(4217), 880-881.
2. Cragg, G. M., & Newman, D. J. (2013). Natural products: a continuing source of novel drug leads. *Biochimica et Biophysica Acta (BBA)-General Subjects*, 1830(6), 3670-3695.
3. Ansari, M. K. A., Iqbal, M., Chaachouay, N., Ansari, A. A., & Owens, G. (2023). 10 The Concept and Status of. *Plants as Medicine and Aromatics: Pharmacognosy, Ecology and Conservation*, 129.
4. Catic, T., Oborovic, I., Redzic, E., Sukalo, A., Skrbo, A., & Mašić, I. (2018). Traditional Chinese Medicine—An Overview. *Int J Biomed Healthc*, 6(1), 35-50.
5. Bai, D., Nowak, M., Lu, D., Wang, Q., Fitzgerald, M., Zhang, H., ... & Luo, L. (2025). The outcast of medicine: metals in medicine--from traditional mineral medicine to metallodrugs. *Frontiers in Pharmacology*, 16, 1542560.





WISELEAF SCIENTIFIC VENTURES

6. Yan, X., Xie, G., Zhou, J., & Milne, G. W. (2018). *Traditional chinese medicines: molecular structures, natural sources and applications*. Routledge.
7. Kumari, M. History of Indian Traditional Medicine: A Medical Inheritance.
8. Adhikari, P. P., & Paul, S. B. (2018). History of Indian traditional medicine: a medical inheritance. *History*, 11(1), 421.
9. Koithan M, Farrell C. Indigenous Native American Healing Traditions. *J Nurse Pract*. 2010 Jun 1;6(6):477-478. doi: 10.1016/j.nurpra.2010.03.016. PMID: 20689671; PMCID: PMC2913884.
10. Bachhav, A., Ganpat, A. T., Yogesh, E. S., Rajendra, R. A., & Dadaji, P. A. (2024). Current scenario of herbal medicines & future prospectus.
11. Vickers A, Zollman C, Lee R. Herbal medicine. *West J Med*. 2001 Aug;175(2):125-8. doi: 10.1136/ewj.175.2.125. PMID: 1183560; PMCID: PMC1071505.
12. Budreviciute A, Damiati S, Sabir DK, Onder K, Schuller-Goetzburg P, Plakys G, Katileviciute A, Khoja S, Kodzius R. Management and Prevention Strategies for Non-communicable Diseases (NCDs) and Their Risk Factors. *Front Public Health*. 2020 Nov 26;8:574111. doi: 10.3389/fpubh.2020.574111. PMID: 33324597; PMCID: PMC7726193.
13. Ramesh S, Kosalram K. The burden of non-communicable diseases: A scoping review focus on the context of India. *J Educ Health Promot*. 2023 Feb 28;12:41. doi: 10.4103/jehp.jehp_1113_22. PMID: 37113407; PMCID: PMC10127498.
14. World Health Organization. (2021). *Noncommunicable diseases*. Geneva: World Health Organization. Retrieved from <https://www.who.int/news-room/factsheets/detail/noncommunicable-diseases>
15. McKeown RE. The Epidemiologic Transition: Changing Patterns of Mortality and Population Dynamics. *Am J Lifestyle Med*. 2009 Jul 1;3(1 Suppl):19S-26S. doi: 10.1177/1559827609335350. PMID: 20161566; PMCID: PMC2805833.
16. Bloom, D. E., Cafiero, E., Jané-Llopis, E., Abrahams-Gessel, S., Bloom, L. R., Fathima, S., ... & Weiss, J. (2012). *The global economic burden of noncommunicable diseases* (No. 8712). Program on the Global Demography of Aging.
17. Ryan Ng, Rinku Sutradhar, Zhan Yao, Walter P Wodchis, Laura C Rosella, Smoking, drinking, diet and physical activity—modifiable lifestyle risk factors and their associations with age to first chronic disease, *International Journal of Epidemiology*, Volume 49, Issue 1, February 2020, Pages 113–130, <https://doi.org/10.1093/ije/dyz078>
18. Dhandapani, S., Afshan, K., Shreya, S., Vincy, C. L., Yuvaraj, V., & Krithika, V. (2024). Dietary Intake, Lifestyle Factors, and Metabolic Risk: Insights from Health Check-Ups at a Private Healthcare Facility in Coimbatore, India. *Amerta Nutrition*, 8(4).
19. Ekor, M. (2014). The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety. *Frontiers in pharmacology*, 4, 177.





WISELEAF SCIENTIFIC VENTURES

20. Miraldi, E., & Bains, G. (2018). Medicinal plants and health in human history: From empirical use to modern phytotherapy. *Journal of the Siena academy of Sciences*, 10(1).
21. Ramzan, I. (Ed.). (2015). *Phytotherapies: Efficacy, Safety, and Regulation*. John Wiley & Sons.
22. Efferth T, Koch E. Complex interactions between phytochemicals. The multi-target therapeutic concept of phytotherapy. *Curr Drug Targets*. 2011 Jan;12(1):122-32. doi: 10.2174/138945011793591626. PMID: 20735354.
23. Heinrich M, Appendino G, Efferth T, Fürst R, Izzo AA, Kayser O, Pezzuto JM, Viljoen A. Best practice in research - Overcoming common challenges in phytopharmacological research. *J Ethnopharmacol*. 2020 Jan 10;246:112230. doi: 10.1016/j.jep.2019.112230. Epub 2019 Sep 14. PMID: 31526860.
24. Erickson, P. I. (2007). *Ethnomedicine*. Waveland press.
25. Pirintsos, S., Panagiotopoulos, A., Bariotakis, M., Daskalakis, V., Lionis, C., Sourvinos, G., Karakasiliotis, I., Kampa, M., & Castanas, E. (2022). From Traditional Ethnopharmacology to Modern Natural Drug Discovery: A Methodology Discussion and Specific Examples. *Molecules*, 27(13), 4060. <https://doi.org/10.3390/molecules27134060>
26. Barti, H., Pant, B., Joshi, S., & Kumar, S. Ethnopharmacology: Harnessing Traditional Knowledge for Advancements in Modern Drug Discovery.
27. Sharma, A., Patel, S. K., & Singh, G. S. (2024). Revitalizing Traditional Knowledge of the Himalayan Indigenous Tribes: An Ethnoecological and Ethnobotanical Approach. In *Learning 'from' and 'with' the Locals: Traditional Knowledge Systems for Environmental Sustainability in the Himalayas* (pp. 111-133). Cham: Springer Nature Switzerland.
28. AQIL, D. Z., & JAMEEL, D. A. Holistic Healing Redefined: Integrating Spirituality, Mental Health, and Human Rights. *Sustainable Development in the Era of Artificial Intelligence*, 1.
29. Goyal MR, Chauhan A. Holistic Approach of Nutrients and Traditional Natural Medicines for Human Health: A Review. *Future Integr Med*. 2024;3(3):197-208. doi: 10.14218/FIM.2023.00089.
30. Wachtel-Galor S, Benzie IFF. Herbal Medicine: An Introduction to Its History, Usage, Regulation, Current Trends, and Research Needs. In: Benzie IFF, Wachtel-Galor S, editors. *Herbal Medicine: Biomolecular and Clinical Aspects*. 2nd ed. Boca Raton (FL): CRC Press/Taylor & Francis; 2011. Chapter 1. PMID: 22593939.
31. Antar SA, Ashour NA, Sharaky M, Khattab M, Ashour NA, Zaid RT, Roh EJ, Elkamhawy A, Al-Karmalawy AA. Diabetes mellitus: Classification, mediators, and





WISELEAF SCIENTIFIC VENTURES

- complications; A gate to identify potential targets for the development of new effective treatments. *Biomedicine & Pharmacotherapy*. 2023 Dec 1;168:115734.
32. Kumar A, Gangwar R, Ahmad Zargar A, Kumar R, Sharma A. Prevalence of diabetes in India: A review of IDF diabetes atlas 10th edition. *Current diabetes reviews*. 2024 Jan 1;20(1):105-14.
 33. Tran N, Pham B, Le L. Bioactive compounds in anti-diabetic plants: From herbal medicine to modern drug discovery. *Biology*. 2020 Aug 28;9(9):252.
 34. Rawat Mukesh RM, Parmar Namita PN. Medicinal plants with antidiabetic potential-a review.
 35. Gaonkar VP, Hullatti K. Indian Traditional medicinal plants as a source of potent Anti-diabetic agents: A Review. *Journal of diabetes & metabolic disorders*. 2020 Dec;19(2):1895-908.
 36. Lockhart PB, Sun YP. Diseases of the cardiovascular system. *Burket's Oral Medicine*. 2021 Aug 30:505-52.
 37. Di Cesare M, Perel P, Taylor S, Kabudula C, Bixby H, Gaziano TA, McGhie DV, Mwangi J, Pervan B, Narula J, Pineiro D, Pinto FJ. The Heart of the World. *Glob Heart*. 2024 Jan 25;19(1):11. doi: 10.5334/gh.1288. PMID: 38273998; PMCID: PMC10809869.
 38. Higashi Y. Roles of oxidative stress and inflammation in vascular endothelial dysfunction-related disease. *Antioxidants*. 2022 Sep 30;11(10):1958.
 39. Cervantes Gracia K, Llanas-Cornejo D, Husi H. CVD and oxidative stress. *Journal of clinical medicine*. 2017 Feb 20;6(2):22.
 40. Adegbola P, Aderibigbe I, Hammed W, Omotayo T. Antioxidant and anti-inflammatory medicinal plants have potential role in the treatment of cardiovascular disease: a review. *American journal of cardiovascular disease*. 2017 Apr 15;7(2):19.
 41. Alam MJ, Uppulapu SK, Maulik SK, Banerjee SK. Ethnopharmacological and therapeutic potential of *Terminalia arjuna* and *Camellia sinensis* against cardiovascular diseases: Evidence and experimental studies. In *Evidence-Based Validation of Herbal Medicine* 2022 Jan 1 (pp. 651-669). Elsevier.
 42. Ramesh P, Palaniappan A. *Terminalia arjuna*, a Cardioprotective Herbal Medicine-Relevancy in the Modern Era of Pharmaceuticals and Green Nanomedicine-A Review. *Pharmaceuticals (Basel)*. 2023 Jan 13;16(1):126. doi: 10.3390/ph16010126. PMID: 36678623; PMCID: PMC9865560.
 43. Rahman K, Lowe GM. Garlic and cardiovascular disease: a critical review. *The Journal of nutrition*. 2006 Mar 1;136(3):736S-40S.
 44. Thangapazham RL, Sharma A, Maheshwari RK. Multiple molecular targets in cancer chemoprevention by curcumin. *The AAPS journal*. 2006 Sep 1;8(3):52.





WISELEAF SCIENTIFIC VENTURES

45. Mghanga FP, Seth JA. Epidemiology of Cancer in Tanzania Based on GLOBOCAN 2022 Estimates of Burden and Trends.
46. Gupta SC, Kismali G, Aggarwal BB. Curcumin, a component of turmeric: from farm to pharmacy. *Biofactors*. 2013 Jan;39(1):2-13.
47. Khan MA, Ali R, Parveen R, Najmi AK, Ahmad S. Pharmacological evidences for cytotoxic and antitumor properties of Boswellic acids from *Boswellia serrata*. *Journal of ethnopharmacology*. 2016 Sep 15;191:315-23.
48. Kumazoe M, Tachibana H. Anti-cancer effect of EGCG and its mechanisms. *Functional Foods in Health and Disease*. 2016 Feb 3;6(2):70-8.
49. Coaccioli S, Sarzi-Puttini P, Zis P, Rinonapoli G, Varrassi G. Osteoarthritis: new insight on its pathophysiology. *Journal of clinical medicine*. 2022 Oct 12;11(20):6013.
50. Steinmetz JD, Culbreth GT, Haile LM, Rafferty Q, Lo J, Fukutaki KG, Cruz JA, Smith AE, Vollset SE, Brooks PM, Cross M. Global, regional, and national burden of osteoarthritis, 1990–2020 and projections to 2050: a systematic analysis for the Global Burden of Disease Study 2021. *The Lancet Rheumatology*. 2023 Sep 1;5(9):e508-22.
51. Aborehab NM, El Bishbishy MH, Refaiy A, Waly NE. A putative Chondroprotective role for IL-1 β and MPO in herbal treatment of experimental osteoarthritis. *BMC complementary and alternative medicine*. 2017 Nov 22;17(1):495.
52. Yücel Ç, Karatoprak GŞ, Açıkara ÖB, Akkol EK, Barak TH, Sobarzo-Sánchez E, Aschner M, Shirooie S. Immunomodulatory and anti-inflammatory therapeutic potential of gingerols and their nanoformulations. *Frontiers in pharmacology*. 2022 Sep 5;13:902551.
53. Verma S, Panchpuri M, Dwibedi V, Rath SK, Devi A. Exploring herbal synergies in the management of rheumatoid arthritis: a multifaceted approach to inflammation and joint health. *Inflammopharmacology*. 2025 Oct 4:1-28.
54. Lelos M. Overview of Alzheimer's and Parkinson's diseases and the role of protein aggregation in these neurodegenerative diseases. In *Handbook of Innovations in Central Nervous System Regenerative Medicine 2020* Jan 1 (pp. 29-53). Elsevier.
55. Venkatesan R, Ji E, Kim SY. Phytochemicals that regulate neurodegenerative disease by targeting neurotrophins: a comprehensive review. *BioMed research international*. 2015;2015(1):814068.
56. Kadiri SK, Tiwari P, Roy SP, Bhowmik S. *Herbal Medicine and Neurological Diseases*. In *Herbal Pharmacopeia 2025* (pp. 287-304). CRC Press.
57. Ghosh N, Ali A, Ghosh R, Das S, C Mandal S, Pal M. Chronic inflammatory diseases: Progress and prospect with herbal medicine. *Current Pharmaceutical Design*. 2016 Jan 1;22(2):247-64.
58. Razavi BM, Ghasemzadeh Rahbardar M, Hosseinzadeh H. A review of therapeutic potentials of turmeric (*Curcuma longa*) and its active constituent, curcumin, on





WISELEAF SCIENTIFIC VENTURES

- inflammatory disorders, pain, and their related patents. *Phytotherapy Research*. 2021 Dec;35(12):6489-513.
59. Neha Devi*, Ritunja Singh, Dr. Arpita Singh, Herbal Medicines as Anti-Inflammatory Agents: A Comprehensive Review, *Int. J. of Pharm. Sci.*, 2025, Vol 3, Issue 6, 1399-1405. <https://doi.org/10.5281/zenodo.15613865>
60. Martínez-Coria H, Arrieta-Cruz I, Gutiérrez-Juárez R, López-Valdés HE. Anti-inflammatory effects of flavonoids in common neurological disorders associated with aging. *International journal of molecular sciences*. 2023 Feb 21;24(5):4297.
61. Chiang MC, Tsai TY, Wang CJ. The potential benefits of quercetin for brain health: a review of anti-inflammatory and neuroprotective mechanisms. *International journal of molecular sciences*. 2023 Mar 28;24(7):6328.
62. Bellik Y, Boukraâ L, Alzahrani HA, Bakhotmah BA, Abdellah F, Hammoudi SM, Iguer-Ouada M. Molecular mechanism underlying anti-inflammatory and anti-allergic activities of phytochemicals: an update. *Molecules*. 2012 Dec 27;18(1):322-53.
63. Jomova K, Raptova R, Alomar SY, Alwasel SH, Nepovimova E, Kuca K, Valko M. Reactive oxygen species, toxicity, oxidative stress, and antioxidants: chronic diseases and aging. *Archives of toxicology*. 2023 Oct;97(10):2499-574.
64. Kumar S, Pandey AK. Free radicals: health implications and their mitigation by herbals.
65. Shahcheraghi SH, Salemi F, Peirovi N, Ayatollahi J, Alam W, Khan H, Saso L. Nrf2 regulation by curcumin: molecular aspects for therapeutic prospects. *Molecules*. 2021 Dec 28;27(1):167.
66. Na HK, Surh YJ. Modulation of Nrf2-mediated antioxidant and detoxifying enzyme induction by the green tea polyphenol EGCG. *Food and Chemical Toxicology*. 2008 Apr 1;46(4):1271-8.
67. Thiruvengadam M, Venkidasamy B, Subramanian U, Samynathan R, Ali Shariati M, Rebezov M, Girish S, Thangavel S, Dhanapal AR, Fedoseeva N, Lee J. Bioactive compounds in oxidative stress-mediated diseases: targeting the NRF2/ARE signaling pathway and epigenetic regulation. *Antioxidants*. 2021 Nov 23;10(12):1859.
68. He B, Chen D, Zhang X, Yang R, Yang Y, Chen P, Shen Z. Oxidative stress and ginsenosides: An update on the molecular mechanisms. *Oxidative medicine and cellular longevity*. 2022;2022(1):9299574.
69. He L, He T, Farrar S, Ji L, Liu T, Ma X. Antioxidants maintain cellular redox homeostasis by elimination of reactive oxygen species. *Cellular Physiology and Biochemistry*. 2017 Nov 17;44(2):532-53.
70. Hooda P, Malik R, Bhatia S, Al-Harrasi A, Najmi A, Zoghebi K, Halawi MA, Makeen HA, Mohan S. Phytoimmunomodulators: A review of natural modulators for complex immune system. *Heliyon*. 2024 Jan 15;10(1).





WISELEAF SCIENTIFIC VENTURES

71. 2. Verma J, Sarvanan K. THE ROLE OF HERBAL MEDICINE IN IMMUNE SYSTEM ENHANCEMENT: A TRADITIONAL AND MODERN PERSPECTIVE. *viewpoints.*;3:4.
72. 3. Chen Y, Fan W, Zhao Y, Liu M, Hu L, Zhang W. Progress in the regulation of immune cells in the tumor microenvironment by bioactive compounds of traditional Chinese medicine. *Molecules.* 2024 May 17;29(10):2374.
73. 4 Ratan ZA, Youn SH, Kwak YS, Han CK, Haidere MF, Kim JK, Min H, Jung YJ, Hosseinzadeh H, Hyun SH, Cho JY. Adaptogenic effects of Panax ginseng on modulation of immune functions. *Journal of ginseng research.* 2021 Jan 1;45(1):32-40.
74. Zhao C, Yang C, Wai ST, Zhang Y, P. Portillo M, Paoli P, Wu Y, San Cheang W, Liu B, Carpené C, Xiao J. Regulation of glucose metabolism by bioactive phytochemicals for the management of type 2 diabetes mellitus. *Critical Reviews in Food Science and Nutrition.* 2019 Mar 26;59(6):830-47.
75. Saxena V, Danish R, Kaushik R, Verma KK, Sharma V. A Comprehensive Review on Natural Remedies for Diabetes: A Metabolic Disorder. *Journal of Applied Pharmaceutical Sciences and Research.* 2022 Dec 13;5(3):1-6.
76. Gauttam VK, Munjal K, Chopra H, Ahmad A, Rana MK, Kamal MA. A Mechanistic Review on Therapeutic Potential of Medicinal Plants and their Pharmacologically Active Molecules for Targeting Metabolic Syndrome. *Current Pharmaceutical Design.* 2024 Jan 1;30(1):10-30.
77. Anwar KR, Badruddeen, Akhtar J, Khan MI, Ahmad M. An Outlook on Pathological Pathways of Diabetes and Molecular Mechanisms of Anti-diabetic Phytobioactives. *Letters in Functional Foods.* 2024;1(1):e180723218858.
78. Dzah CS, Asante-Donyinah D, Letsyo E, Dzikunoo J, Adams ZS. Dietary polyphenols and obesity: A review of polyphenol effects on lipid and glucose metabolism, mitochondrial homeostasis, and starch digestibility and absorption. *Plant Foods for Human Nutrition.* 2023 Mar;78(1):1-2.
79. Martiniakova M, Sarocka A, Penzes N, Biro R, Kovacova V, Mondockova V, Sevcikova A, Ciernikova S, Omelka R. Protective role of dietary polyphenols in the management and treatment of type 2 diabetes mellitus. *Nutrients.* 2025 Jan 13;17(2):275.
80. Clemente-Suárez VJ, Martín-Rodríguez A, Redondo-Flórez L, López-Mora C, Yáñez-Sepúlveda R, Tornero-Aguilera JF. New insights and potential therapeutic interventions in metabolic diseases. *International journal of molecular sciences.* 2023 Jun 26;24(13):10672.
81. Pinzon RT, Buwana F. Potential Therapeutic Effects of Curcuma longa extract in Patients with Osteoarthritis: A Randomized Controlled Trial. *Journal of Pharmaceutical Sciences and Research.* 2019 Nov 1;11(11):3628-33.





WISELEAF SCIENTIFIC VENTURES

82. Zeng L, Yang T, Yang K, Yu G, Li J, Xiang W, Chen H. Efficacy and safety of curcumin and curcuma longa extract in the treatment of arthritis: a systematic review and meta-analysis of randomized controlled trial. *Frontiers in immunology*. 2022 Jul 22;13:891822.
83. Akram M, Shahab-Uddin AA, Usmanhane KH, Hannan AB, Mohiuddin E, Asif M. Curcuma longa and curcumin: a review article. *Rom J Biol Plant Biol*. 2010;55(2):65-70.
84. Wolfram S. Effects of green tea and EGCG on cardiovascular and metabolic health. *Journal of the American College of Nutrition*. 2007 Aug 1;26(4):373S-88S.
85. Anandh Babu PV, Liu D. Green tea catechins and cardiovascular health: an update. *Current medicinal chemistry*. 2008 Aug 1;15(18):1840-50.
86. Mahto K, Kuwar OK, Maloo A, Kumar A. Therapeutic potential of *Boswellia Serrata* in arthritis management: mechanistic insights into COX-2, 5-LOX, and NFκB modulation. *Inflammopharmacology*. 2025 Aug 14:1-2.
87. Efferth T, Oesch F. Anti-inflammatory and anti-cancer activities of frankincense: Targets, treatments and toxicities. In *Seminars in cancer biology* 2022 May 1 (Vol. 80, pp. 39-57). Academic Press.
88. Sikandan A, Shinomiya T, Nagahara Y. Ashwagandha root extract exerts anti-inflammatory effects in HaCaT cells by inhibiting the MAPK/NF-κB pathways and by regulating cytokines. *International journal of molecular medicine*. 2018 Aug 1;42(1):425-34.
89. Singh A, Saharan VA, Garg R, Gupta VB. Effect of time on extraction of Ashwagandha in various Hydroalcoholic compositions and their anti-inflammatory activity. *International Journal of Green Pharmacy (IJGP)*. 2011;5(1).
90. Neto LJ, de Araujo MR, Junior RC, Machado NM, Joshi RK, dos Santos Buglio D, Lamas CB, Direito R, Laurindo LF, Tanaka M, Barbalho SM. Investigating the neuroprotective and cognitive-enhancing effects of *Bacopa monnieri*: a systematic review focused on inflammation, oxidative stress, mitochondrial dysfunction, and apoptosis. *Antioxidants*. 2024 Mar 25;13(4):393.
91. Valotto Neto LJ, Reverete de Araujo M, Moretti Junior RC, Mendes Machado N, Joshi RK, dos Santos Buglio D, Barbalho Lamas C, Direito R, Fornari Laurindo L, Tanaka M, Barbalho SM. Investigating the neuroprotective and cognitive-enhancing effects of *Bacopa monnieri*: a systematic review focused on inflammation, oxidative stress, mitochondrial dysfunction, and apoptosis. *Antioxidants*. 2024 Apr;13(4):393.
92. Xie W, Su F, Wang G, Peng Z, Xu Y, Zhang Y, Xu N, Hou K, Hu Z, Chen Y, Chen R. Glucose-lowering effect of berberine on type 2 diabetes: A systematic review and meta-analysis. *Frontiers in pharmacology*. 2022 Nov 16;13:1015045.





WISELEAF SCIENTIFIC VENTURES

93. Liang Y, Xu X, Yin M, Zhang Y, Huang L, Chen R, Ni J. Effects of berberine on blood glucose in patients with type 2 diabetes mellitus: a systematic literature review and a meta-analysis. *Endocrine journal*. 2019;66(1):51-63.
94. Aralelimath VR, Bhise SB. ANTI-DIABETIC EFFECTS OF GYMNEMA SYLVESTER EXTRACT ON STREPTOZOTOCIN INDUCED DIABETIC RATS AND POSSIBLE β -CELL PROTECTIVE AND REGENERATIVE EVALUATIONS. *Digest Journal of Nanomaterials & Biostructures (DJNB)*. 2012 Jan 1;7(1).
95. Laha S, Paul S. *Gymnema sylvestre* (Gurmar): A potent herb with anti-diabetic and antioxidant potential. *Pharmacognosy Journal*. 2019;11(2).
96. Ahmad P, Alvi SS, Khan MS. Functioning of organosulfur compounds from garlic (*allium sativum* linn) in targeting risk factor-mediated atherosclerosis: A cross talk between alternative and modern medicine. In *Natural Bio-active Compounds: Volume 1: Production and Applications 2019 Sep 7* (pp. 561-585). Singapore: Springer Singapore.
97. Xiong XJ, Wang PQ, Li SJ, Li XK, Zhang YQ, Wang J. Garlic for hypertension: A systematic review and meta-analysis of randomized controlled trials. *Phytomedicine*. 2015 Mar 15;22(3):352-61.
98. Rahman K. Effects of garlic on platelet biochemistry and physiology. *Molecular nutrition & food research*. 2007 Nov;51(11):1335-44.
99. Vargas-Mendoza N, Madrigal-Santillán E, Morales-González Á, Esquivel-Soto J, Esquivel-Chirino C, y González-Rubio MG, Gayosso-de-Lucio JA, Morales-González JA. Hepatoprotective effect of silymarin. *World journal of hepatology*. 2014 Mar 27;6(3):144.
100. Surai PF. Silymarin as a vitagene modulator: Effects on mitochondria integrity in stress conditions. In *Molecular Nutrition and Mitochondria 2023 Jan 1* (pp. 535-559). Academic Press.
101. George M, Rajkumar A, Nair AK, Vincent B, VR C, Joseph L. A Review on Antidiabetic Properties of *Momordica charantia*. *Journal of Pharma Insights and Research*. 2025 Jun 5;3(3):429-37.
102. Simina A, Mate C, Onisan E, Petolescu C, Sărac I. Uncovering the role of *Momordica charantia* in diabetes: therapeutic and biotechnological perspectives. *JOURNAL of Horticulture, Forestry and Biotechnology*. 2024 Dec 11;28(2):365-70.
103. Patwardhan B. Ayurveda and systems biology. *Ann Ayurvedic Med*. 2014;3:5-7.
104. Hegde SN, K LD, Choudhary M, Menon N, Singh G. A comprehensive metabolome profiling of *Terminalia chebula*, *Terminalia bellerica*, and *Phyllanthus emblica* to explore the medicinal potential of Triphala. *Scientific Reports*. 2024 Dec 30;14(1):31635.





WISELEAF SCIENTIFIC VENTURES

105. Kundury KK, Bhavani Balakrishnan MV, Vasudev A, Singh P, Mullapally SK. Clinical profiles, patient expectations and outcomes from an integrative oncology clinic in India: A novel integrated model of care in oncology.
106. Heinrich M, Jalil B, Abdel-Tawab M, Echeverria J, Kulić Ž, McGaw LJ, Pezzuto JM, Potterat O, Wang JB. Best practice in the chemical characterisation of extracts used in pharmacological and toxicological research—the ConPhyMP—guidelines. *Frontiers in Pharmacology*. 2022 Sep 13;13:953205.
107. Calahan J, Howard D, Almalki AJ, Gupta MP, Calderón AI. Chemical adulterants in herbal medicinal products: a review. *Planta Medica*. 2016 Apr;82(06):505-15.
108. Gaur, J.. (2021). DETECTION OF ADULTERANTS IN HERBAL FORMULATIONS: A REVIEW. 33-39.
109. Pore AV, Bais SK, Navale TB. REVIEW ON ADULTERATIONS IN HERBAL FORMULATION.
110. Zhang J, Wider B, Shang H, Li X, Ernst E. Quality of herbal medicines: challenges and solutions. *Complementary therapies in medicine*. 2012 Feb 1;20(1-2):100-6.
111. Posadzki P, Watson LK, Ernst E. Adverse effects of herbal medicines: an overview of systematic reviews. *Clinical medicine*. 2013 Feb 1;13(1):7-12.
112. Khuspe, Pankaj & Swapnil, Phade & Prajakta, Inamdar & Sakshi, Kakade & Vaishnavi, Ingale & Srushti, Magar & Aishwarya, Thavare. (2024). Overview of herbal drugs: Regulatory perspective with special emphasis on global market. *Yemen Journal of Medicine*. 3. 207-217. 10.18231/j.yjom.2024.022.
113. Thakkar S, Anklam E, Xu A, Ulberth F, Li J, Li B, Hugas M, Sarma N, Crerar S, Swift S, Hakamatsuka T. Regulatory landscape of dietary supplements and herbal medicines from a global perspective. *Regulatory Toxicology and Pharmacology*. 2020 Jul 1;114:104647.
114. Burns L, Le Roux N, Kalesnik-Orszulak R, Christian J, Dudinak J, Rockhold F, Khozin S, O'Donnell J. Real-world evidence for regulatory decision-making: updated guidance from around the world. *Frontiers in medicine*. 2023 Oct 30;10:1236462.
115. Pushpangadan P, George V, Ijiru TP, Chithra MA. Biodiversity, bioprospecting, traditional knowledge. Sustainable development and value added products: a review. *Journal of Traditional Medicine & Clinical Naturopathy*. 2018;7(01):1-7.
116. Jessamine S. International Harmonization. *WHO Drug Information*. 2008;22(4).
117. Salman, Shaik & Priyanka, Bhyri & Sri, Ganji & Boddeda, Bhavani. (2025). Emerging trends in advanced herbal pharmaceuticals: From bench to bedside. *GSC*





WISELEAF SCIENTIFIC VENTURES

- Biological and Pharmaceutical Sciences. 32. 050-059.
10.30574/gscbps.2025.32.2.0309
118. Aslam MS, Kim YJ. Herbal medicine in the modern age: The era of personalized precision. *Journal of Integrative Medicine*. 2025 Aug 25.
119. Bagheri M, van Nostrum CF, Kok RJ, Storm G, Hennink WE, Heger M. Utility of intravenous curcumin nanodelivery systems for improving in vivo pharmacokinetics and anticancer pharmacodynamics. *Molecular Pharmaceutics*. 2022 Aug 16;19(9):3057-74.
120. Guo C, Xu S, Guo X. Metabolic Engineering of Terpenoid Biosynthesis in Medicinal Plants: From Genomic Insights to Biotechnological Applications. *Current Issues in Molecular Biology*. 2025 Sep 5;47(9):723.
121. Patwardhan B, Wieland LS, Aginam O, Chuthaputti A, Ghelman R, Ghods R, Soon GC, Matsabisa MG, Seifert G, Tu'Itahi S, Chol KS. Evidence-based traditional medicine for transforming global health and well-being. *Journal of Integrative and Complementary Medicine*. 2023 Sep 1;29(9):527-30.





WISELEAF SCIENTIFIC VENTURES

HEALING ROOTS: INTEGRATIVE HERBAL APPROACHES TO CHRONIC ILLNESS

CHAPTER 2- HERBS FOR DIABETES MANAGEMENT

Aditya Shishodia*, Devashish Pal, Manvi Jha, Ashok Kumar

Sanskar College of Pharmacy & Research, Ghaziabad, 201302, Uttar Pradesh,
India

Email: adityarana9221@gmail.com

ABSTRACT

Type 2 diabetes mellitus represents a progressive metabolic disorder characterized by compromised insulin secretion, impaired insulin signaling, and resulting hyperglycemia affecting over 400 million individuals globally, with contemporary antidiabetic pharmacotherapy frequently producing adverse metabolic side effects and limited efficacy in subpopulations demonstrating insulin resistance or therapeutic non-responsiveness. Traditional medicine systems have established herbal therapeutic approaches for diabetes management across centuries of clinical application, with contemporary research validating multiple medicinal plants as genuine alternatives for glycemic control and metabolic improvement. Medicinal herbs including *Gymnema sylvestre*, *Momordica charantia*, *Trigonella foenum graecum*, *Tinospora cordifolia*, and *Curcuma longa* contain bioactive phytochemical constituents demonstrating multiple complementary mechanisms targeting distinct aspects of glucose homeostasis including pancreatic β -cell regeneration, insulin secretion enhancement, and glucose transporter upregulation. Meta-analytic evidence demonstrates that Aloe vera leaf gel, Psyllium fiber, and fenugreek seeds produce HbA1c reductions equivalent to conventional antidiabetic agents (mean differences ranging from 0.85-0.99%), while berberine monotherapy demonstrates comparable efficacy to metformin in reducing fasting blood glucose and HbA1c levels. These herbal approaches operate through sophisticated molecular mechanisms including NF- κ B pathway inhibition, peroxisome proliferator-activated receptor modulation, and AMP-activated protein kinase activation without the hepatotoxic or gastrointestinal adverse effects associated with conventional therapeutics. Integration of rigorously validated herbal remedies within comprehensive diabetes management frameworks offers promising complementary therapeutic strategies warranting further clinical investigation and standardization protocols

Keywords: Diabetes; Blood Sugar; Herbs; Plants; Management.





WISELEAF SCIENTIFIC VENTURES

1. Introduction

1.1 Overview of Diabetes Mellitus

The term Diabetes Mellitus originates from the Greek word diabetes, meaning “siphon” or “to pass through,” and the Latin word mellitus, meaning “sweet.” The term diabetes was first introduced by Apollonius of Memphis between 250 and 300 BCE. Ancient Greek, Indian, and Egyptian civilizations were among the earliest to recognize the characteristic sweetness of urine in affected individuals, which ultimately led to the designation Diabetes Mellitus. In 1889, Mering and Minkowski established the pivotal role of the pancreas in the pathogenesis of diabetes. Subsequently, in 1922, Banting, Best, and Collip successfully isolated and purified the hormone insulin from the pancreas of cows at the University of Toronto, marking a significant milestone in the therapeutic management of diabetes. Over the ensuing decades, extensive research and numerous scientific advancements have been achieved in understanding and managing this metabolic disorder. Despite these developments, diabetes continues to be a major global health concern and remains one of the most prevalent chronic diseases worldwide. In the United States, it persists as the seventh leading cause of mortality. [1]

1.2 Symptoms of Diabetes Mellitus

The main common symptoms associated with Diabetes are below:

1. Increased thirst
2. Weight loss
3. Increased urination
4. Hunger due to starvation of cells
5. Fatigue
6. Slow healing of wounds
7. Yeast infections [2]
8. Tingling sensation

1.3 Types of Diabetes

There are three major categories of Diabetes that can be given below –

A. Type 1 Diabetes

Type 1 diabetes mellitus (T1DM) occurs due to the body’s inability to produce adequate insulin. This condition primarily arises from the autoimmune destruction of pancreatic beta cells, which are responsible for insulin production. Individuals affected by T1DM require insulin from external sources to maintain normal blood glucose levels and sustain life. Type 1 diabetes accounts for approximately 5–10% of all diagnosed diabetes cases (Maitra, 2009). Since their pancreas fails to generate sufficient insulin, patients must rely on lifelong insulin therapy.





WISELEAF SCIENTIFIC VENTURES

B. Type 2 Diabetes

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by impaired glucose homeostasis resulting from insulin resistance and/or inadequate compensatory insulin secretion. This dysregulation leads to persistent hyperglycemia, which, if uncontrolled, contributes to progressive metabolic and vascular dysfunction. Prolonged hyperglycemia associated with T2DM induces both microvascular and macrovascular complications, including neuropathy, nephropathy, and cardiovascular diseases. These pathophysiological alterations arise primarily from oxidative stress, inflammation, and endothelial dysfunction. Despite its chronic nature, T2DM is largely preventable through lifestyle modification and early risk assessment. The major etiological determinants include excess adiposity, physical inactivity, and genetic susceptibility, which collectively impair insulin signaling pathways and glucose uptake mechanisms. [3,4]

C. Gestational Diabetes

Gestational diabetes mellitus (GDM) is characterized by glucose intolerance resulting in hyperglycemia, with blood glucose levels exceeding normal physiological ranges but remaining below the threshold for overt diabetes mellitus. This condition manifests during pregnancy and is typically identified through routine prenatal screening procedures rather than through the presentation of clinical symptoms. Women diagnosed with gestational diabetes are at a significantly increased risk of adverse maternal and fetal outcomes, including complications during gestation and parturition. Furthermore, both affected mothers and their offspring possess a heightened long-term risk of developing type 2 diabetes mellitus and related metabolic disorders in later life. [5-7]

1.4 Global Prevalence and Health Impact

The global prevalence of diabetes mellitus (DM) has demonstrated a remarkable increase over the past three decades. The number of individuals affected by diabetes rose from approximately 200 million in 1990 to 830 million in 2022, underscoring a major public health challenge (World Health Organization [WHO], 2023). The rise in prevalence has been particularly pronounced in low- and middle-income countries (LMICs), where rapid urbanization, sedentary lifestyles, and nutritional transitions have accelerated the disease burden compared to high-income countries (HICs) (WHO, 2023). Despite the availability of effective treatment modalities, over half of individuals living with diabetes did not receive pharmacological therapy in 2022, with treatment coverage lowest in LMICs (WHO, 2023). [8] Diabetes mellitus remains a principal cause of morbidity and mortality worldwide, associated with severe complications such as retinopathy leading to blindness, nephropathy resulting in kidney failure, cardiovascular diseases (heart attacks and strokes), and peripheral arterial disease culminating in lower-limb amputations (WHO, 2023). In





WISELEAF SCIENTIFIC VENTURES

2021, diabetes and diabetes-associated kidney disease accounted for more than 2 million deaths globally. Additionally, approximately 11% of all cardiovascular deaths were attributable to hyperglycemia (International Diabetes Federation [IDF], 2021). An estimated 240 million individuals worldwide are believed to live with undiagnosed diabetes, representing nearly half of all adults with the condition (IDF, 2021). According to the IDF Diabetes Atlas (10th edition), in 2021, there were 537 million adults aged 20–79 years (10.5% of the global population) living with diabetes, with global healthcare expenditures estimated at USD 966 billion (IDF, 2021). These costs are projected to surpass USD 1,054 billion by 2045, reflecting the escalating economic burden of diabetes. Furthermore, the global prevalence of DM is projected to increase to 643 million (11.3%) by 2030 and 783 million (12.2%) by 2045, indicating a sustained upward trajectory in disease incidence (IDF, 2021). Adopting healthy lifestyle practices—including a balanced diet, regular physical activity, maintenance of a healthy body weight, and avoidance of tobacco use—plays a critical role in the prevention or delay of type 2 diabetes mellitus (T2DM) onset (WHO, 2023). In addition, early diagnosis and effective management through dietary control, exercise, pharmacotherapy, and regular screening can substantially reduce the risk of complications and improve patient outcomes (WHO, 2023). [9]

1.5 Limitation of Conventional Antidiabetic Drug

Conventional pharmacotherapy for diabetes mellitus (DM) — comprising insulin and oral hypoglycemic agents such as sulfonylureas, biguanides (metformin), thiazolidinediones (TZDs), α -glucosidase inhibitors, and meglitinides — has been the mainstay of treatment for decades. Although these agents are effective in controlling blood glucose levels, they possess several limitations that reduce their long-term clinical utility. [10]

1. Adverse Effect and Safety Concern
 - Many conventional antidiabetic agents are associated with undesirable side effects that compromise patient safety and adherence:
 - A. Sulfonylureas and meglitinides promote insulin secretion from pancreatic β -cells, but frequently cause hypoglycemia and weight gain
 - B. Thiazolidinedione's (e.g., pioglitazone, rosiglitazone) enhance insulin sensitivity but are linked to fluid retention, osteoporotic fractures, and increased cardiovascular risk
 - C. Metformin, though a first-line therapy, may cause gastrointestinal discomfort and in rare instances lactic acidosis
2. Limited durability of Glycemic control
 - The efficacy of most oral antidiabetic drugs diminishes over time due to the progressive decline of pancreatic β -cell function and persistent insulin resistance, a





WISELEAF SCIENTIFIC VENTURES

phenomenon termed secondary failure. Patients often require combination therapy or insulin supplementation to maintain glycemic targets. [11]

1.6 Role of Herbs for Diabetes management

Several studies have demonstrated the therapeutic potential of medicinal plants possessing hypoglycemic activity in the management of diabetes mellitus. The principal bioactive phytoconstituents implicated in antidiabetic effects include flavonoids, tannins, phenolic compounds, and alkaloids. The presence of these metabolites underscores the pharmacological significance of such plants in glycemic regulation. For instance, tannins have been shown to enhance pancreatic β -cell function, thereby promoting insulin secretion. Similarly, quercetin, a potent antioxidant, exerts its protective effects through multiple mechanisms, including the scavenging of reactive oxygen species, inhibition of lipid peroxidation, and chelation of metal ions. The hypoglycemic mechanisms of medicinal plants may involve several pathways, such as stimulation of insulin secretion, facilitation of glucose uptake by adipose and muscle tissues, inhibition of intestinal glucose absorption, and suppression of hepatic gluconeogenesis. Collectively, these mechanisms contribute to the attenuation or prevention of diabetic complications. Furthermore, in experimental research, streptozotocin (STZ)-induced diabetic rats are widely employed as a standard animal model for evaluating the antidiabetic efficacy of plant extracts. [12]

2. Pathophysiology of Diabetes Mellitus

2.1 Mechanism of insulin secretion and action Mechanism of Glucose-Mediated Insulin Secretion

1. Initiation of the First Phase of Insulin Secretion

Elevation of extracellular glucose concentration initiates the first phase of glucose-stimulated insulin secretion (GSIS) through the exocytosis of pre-stored insulin granules from pancreatic β -cells. This rapid response represents the immediate release of insulin from the readily releasable pool of secretory granules.

2. Glucose Uptake and Metabolic Sensing

Upon entry into the β -cell, glucose is phosphorylated by glucokinase, serving as the rate-limiting step in glucose metabolism. This phosphorylation converts glucose into glucose-6-phosphate (G6P), which enters the glycolytic pathway, subsequently enhancing ATP production. The increase in the intracellular ATP/ADP ratio is a critical metabolic signal linking glucose metabolism to insulin secretion [13]





WISELEAF SCIENTIFIC VENTURES

3. Electrical Activity and Membrane Depolarization

The rise in ATP concentration leads to the closure of ATP-sensitive potassium (K^+ -ATP) channels located on the plasma membrane. The inhibition of K^+ efflux induces membrane depolarization, which subsequently activates voltage-dependent calcium channels (VDCCs). The opening of these channels allows Ca^{2+} influx, resulting in a marked elevation of cytosolic calcium levels.

4. Calcium-Dependent Exocytosis of Insulin Granules

The increase in intracellular Ca^{2+} concentration ($[Ca^{2+}]_i$) serves as the principal trigger for the exocytosis of insulin-containing granules. This calcium-dependent process produces the pulsatile release of insulin, characteristic of the first phase of GSIS

5. Amplifying Pathways of Insulin Secretion

The secretory response is further potentiated by both K^+ -ATP channel-independent pathways, which can be classified as:

- (a) Ca^{2+} -dependent amplification, involving intracellular calcium signaling cascades independent of K^+ -ATP channel closure.
- (b) Ca^{2+} -independent amplification, which enhances insulin granule mobilization and fusion without directly altering calcium dynamics. These mechanisms collectively sustain and modulate the insulin secretory response to glucose. [14]

6. Role of Additional Mediators and Signaling Molecules

Several autocrine, paracrine, and hormonal factors modulate β -cell activity through secondary messenger systems: Activation of phospholipases and protein kinase C (PKC) by neurotransmitters such as acetylcholine enhances insulin secretion. Stimulation of adenylyl cyclase increases intracellular cyclic AMP (cAMP) levels, thereby activating protein kinase A (PKA). This pathway potentiates insulin exocytosis in response to incretin hormones including: Vasoactive Intestinal Peptide (VIP) Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) Glucagon-Like Peptide-1 (GLP-1) Glucose-Dependent Insulinotropic Polypeptide (GIP)

7. Stimulated Insulin Secretion

The second phase of insulin secretion represents a sustained release phase that follows the initial burst. It is primarily mediated by the recruitment and refilling of secretory granules from the reserve pool, which are translocated to the plasma membrane for subsequent exocytosis. This phase is significantly modulated by the above-mentioned incretin hormones and intracellular signaling networks. [15,16]

2.2 Causes and risk factor

The main causes of Diabetes Mellitus are given below-

- Autoimmune response
- Genetics
- Environmental factors
- Lifestyle
- Age
- Disease state





WISELEAF SCIENTIFIC VENTURES

The various risk factor given below that related to diabetes mellitus –

a. **Physical Activity**

Physical inactivity is a critical determinant in the pathogenesis of prediabetes and T2DM. Regular engagement in physical exercise improves insulin sensitivity, thereby facilitating more efficient utilization of endogenous insulin. Evidence suggests that even moderate-intensity physical activity—such as brisk walking for 30 minutes on at least five days per week—can substantially reduce the risk of both diabetes and cardiovascular diseases. [17]

b. **Smoking**

Tobacco use is associated with an increased risk of insulin resistance and the subsequent development of diabetes. Smoking cessation, supported by pharmacological aids, behavioral counseling, and digital resources, is strongly recommended to mitigate this risk and improve overall metabolic health.

c. **Family**

History A positive family history of diabetes, particularly among first-degree relatives such as parents or siblings, significantly increases an individual's susceptibility to developing the disease. Therefore, sharing family health information with healthcare professionals is essential for personalized risk assessment and preventive management. [18]

d. **Age**

Advancing age correlates positively with an increased incidence of prediabetes and T2DM. Although Type 2 diabetes most commonly manifests in middle-aged and older adults—typically after the age of 45—its prevalence among children and adolescents has risen significantly in recent years, largely attributable to sedentary lifestyles and obesity. [19,20]

e. **Race and ethnicity**

Ethnic background is a recognized non-modifiable risk factor for diabetes. Individuals of African American, Asian American, Hispanic/Latino, Native American, or Pacific Islander descent demonstrate a higher prevalence and predisposition to T2DM compared to other populations, likely due to a combination of genetic, environmental, and socioeconomic influences. [21-23]

3. **Concept Of Herbal Medicine In Diabetes**

The utilization of herbal medicine in the management of diabetes mellitus extends back several millennia and constitutes an integral component of the medical heritage of numerous ancient civilizations. Within the Ayurvedic medical tradition of India, a disorder referred to as Madhumeha—literally translating to “honey urine”—was delineated in classical texts such as the Charaka Samhita and Sushruta Samhita. The symptomatology described in these treatises, characterized by excessive urination and sweetness of urine,





WISELEAF SCIENTIFIC VENTURES

exhibits a striking resemblance to the clinical manifestations recognized today as diabetes mellitus. Analogously, in Traditional Chinese Medicine (TCM), the condition termed Xiaoke disease has long been treated through botanical formulations aimed at restoring metabolic balance. This syndrome, typified by polyuria, polydipsia, and progressive weight loss, corresponds closely to the metabolic dysregulation observed in contemporary cases of diabetes. Beyond the Indian and Chinese medical systems, ethnomedical practices across Africa, the Middle East, and the Americas have also recorded extensive use of medicinal plants exhibiting hypoglycemic and insulin-mimetic properties [24]. Cumulative ethnopharmacological evidence indicates that approximately 60% of the global population continues to depend on traditional, plant-derived medicinal systems for primary healthcare, particularly for the management of chronic metabolic disorders such as diabetes mellitus (World Health Organization).

Table 1: Medicinal Plants with Antidiabetic Potential: Family, Mechanism, Formulation, and Dosage²⁵⁻²⁶

Plant (Scientific / Common Name)	Mechanism of Action	Typical Formulation and Dosage (Studies / Market Use)	Family
Trigonella foenum-graecum (Fenugreek)	4-Hydroxyisoleucine stimulates insulin secretion; fiber delays intestinal glucose absorption; improves GLUT-4 mediated glucose uptake.	Seed powder (5–25 g/day); standardized extract 335 mg three times daily; capsules/tablets.	Fabaceae
Azadirachta indica (Neem)	Enhances insulin sensitivity; antioxidant; reduces inflammatory cytokines (TNF- α , IL-6);	Standardized leaf extract 250–500 mg twice daily; capsule/tablet.	Meliaceae





WISELEAF SCIENTIFIC VENTURES

	β -cell protection.		
Syzygium cumini (Jamun / Java Plum)	Stimulates insulin secretion; enhances glycogen synthesis; β - cell protection; antioxidant activity.	Seed powder 10 g/day for 30–90 days; aqueous extract 500 mg twice daily.	Myrtaceae
Aloe vera	Enhances insulin secretion and glucose uptake; antioxidant and anti-inflammatory effects.	Gel extract 300 mg twice daily for 8–12 weeks; juice/capsules.	Asphodelaceae
Ocimum sanctum	Stimulates insulin secretion; antioxidant; inhibits α amylase and α glucosidase.	Leaf extract capsule 250 mg twice daily; decoction.	Laminaceae
(Tulsi / Holy Basil)	Gymnemic acids regenerate β cells; inhibit glucose absorption; enhance insulin release.	Standardized extract 200–400 mg/day ($\geq 25\%$ gymnemic acids); capsules/tablets.	Apocynaceae





WISELEAF SCIENTIFIC VENTURES

Cinnamomum cassia (Cinnamon)	Insulin receptor kinase activation; inhibits α glucosidase; enhances glycogen synthesis; delays gastric emptying.	Powdered bark 1–3 g/day; capsules 500 mg twice daily.	Lauraceae
Curcuma longa (Turmeric)	Curcumin activates AMPK/PPAR γ ; improves insulin sensitivity; antioxidant and antiinflammatory	Standardized curcumin 500–1,500 mg/day, often with piperine.	Zingiberaceae
Other Promising Plants (Tinospora cordifolia, Pterocarpus marsupium, Salacia reticulata, Berberis aristata)	Insulin mimetic effects; α glucosidase inhibition; β cell protection.	Standardized extracts 250–500 mg twice daily; decoctions.	Menispermaceae Fabaceae Celastraceae Berberidaceae

Conclusion

Medicinal herbs represent a substantial and expanding resource in the therapeutic landscape for diabetes mellitus management, offering complementary approaches addressing multiple pathogenic mechanisms underlying hyperglycemia and metabolic dysfunction. The convergence of ethnopharmacological evidence, animal model studies, and increasingly rigorous clinical investigations establishes that carefully selected medicinal plants including *Gymnema sylvestre*, *Momordica charantia*, *Trigonella foenum-graecum*, *Berberis aristata* (berberine), and *Cinnamon verum* produce clinically meaningful reductions in glycemic markers including fasting blood glucose and HbA1c levels equivalent to or comparable with established conventional antidiabetic pharmacotherapy. These herbal approaches operate through sophisticated multitarget mechanisms including pancreatic β -cell regeneration, insulin secretion enhancement, glucose transporter upregulation, and modulation of critical cellular signaling pathways (NF- κ B, AMPK, PPAR γ), providing holistic therapeutic action addressing the complex pathophysiology of diabetes rather than single-pathway intervention characteristic of conventional drugs. The favorable adverse effect profiles reported across multiple clinical





WISELEAF SCIENTIFIC VENTURES

trials, coupled with substantial cost-accessibility advantages, particularly in resource-limited healthcare settings, render herbal diabetes therapeutics especially valuable for vulnerable populations with limited access to modern pharmacotherapy. However, widespread clinical integration requires rigorous standardization protocols establishing consistent phytochemical composition, comprehensive evaluation of herb-drug interactions with commonly prescribed antidiabetic agents, and large-scale multicenter randomized controlled trials confirming long-term efficacy and safety. Future advancement of herbal diabetes management depends upon collaborative efforts bridging traditional knowledge with contemporary scientific validation, implementing WHO quality control guidelines, developing molecular fingerprinting technologies for ingredient authentication, and establishing robust regulatory frameworks ensuring product reliability and consumer protection. With these evidence-based approaches, herbal medicines can become integral components of comprehensive, accessible, and culturally appropriate diabetes management strategies addressing this escalating global health challenge.

REFERENCES

1. Grover JK, Yadav S, Vats V. Medicinal plants of India with antidiabetic potential. *J Ethnopharmacol.* 2002;81(1):81-100.
2. Scartezzini P, Sproni E. Review on some plants of Indian traditional medicine with antioxidant activity. *J Ethnopharmacol.* 2000;71(1-2):23-43.
3. Seth SD, Sharma B. Medicinal plants of India. *Indian J Med Res.* 2004;120(1):9-11.
4. Centers for Disease Control and Prevention. National diabetes statistics report, 2022. Atlanta (GA): Centers for Disease Control and Prevention, US Department of Health and Human Services; 2022. Updated 2022 Sep 30 [cited 2022 Nov 1]. Available from: <https://www.cdc.gov/diabetes/data/statistics-report/index.html>
5. Centers for Disease Control and Prevention. National diabetes statistics report, 2022. Atlanta (GA): Centers for Disease Control and Prevention, US Department of Health and Human Services; 2022. Updated 2022 Jan 18 [cited 2022 Aug 4]. Available from: <https://www.cdc.gov/diabetes/data/statistics-report/index.html>
6. Barnett AH, Eff C, Leslie RD, Pyke DA. Diabetes in identical twins. A study of 200 pairs. *Diabetologia.* 1981;20(2):87-93.





WISELEAF SCIENTIFIC VENTURES

7. American Diabetes Association. Classification and diagnosis of diabetes mellitus: standards of medical care in diabetes - 2018. *Diabetes Care*. 2018;41(Suppl 1):S13-S27.
8. Thomas CC, Philipson LH. Update on diabetes classification. *Med Clin North Am*. 2015;99(1):1-16.
9. Pihoker C, Gilliam LK, Hampe CS, Lernmark A. Autoantibodies in diabetes. *Diabetes*. 2005;54(Suppl 2):S52-S61.
10. Atkinson MA, Eisenbarth GS. Type 1 diabetes: new perspectives on disease pathogenesis and treatment. *Lancet*. 2001;358(9277):221-9.
11. Institute for Health Metrics and Evaluation. *Global Burden of Disease Study 2021*. Seattle (WA): Institute for Health Metrics and Evaluation; 2024.
12. Hashim MJ, Mustafa H, Ali H. Knowledge of diabetes among patients in the United Arab Emirates and trends since 2001: a study using the Michigan Diabetes Knowledge Test. *East Mediterr Health J*. 2017;22(10):742-8.
13. Al Slail FY, Abid O, Assiri AM, Memish ZA, Ali MK. Cardiovascular risk profiles of adults with type-2 diabetes treated at urban hospitals in Riyadh, Saudi Arabia. *J Epidemiol Glob Health*. 2016;6(29):29-36.
14. Blas E, Kuru A, editors. *Equity, social determinants and public health programmes*. Geneva: World Health Organization; 2010. Chapter: Diabetes: Equity and social determinants.
15. International Diabetes Federation. *IDF diabetes atlas*. 9th ed. Brussels: International Diabetes Federation; 2019.
16. Mammen MV, Anand A, Mishra A. Herbal plants as novel anti-diabetic agents: phytochemical profiles, mechanisms, and clinical evidence. *Rev Diabet Stud*. 2025;21(Suppl 9):S159-S178.
17. Rampura ZF, Panwar SS. Herbal antidiabetics: an evidence-based review of medicinal plants used in type 2 diabetes. *J Pharmacogn Phytochem*. 2025;14(5):250-7.
18. Nikniaz L, Akbarzadeh MA, Hosseinifard H, Hosseini MS, Argani H, Shokri A, et al. Effectiveness of medicinal plants for glycaemic control in type 2 diabetes: overview of meta-analyses. *Phytother Res*. 2021;35(12):6639-52.
19. Gupta RC, Chang D, Nammi S, Bensoussan A, Bilinski K, Roufogalis BD. Interactions between antidiabetic drugs and herbs: an overview of mechanisms of action and clinical implications. *Diabetol Metab Syndr*. 2017;9:59.
20. Akash MSH, Rehman K, Chen S. Role of medicinal plants in the treatment of diabetes: a systematic review. *J Evid Based Complementary Altern Med*. 2016;21(3):152-70.
21. Baig MS, Naaz Q, Ahmad MI, Siddiqui MI. Plant bioactive compounds and their mechanistic approaches in the treatment of diabetes. *Future J Pharm Sci*. 2022;8(1):43.





WISELEAF SCIENTIFIC VENTURES

22. Jha AN. Herbal drug used in the treatment of diabetes: a review. *Res Rev J Herb Sci.* 2023;12(2):1-8.
23. Yeh GY, Eisenberg DM, Kaptchuk TJ, Phillips RS. Meta-analysis of the effect of herbal supplements on glycemic control in type 2 diabetes. *Diabetes Care.* 2011;34(4):1089-94.
24. Al-Ishaq RK, Liskova A, Kubatka P, Büsselberg D. Evidence-based human clinical trials on antidiabetic herbal remedies commonly used in the Middle East. *Molecules.* 2023;28(13):5164.
25. Bunyapraphatsara N, Yongchaiyudha S, Rungpitarangsi V, Chokechaijaroenporn O. Antidiabetic activity of Aloe vera L juice. II. Clinical trial in diabetes mellitus patients in combination with glibenclamide. *Phytomedicine.* 1996;3(3):245-54.
26. Cefalu WT. Insulin resistance: cellular and clinical concepts. *Exp Biol Med (Maywood).* 2001;226(1):13-26





WISELEAF SCIENTIFIC VENTURES

HEALING ROOTS: INTEGRATIVE HERBAL APPROACHES TO CHRONIC ILLNESS

CHAPTER 3- CARDIOVASCULAR HEALTH AND HERBAL REMEDIES

Kirti Singh Tomar^{1*}, Shailendra Kumar², Shivani Sharma¹, Himanshu Singh³

¹Department of Pharmacy, Sanskar College of Pharmacy & Research, Ghaziabad, 201302,
Uttar Pradesh, India

²Department of Pharmaceutics, Lecturer, JMS Pharmacy college, Masuri, Ghaziabad,
201015, Uttar Pradesh, India

³Department of Pharmacy, H.R. institute of Pharmacy, Ghaziabad, Uttar Pradesh 201003,
India

Email: kirtitomar2001@gmail.com

ABSTRACT

Cardiovascular disease remains the leading global cause of mortality, with oxidative stress and chronic inflammation as fundamental pathophysiological mechanisms. Herbal remedies containing bioactive compounds including flavonoids, polyphenols, and terpenoids offer complementary therapeutic approaches with favorable safety profiles and cost-effectiveness. This chapter examines eight major herbal remedies: garlic reduces blood pressure through ACE inhibition and nitric oxide enhancement; hawthorn improves cardiac contractility and exercise tolerance in heart failure patients; turmeric/curcumin inhibits NF- κ B signaling reducing inflammatory cytokines and atherosclerotic plaque formation; ginseng enhances endothelial function with species-specific blood pressure effects; green tea catechins provide cardioprotection through myocardial ischemia-reperfusion injury reduction; flaxseed omega-3 compounds improve arterial compliance and lipid profiles; Terminalia arjuna increases baroreflex sensitivity and decreases anginal frequency; and berberine significantly reduces LDL cholesterol and triglycerides. These remedies operate through interconnected molecular pathways involving oxidative stress reduction, lipid metabolism modulation, and improved endothelial function. Clinical integration requires careful assessment of drug-herb interactions, particularly with anticoagulants and cardiac glycosides. When appropriately integrated with conventional pharmacotherapy, herbal remedies demonstrate substantial potential for cardiovascular disease prevention and management.





WISELEAF SCIENTIFIC VENTURES

Keywords: Herbs; Medicine; Cardiovascular; Natural; Plant-based therapy

1. Introduction

Cardiovascular diseases represent the leading cause of global mortality, accounting for approximately 17.9 million deaths annually, with ischemic heart disease and stroke as the primary contributors. [1,2] Despite advances in pharmacotherapy, the prevalence of cardiovascular disease continues to rise due to aging populations and lifestyle-related risk factors including hypertension, dyslipidemia, diabetes, and obesity.[3,4] Herbal remedies have been employed in traditional medicine systems for thousands of years to manage cardiovascular disorders, offering potential therapeutic alternatives with favorable safety profiles and improved cost-effectiveness. This chapter examines cardiovascular benefits of herbal remedies, their mechanisms of action, clinical evidence, and safety considerations.

Cardiovascular disease encompasses multiple conditions affecting the heart and blood vessels, including hypertension, atherosclerosis, heart failure, myocardial infarction, and stroke. Two fundamental pathophysiological mechanisms underlying cardiovascular disease development are oxidative stress and chronic inflammation, which perpetuate vascular dysfunction. Oxidative stress, characterized by an imbalance between reactive oxygen species (ROS) production and antioxidant defense systems, triggers atherosclerotic disease progression through mechanisms including LDL oxidation, endothelial dysfunction, and myocardial ischemic injury.[5-7] Chronic low-grade inflammation driven by inflammatory cells and cytokines contributes to atherosclerotic plaque initiation and predisposes patients to acute thrombotic events. Recognition of these pathophysiological mechanisms has directed therapeutic attention toward herbal preparations rich in bioactive compounds with antioxidant and anti-inflammatory properties, offering complementary approaches to conventional pharmacotherapy. [8-11]

2. Mechanism of Cardioprotection by herbs

Medicinal plants contain diverse bioactive compounds including flavonoids, polyphenols, terpenoids, saponins, and alkaloids that exert cardioprotective effects through multiple molecular pathways.[12,13] Flavonoids and polyphenolic compounds function as free radical scavengers, reducing oxidative stress by neutralizing reactive oxygen species and preserving endothelial nitric oxide (NO) bioavailability, which is essential for vascular relaxation and normal vascular tone. Many herbal compounds demonstrate potent anti-inflammatory effects by inhibiting nuclear factor kappa B (NFκB) signaling pathways, reducing expression of pro-inflammatory cytokines





WISELEAF SCIENTIFIC VENTURES

including TNF- α , IL-6, and C-reactive protein, which are implicated in atherosclerosis progression and cardiovascular dysfunction. Certain herbal remedies modulate lipid metabolism through multiple pathways including inhibition of hepatic HMG-CoA reductase, enhanced LDL receptor expression, suppressed cholesterol biosynthesis, and reduced lipid peroxidation, collectively contributing to improved lipid profiles and reduced atherosclerotic plaque formation.[14,15] Furthermore, herbal compounds improve endothelial function through enhanced nitric oxide production, restoration of endothelial-dependent vasodilation, and reduced vascular inflammation, all essential for maintaining cardiovascular homeostasis and preventing atherothrombotic events.[16,17]

3. Herbal remedies in cardiovascular management

A. Garlic (*Allium sativum*)

It represents one of the most extensively studied herbal remedies for cardiovascular health, with its cardiovascular benefits attributed to organosulfur compounds including allicin, ajoene, and diallyl disulfides.[18,19] Clinical trials and meta-analyses demonstrate that garlic supplementation produces significant reductions in both systolic and diastolic blood pressure, with systematic reviews indicating average reductions of approximately 8.3 ± 1.9 mmHg for systolic and 5.5 ± 1.9 mmHg for diastolic blood pressure in hypertensive patients. The antihypertensive mechanism involves multiple pathways: allicin functions as a natural ACE inhibitor promoting arterial vasodilation; organosulfur compounds serve as hydrogen sulfide (H₂S) donors inducing vascular smooth muscle relaxation; and garlic-derived compounds enhance endothelial nitric oxide production, promoting NO-mediated vasodilation. Beyond blood pressure reduction, garlic produces favorable effects on lipid profiles, with studies demonstrating significant reductions in serum total cholesterol, triglycerides, and LDL cholesterol while maintaining or slightly increasing HDL cholesterol. [20] The lipid lowering effects occur through inhibition of hepatic enzymes involved in cholesterol synthesis, combined with enhanced cholesterol excretion through increased acidic and neutral steroid elimination. Garlic also exhibits potent antithrombotic effects through suppression of platelet aggregation and inhibition of thromboxane formation, with both allicin and water-soluble organosulfur compounds contributing to these effects. Moreover, garlic preparations enhance endogenous antioxidant status through increased total antioxidant status and reduced oxidized LDL and urinary markers of oxidative stress.

B. Hawthorn (*Crataegus spp.*)





WISELEAF SCIENTIFIC VENTURES

It has acquired prominence in modern herbal medicine as an important cardiovascular tonic particularly useful for managing heart failure and angina pectoris.[21] The leaves, flowers, and fruits contain oligomeric procyanidins, flavonoids (including epicatechin and quercetin), and catechins that collectively contribute to the plant's cardiovascular effects. Preclinical research demonstrates that hawthorn extracts enhance sodium-potassium ATPase activity and improve calcium transport in cardiomyocytes, resulting in increased cardiac contractility and cardiac output. Hawthorn exerts antiarrhythmic effects through mechanisms similar to class III antiarrhythmic drugs, modifies vascular tone through vasodilation in coronary and peripheral vessels, and inhibits angiotensin-converting enzyme activity. Additionally, hawthorn demonstrates potent antioxidant properties at the cellular and mitochondrial levels, with reduction of intracellular reactive oxygen species production and protection against oxidative myocardial damage. A comprehensive meta-analysis of randomized controlled trials involving more than 750 participants found that hawthorn extract was significantly more effective than placebo for improving exercise tolerance, decreasing symptoms of shortness of breath and fatigue, and enhancing cardiac function in patients with mild to moderate chronic heart failure (NYHA functional class I to III). However, more recent large-scale clinical trials have yielded more equivocal results, with studies demonstrating that hawthorn provided only modest improvements in left ventricular ejection fraction but no significant symptomatic benefits when administered with standard evidence-based heart failure therapy.[22] Despite these mixed findings in advanced heart failure patients, positive effects have been consistently demonstrated in earlier or milder stages of heart disease. Furthermore, hawthorn has demonstrated modest antihypertensive effects in several randomized clinical trials, with reductions in diastolic blood pressure being most consistently observed.

C. Turmeric (*Curcuma longa*)

Turmeric has been extensively investigated for its cardiovascular protective properties, with curcumin, a polyphenolic compound present at 3-6% in turmeric, identified as the primary bioactive constituent responsible for cardioprotective effects.[23] Curcumin exerts multifaceted protective mechanisms including reduction of reactive oxygen species production through direct free radical scavenging and enhancement of endogenous antioxidant enzyme activities including superoxide dismutase, catalase, and glutathione peroxidase. Furthermore, curcumin inhibits nuclear factor kappa B (NF- κ B) signaling pathway, reducing pro-inflammatory transcription factors and suppressing production of inflammatory cytokines including TNF- α , IL-6, and C-reactive protein. Regarding myocardial ischemia-reperfusion injury, curcumin provides robust protection through multiple mechanisms including activation of Sirt1 histone deacetylase, which reduces oxidative stress-induced mitochondrial damage and





WISELEAF SCIENTIFIC VENTURES

cardiomyocyte apoptosis. For hypertension, experimental studies demonstrate that curcumin reduces blood pressure through regulation of uncoupling protein-2/nitric oxide signaling and improved vascular endothelial function. For atherosclerosis, animal model studies consistently demonstrate that curcumin reduces atherosclerotic plaque size through reduction of plasma cholesterol and LDL cholesterol levels, inhibition of LDL oxidation and foam cell formation, and stabilization of existing plaques through reduction of matrix metalloproteinase-9 activity.

D. Ginseng (*Panax Ginseng*)

Ginseng, particularly Asian ginseng (*Panax ginseng*) and Korean red ginseng, represents a widely used herbal remedy with substantial clinical evidence supporting beneficial effects on multiple cardiovascular parameters.[24] The active constituents include ginsenosides (panaxosides), polysaccharides, and phenolic compounds that collectively mediate cardiovascular effects. Mechanistically, ginseng enhances endothelial function through dose-dependent phosphorylation of endothelial nitric oxide synthase (eNOS) leading to increased NO production, papaverine-like smooth muscle relaxation of vascular tissue, and modulation of vascular endothelial growth factor signaling. Systematic reviews and meta-analyses of randomized clinical trials demonstrate that Korean red ginseng produces acute reductions in systolic and diastolic blood pressure (average reductions of 6.5 mm Hg systolic and 5.0 mm Hg diastolic in prehypertensive subjects after 12 weeks), with long-term studies showing significant blood pressure-lowering effects. In contrast, North American ginseng has demonstrated neutral acute effects on blood pressure in hypertensive individuals, suggesting species-specific differences. The antihypertensive effects are associated with increased plasma nitric oxide concentrations and enhanced dihydrobiopterin levels (a cofactor essential for eNOS function), combined with decreased lipoprotein-associated phospholipase A₂ activity. Clinical trials demonstrate that ginseng improves arterial stiffness, enhances augmentation index (a measure of arterial wave reflection), and improves endothelial function in patients with hypertension and comorbid diabetes mellitus. At the cellular level, ginseng exhibits cardioprotective effects through antioxidant mechanisms and enhancement of cardiac function in experimental models of myocardial injury.

E. Green tea (*Camilia sinensis*)

Green tea represents one of the richest dietary sources of polyphenolic catechins, particularly epigallocatechin gallate (EGCG), which comprises up to 50% of green tea catechins.[25] Epidemiological studies demonstrate dose-response relationships between green tea consumption and cardiovascular health benefits, with regular





WISELEAF SCIENTIFIC VENTURES

consumption of 5-6 or more cups daily associated with pronounced cardiovascular benefits.

Mechanistically, EGCG and other green tea polyphenols exert cardioprotection through multiple pathways including direct reactive oxygen species scavenging, prevention of intracellular calcium overload, inhibition of inflammatory responses and cardiomyocyte apoptosis, and promotion of free radical scavenging by enhancing endogenous antioxidant enzyme activities. Additionally, EGCG alleviates atherosclerosis through reduction of lipid peroxidation and improved lipid profiles, inhibits arrhythmia development, ameliorates heart failure, and prevents cardiac hypertrophy. Clinical trials examining EGCG effects on endothelial function demonstrate that curcumin supplementation can reduce exercise-induced decreases in flow-mediated dilation with randomized controlled trials showing that curcumin supplementation (0.2 g daily for 8 weeks) significantly increased flow-mediated dilation in healthy young subjects. Meta-analyses confirm that green tea and EGCG supplementation improve flow-mediated dilation and endothelial function.[26]

F. Flaxseed

Flaxseed represents one of the richest vegetarian sources of alpha-linolenic acid (ALA), a plant-based omega-3 polyunsaturated fatty acid comprising approximately 50% of total polyunsaturated fatty acids in flaxseed oil.[27] In addition to omega-3 content, flaxseed contains abundant dietary fiber and lignans (phytoestrogens), which contribute to diverse cardiovascular benefits.[89][90] Epidemiological evidence demonstrates an association between dietary ALA consumption and reduced cardiovascular risk, with studies indicating that dietary ALA in the highest quartile was associated with significantly lower prevalence of hypertension and lower systolic blood pressure. Mechanistically, ALA may lower blood pressure by serving as a precursor for eicosanoids, which generate prostaglandins and leukotrienes that reduce vascular tone and improve arterial compliance.[28] Clinical intervention trials examining flaxseed supplementation effects on blood pressure demonstrate that dietary flaxseed supplementation (8 g/day of ALA) produces significant reductions in systolic and diastolic blood pressure in dyslipidemic patients, accompanied by improvements in systemic arterial compliance. Additionally, comprehensive reviews of flaxseed's lipid-lowering effects indicate that dietary flaxseed supplementation produces modest reductions in blood total cholesterol (0-18% reduction range) and LDL cholesterol levels (0-11% reduction range) in most studies.

A clinical trial comparing flaxseed oil and fish oil in patients with type 2 diabetes mellitus and coronary heart disease found that flaxseed oil was more effective than fish oil in reducing serum insulin levels and high-sensitivity C-reactive protein (hs-CRP)





WISELEAF SCIENTIFIC VENTURES

levels for diabetic patients with concurrent heart disease. The proposed mechanisms for flaxseed's cardiovascular benefits include ALA-mediated enhancement of vascular relaxation properties, prevention of LDL cholesterol oxidation, and enhancement of endothelial protective mechanisms through improved prostaglandin and leukotriene metabolism.

G. *Terminalia Arjuna*

Terminalia arjuna, a traditional Ayurvedic herb whose bark has been used for millennia, represents one of the most comprehensively studied herbal remedies in experimental cardiovascular pharmacology. The bark extract contains diverse bioactive compounds including arjunolic acid, tannins, flavonoids, and triterpenoids that collectively mediate cardioprotective effects.[29] Experimental studies in animal models of chronic heart failure demonstrate that *Terminalia arjuna* extract produces significant protective effects including improved left ventricular function, enhanced baroreflex sensitivity (a marker of cardiovascular autonomic control), and attenuation of ventricular hypertrophy and myocardial fibrosis. The cardioprotective mechanisms involve enhanced endogenous antioxidant enzyme activities including increased expression and activity of superoxide dismutase, catalase, and glutathione peroxidase, combined with suppression of lipid peroxidation markers. Additionally, *Terminalia arjuna* significantly reduces inflammatory cytokine production including TNF- α and IL-6, contributing to attenuation of myocardial inflammation and remodeling. In clinical trials involving patients with stable angina pectoris or post-infarction angina, administration of *Terminalia arjuna* bark powder led to significant decreases in mean anginal frequency, marked improvement in electrocardiographic changes, and significant reductions in plasma cortisol and serum cholesterol levels. Furthermore, clinical studies demonstrate lipoprotein-lowering effects and inhibition of platelet adhesion and aggregation, contributing to cardioprotective efficacy.[106] One herbo-mineral preparation containing *Terminalia arjuna* has been found to possess significant antithrombotic activity, effectively inhibiting platelet adhesion and aggregation, with clinical studies demonstrating promising effects on ischemic cardiomyopathy.

H. Berberine (*Coptis Chinensis*)

Berberine, an isoquinoline alkaloid extracted from multiple plant species including *Coptis chinensis*, has been routinely used in Asian traditional medicine and is increasingly recognized as having substantial cardiovascular benefits with strong clinical evidence. Systematic reviews and meta-analyses of randomized controlled trials demonstrate that berberine produces significant reductions in LDL cholesterol (ranging from approximately 20 to 50 mg/dL reductions), triglycerides (reductions of





WISELEAF SCIENTIFIC VENTURES

approximately 25 to 55 mg/dL), and total cholesterol, while producing modest increases in HDL cholesterol.[30]

4. Safety considerations and Herb-drug interactions

While herbal remedies generally demonstrate favorable safety profiles compared to synthetic pharmaceuticals, important safety considerations warrant clinical attention, particularly regarding potential interactions with conventional cardiovascular medications.[31,32] Patients receiving anticoagulant therapy with warfarin represent the highest-risk population for herb-drug interactions, with multiple herbal remedies demonstrating the potential to potentiate or reduce warfarin anticoagulant effects. Herbal agents that may increase warfarin effects include boldo, fenugreek, garlic, danshen, devil's claw, dong quai, ginkgo biloba, and papaya, whereas ginseng, green tea, soy, and St. John's wort have demonstrated capacity to reduce warfarin effects.[33] Similarly, ginkgo biloba combined with aspirin therapy has been associated with spontaneous hyphema (bleeding into the anterior chamber of the eye), indicating potential for potentiation of bleeding risk when combined with antiplatelet agents.[34] Herbal remedies may also interact with cardiac glycosides (such as digoxin) through mechanisms including reduced plasma digoxin concentration when coadministered with certain herbs, which reduce drug bioavailability through effects on intestinal absorption or hepatic metabolism. Additionally, certain herbs may produce additive hemodynamic effects; for example, coadministration of ginkgo biloba with thiazide diuretics has been associated with hypertension.[35] Liquorice consumption combined with antihypertensive or anticoagulant therapy has been documented to produce hypokalemia through mineralocorticoid-like effects, potentially precipitating cardiac arrhythmias. Furthermore, while individual herbal remedies generally demonstrate acceptable safety profiles when used as monotherapy, limited data exist regarding safety of concurrent use of multiple herbal preparations, and potential for cumulative effects warrants caution in polypharmacy settings.

5. Clinical applications and integration into treatment protocols

Integration of herbal remedies into conventional cardiovascular disease management requires careful consideration of available clinical evidence, patient-specific factors, and potential for drug interactions with existing pharmacotherapy.[37] For primary prevention of cardiovascular disease in asymptomatic individuals with risk factors, herbal remedies with robust clinical evidence and favorable safety profiles may be considered as adjunctive components of comprehensive cardiovascular risk reduction strategies that include lifestyle modification, dietary intervention, and appropriate





WISELEAF SCIENTIFIC VENTURES

pharmacotherapy.[38] Specifically, garlic, hawthorn, Terminalia arjuna, and berberine demonstrate sufficient clinical evidence to support consideration for adjunctive use in patients with mild-to-moderate hypertension or dyslipidemia. For established cardiovascular disease including chronic heart failure, hawthorn and Terminalia arjuna demonstrate utility as adjunctive therapies to improve functional capacity and reduce symptoms, though they should not be considered as replacements for guideline-directed medical therapy including ACE inhibitors, beta-blockers, and aldosterone antagonists.[39] For secondary prevention following myocardial infarction, herbal remedies with antioxidant and anti-inflammatory properties may offer complementary benefits when combined with conventional therapies.[40] All patients considering herbal remedy use should undergo comprehensive assessment by healthcare providers to identify potential drug-herb interactions, evaluate contraindications, and ensure that herbal preparations do not delay or substitute for evidence-based conventional medical therapy.

6. Conclusion

Cardiovascular disease remains a leading cause of global morbidity and mortality, necessitating comprehensive therapeutic approaches that address underlying pathophysiology involving oxidative stress, chronic inflammation, and endothelial dysfunction. Herbal remedies represent a diverse pharmacological resource containing bioactive compounds with demonstrated antioxidant, anti-inflammatory, vasodilatory, and cardioprotective properties that operate through multiple molecular mechanisms. Among the most extensively studied herbal remedies, garlic, hawthorn, turmeric/curcumin, ginseng, green tea, flaxseed, Terminalia arjuna, and berberine demonstrate varying degrees of clinical evidence supporting their cardiovascular benefits across multiple disease states including hypertension, dyslipidemia, atherosclerosis, chronic heart failure, and peripheral vascular disease. The mechanisms through which herbal remedies exert cardioprotection involve reduction of oxidative stress through free radical scavenging and enhancement of endogenous antioxidant defense systems, suppression of chronic inflammation through NF- κ B pathway inhibition, modulation of lipid metabolism, enhancement of endothelial function, and direct myocardial protective effects against ischemia-reperfusion injury. However, integration of herbal remedies into clinical practice must be tempered by recognition of variable quality of clinical evidence across different herbal preparations, potential for herb-drug interactions, and the absolute necessity of ensuring that herbal preparations complement rather than replace guideline-directed conventional medical therapy. Future research should prioritize conduct of large-scale, rigorously designed randomized controlled trials examining specific herbal preparations with standardized





WISELEAF SCIENTIFIC VENTURES

bioactive compound quantification in well-defined patient populations to establish optimal dosing regimens and definitively establish clinical efficacy and safety profiles. Through continued rigorous scientific investigation and careful clinical application, herbal remedies hold promise for contributing meaningfully to cardiovascular disease prevention and management when appropriately integrated into comprehensive therapeutic protocols alongside evidence-based conventional medical therapy.

REFERENCES

1. Roth GA, Mensah GA, Johnson CO, et al. Global burden of cardiovascular diseases and risk factors, 1990-2019: update from the GBD 2019 Study. *J Am Coll Cardiol.* 2020;76(25):2982-3021.
2. GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet.* 2020;396(10258):1204-1222.
3. Mozaffarian D, Benjamin EJ, Go AS, et al. Heart disease and stroke statistics—2015 update: a report from the American Heart Association. *Circulation.* 2015;131(4):e29-e322.
4. Mensah GA, Roth GA, Fuster V. The global burden of cardiovascular diseases and risk factors. *J Am Coll Cardiol.* 2019;74(20):2529-2532.
5. Ohara Y, Peterson TE, Harrison DG. Hypercholesterolemia increases endothelial superoxide anion production. *J Clin Invest.* 1993;91(6):2546-2551.
6. Förstermann U, Munzel T. Endothelial nitric oxide synthase in vascular disease: from marvel to menace. *Circulation.* 2006;113(13):1708-1714.
7. Steven S, Frenis K, Oelze M, et al. Vascular inflammation and oxidative stress: major triggers for cardiovascular disease. *Oxid Med Cell Longev.* 2019;2019:7092151.
8. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. *Circulation.* 2002;105(9):1135-1143.
9. Pashkow FJ. Oxidative stress and inflammation in heart disease: do antioxidants have a role in treatment and/or prevention? *Int J Inflam.* 2011;2011:514623.
10. Hansson GK, Hermansson A. The immune system in atherosclerosis. *Nat Immunol.* 2011;12(3):204-212.
11. Rajasekaran A, Sivagnanam K, Xavier R. Beneficial effects of Terminalia arjuna bark extract on oxidative stress-induced myocardial damage. *Mol Cell Biochem.* 2003;244(1-2):75-83.
12. Scalbert A, Williamson G. Dietary intake and bioavailability of polyphenols. *J Nutr.* 2000;130(8):2073S-2085S.





WISELEAF SCIENTIFIC VENTURES

13. Robards K, Antolovich M. Analytical chemistry of fruit bioflavonoids: a review. *Analyst*. 1997;122(2):11-34.
14. Goldstein JL, Brown MS. Regulation of the mevalonate pathway. *Nature*. 1990;343(6257):425-430.
15. Steinberg D. Atherogenesis in perspective: hypercholesterolemia and inflammation as partners in crime. *Nat Med*. 2002;8(11):1211-1217.
16. Endemann DH, Schiffrin EL. Endothelial dysfunction. *J Am Soc Nephrol*. 2004;15(8):1983-1992.
17. Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and dysfunction. *Circulation*. 2007;115(10):1285-1295.
18. Rahman K. Effects of garlic on platelet biochemistry and physiology. *Mol Nutr Food Res*. 2007;51(11):1335-1344.
19. Banerjee SK, Maulik SK. Effect of garlic on cardiovascular disorders: a review. *Nutr J*. 2002;1(1):4.
20. Ried K, Travica N, Sali A. The effect of aged garlic extract on blood pressure and other cardiovascular risk factors in uncontrolled hypertensives: the AGE at Heart trial. *Integr Blood Press Control*. 2016;9:9-21.
21. Pittler MH, Guo R, Wenisch E. Hawthorn for heart failure. *Cochrane Database Syst Rev*. 2008;(1):CD000961.
22. Zick SM, Gillespie B, Iaccarino D. Hawthorn Extract Randomized Blinded Chronic Heart Failure (HERB CHF) trial. *JACC Heart Fail*. 2009;52(16):1315-1323.
23. Yang C, Zhu Q, Chen Y, et al. Review of the protective mechanism of curcumin on cardiovascular disease. *Drug Des Devel Ther*. 2024;18:165-192.
24. Lee HW, Choi J, Sohn S, et al. Ginseng for treating hypertension: a systematic review and meta-analysis of randomized controlled trials. *J Ginseng Res*. 2017;41(3):299-309.
25. Wolfram S. Effects of green tea and EGCG on cardiovascular and metabolic health. *J Am Coll Nutr*. 2007;26(4):373S-388S.
26. Wei XY, Wang YY, Zhang Y, et al. Cardioprotective effect of epigallocatechin gallate in myocardial ischemiareperfusion injury: a systematic review and meta-analysis. *Sci Rep*. 2023;13(1):13599.
27. Goyal A, Sharma V, Upadhyay N, et al. Flaxseed: a wonder supplement for health. *Nutr Metab (Lond)*. 2014;11:46.
28. Cicero AF, Valagussa L, Aldasoro M, et al. Cardiovascular and metabolic effects of *Linum usitatissimum* (flaxseed) components: an evidence-based review. *Nutrients*. 2020;9(2):158.





WISELEAF SCIENTIFIC VENTURES

29. Barceló-Coblijn G, Murphy EJ. Alpha-linolenic acid and its conversion to longer chain n-3 fatty acids: benefits for human health and a role in maintaining tissue n-3 fatty acid levels. *Prog Lipid Res.* 2009;48(6):355-374.
30. Caligiuri SP, Aukema HM, Ravandi A, et al. Flaxseed consumption reduces cardiovascular disease markers in type 2 diabetic patients. *Nutr Res.* 2014;34(10):868-876.
31. Rajasekaran A, Ramchandra SV, Gopal SV, et al. Cardioprotective effect of Terminalia arjuna bark extract on isoproterenol-induced myocardial injury in rats. *J Ethnopharmacol.* 2004;94(1):67-74.
32. Dwivedi S, Chopra D. Revisiting Terminalia arjuna – an ancient cardiovascular drug. *J Ethnopharmacol.* 2014;144(3):424-441.
33. Kong W, Wei J, Abidi P, et al. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. *Nat Med.* 2004;10(12):1344-1351.
34. Frishman WH, Cheng A, Nawarskas JJ. Herbal medications for cardiovascular disease prevention and treatment. *Cardiol Rev.* 2009;17(4):169-177.
35. Bachheti RK, Rai P, Bachheti A, et al. Prevention and treatment of cardiovascular diseases with medicinal plants. *Pharmaceutics.* 2022;14(7):1347.
36. Hu Z, Yang X, Ho PC, et al. Herb-drug interactions: a literature review. *Drugs.* 2005;65(9):1239-1282.
37. Rowin J, Lewis SL. Spontaneous bilateral subdural hematomas associated with chronic Ginkgo biloba ingestion. *Neurology.* 1996;46(6):1485-1486.
38. Korbecki J, Bajdak-Rusinek K. The effect of ginkgo biloba on the cardiovascular system. *Phytomedicine.* 2019;56:15- 31.
39. Shaito A, Vaya J, Posadino AM. Herbal medicine for cardiovascular diseases: efficacy, mechanisms, and drug interactions. *Front Pharmacol.* 2020;11:422.
40. Newman DJ, Cragg GM. Natural products as sources of new drugs over the last 25 years. *J Nat Prod.* 2016;79(3):629-661.





WISELEAF SCIENTIFIC VENTURES

HEALING ROOTS: INTEGRATIVE HERBAL APPROACHES TO CHRONIC ILLNESS

CHAPTER 4- RESPIRATORY DISEASES AND HERBAL SUPPORT

Anchal Goel*, Manvi Jha, Punit Kumar Mishra, Nilesh Sharma

Sanskar College of Pharmacy and Research, Ghaziabad, 201302, Uttar Pradesh, India

Email: aanchalgoel001@gmail.com

ABSTRACT

Respiratory diseases represent a substantial global health burden, encompassing conditions such as asthma, chronic obstructive pulmonary disease, bronchitis, and infectious respiratory complications. Contemporary pharmaceutical interventions, while therapeutically valuable, often present adverse effects and variable efficacy across patient populations. This chapter examines the therapeutic potential of medicinal plants and their bioactive constituents as complementary and supportive modalities for respiratory health management. We explore the pathophysiological mechanisms underlying common respiratory disorders, emphasizing the role of inflammatory cascades, oxidative stress, and immune dysregulation. The narrative integrates ethnopharmacological evidence with contemporary scientific validation, highlighting botanicals including *Ocimum sanctum*, *Justicia adhatoda*, *Piper longum*, and *Glycyrrhiza glabra*. These plants demonstrate multifaceted pharmacological actions encompassing anti-inflammatory, antioxidant, bronchodilatory, mucolytic, and immunomodulatory properties. We elucidate the molecular mechanisms through which herbal compounds modulate key signaling pathways—including NF- κ B, MAPK, and Nrf2 pathways—relevant to respiratory pathology. Clinical and preclinical investigations demonstrate significant improvements in lung function parameters, respiratory symptom resolution, and enhanced quality of life markers with minimal adverse events. The chapter synthesizes current evidence regarding herbal formulation strategies, bioavailability considerations, and safety profiles. Finally, we discuss integration of evidence-based herbal approaches within contemporary respiratory medicine frameworks, emphasizing the importance of rigorous clinical research to establish optimal therapeutic protocols and dosing regimens for diverse respiratory conditions.

Keywords: Herbs; Medicine; Respiratory; Disorders.





WISELEAF SCIENTIFIC VENTURES

1. Introduction

1.1 Respiratory System Overview and Importance

The respiratory system facilitates vital gas exchange between the external environment and bloodstream through a coordinated network of anatomical structures including nasal cavities, pharynx, trachea, bronchi, bronchioles, and lungs. The lungs contain approximately 300 million alveoli, enabling efficient oxygen diffusion into capillaries for arterial circulation while simultaneously facilitating carbon dioxide removal from blood. The diaphragm and intercostal muscles, innervated by the phrenic nerve (C3-C5), coordinate with upper airway structures to regulate respiratory mechanics and ventilation.[1] Respiratory health encompasses more than isolated pulmonary function, closely linking with cardiovascular and immune system function, any disturbances in respiratory health directly compromise cardiac function and increase infection risk through compromised innate defense mechanisms including nasal filtration, mucociliary clearance, and specialized immune cell populations.[1]

1.2 Common Respiratory Disorders

Respiratory diseases encompass a broad spectrum of conditions affecting airways, lungs, and respiratory muscles, with major disorders including asthma, COPD, pneumonia, pulmonary fibrosis, bronchitis, and bronchiectasis.[2-4] Asthma is characterized by reversible airway obstruction, bronchial hyperresponsiveness, and airway inflammation involving IgE-mediated mast cell degranulation, eosinophil infiltration, and Th2 lymphocyte activation, producing characteristic airway narrowing and mucus hypersecretion.[2,3] COPD represents an irreversible airflow limitation resulting from emphysematous alveolar destruction and chronic small airways disease, with inflammation and oxidative stress as central pathogenic mechanisms.[2,4] Pneumonia results from bacterial or viral invasion of lower respiratory tract, triggering inflammatory responses that manifest as consolidation, fever, and respiratory compromise.[3,4] These conditions collectively pose severe global health burdens due to widespread prevalence and substantial morbidity and mortality rates, particularly affecting vulnerable populations including children and elderly individuals.[2-4]





WISELEAF SCIENTIFIC VENTURES

1.3 Role of Herbal Medicine in Respiratory Care

Traditional medicine systems have developed sophisticated frameworks for respiratory health management utilizing medicinal plants accumulated through centuries of empirical clinical observation.[1] Contemporary research validates many traditional approaches through identification of bioactive phytochemical constituents and their molecular mechanisms of action. Medicinal plants including *Ocimum sanctum* (holy basil), *Justicia adhatoda* (vasaka), *Piper longum* (long pepper), *Glycyrrhiza glabra* (licorice), and *Andrographis paniculata* (kalmegh) contain phytochemical compounds such as polyphenols, ligustrazine, salidroside, resveratrol, and quercetin that offer therapeutic potential for pulmonary diseases through anti-inflammatory, antioxidant, bronchodilatory, mucolytic, and immunomodulatory mechanisms.[1,5,67] These herbal approaches often present favorable adverse effect profiles compared to conventional pharmaceuticals, supporting integration of evidence-based herbal medicine within comprehensive respiratory disease management frameworks.[1,8]

2. Pathophysiology of Major Respiratory Diseases

2.1 Asthma: Inflammatory Mechanisms

Asthma pathophysiology involves complex immunological mechanisms encompassing two distinct airway response phases. The immediate early-phase response involves IgE-mediated mast cell and basophil degranulation releasing histamine, prostaglandins, and leukotrienes, causing rapid bronchoconstriction and acute symptom onset within minutes of allergen exposure. The late-phase response develops over subsequent hours through orchestrated recruitment of eosinophils, basophils, neutrophils, and helper T cells, with T helper 2 (Th2) lymphocytes producing interleukins (IL-4, IL-5, IL-13) sustaining inflammation and promoting airway remodeling through smooth muscle hyperplasia and collagen deposition by myofibroblasts.[2,3]

Airway hyperresponsiveness, a hallmark asthma feature, results from increased histamine availability from activated mast cells, increased airway smooth muscle mass, enhanced vagal tone, and increased intracellular free calcium amplifying smooth muscle contractility. Chronic inflammation and repeated bronchoconstriction produce irreversible structural airway changes termed airway remodeling, characterized by epithelial-mesenchymal transition, epithelial cell





WISELEAF SCIENTIFIC VENTURES

adhesion loss, basement membrane thickening, and increased collagen deposition, ultimately contributing to progressive lung function decline and potential asthma-COPD overlap development.[2,3]

2.2 COPD: Fibrotic and Inflammatory Processes

COPD represents a progressive disease characterized by chronic, incompletely reversible airflow limitation resulting from small airways disease and emphysematous alveolar tissue breakdown. The disease develops through significant chronic inflammatory responses to inhaled irritants, producing bronchial and alveolar remodeling termed small airways disease with progressive airway narrowing and air trapping. Neutrophils and macrophages predominate in COPD inflammatory infiltrates, with smokers demonstrating additional cytotoxic T cell involvement, while some patients exhibit eosinophil involvement similar to asthma.

The protease-antiprotease imbalance represents a critical COPD pathogenic mechanism wherein oxidative stress produced by free radicals from tobacco smoke combines with inadequately inhibited proteases (particularly neutrophil elastase) causing lung connective tissue breakdown and emphysema development. General muscle wasting commonly occurring in COPD reflects systemic inflammatory mediator release from lungs into circulation, contributing to extrapulmonary complications and increased mortality risk independent of pulmonary function parameters.[2,4]

2.3 Infectious Respiratory Diseases

Bacterial pneumonia develops when bacterial invasion and propagation at the alveolar level exceeds host defense capacity, with body inflammatory responses against bacterial invasion producing clinical pneumonia manifestations. Host defenses include mechanical barriers (nasal hair, mucus), chemical defenses (surfactant proteins A and D), and innate immune activation through toll-like receptor recognition, with alveolar macrophages engulfing and eliminating bacteria through phagocytosis and cytokine release. Pathogenic bacteria possess virulence factors facilitating immune evasion, including polysaccharide capsules, adhesion proteins, and biofilm-forming pili, while host inflammatory responses represent primary drivers of clinical manifestations including fever from interleukin-1 and TNF- α release.[3,4]

Viral respiratory infections typically multiply in upper airway epithelium, secondarily infecting lungs through airway secretions or hematogenous spread, with tissue damage mechanisms varying by viral species, some viruses being primarily cytopathic affecting pneumocytes,





WISELEAF SCIENTIFIC VENTURES

while others involve overexuberant immune responses as primary pathogenic mechanisms.[4,9]

3. Herbal Medicines with Demonstrated Respiratory Therapeutic Potential

3.1 *Ocimum sanctum* (Holy Basil/Tulsi): Immunomodulation and Anti-inflammation

Ocimum sanctum represents one of the most extensively studied medicinal plants for respiratory applications, with comprehensive research demonstrating that oral administration in ovalbumin-induced mouse asthma models suppresses Th2 cytokine gene expression (IL-4, IL-5, IL-13), decreases goblet cell hyperplasia and mucus hypersecretion, while increasing Th1 cytokine expression essential for allergic asthma management.[5,10,11] Bioactive constituents including linalool, eugenol, rosmarinic acid, and terpenoids suppress lung inflammation through NF- κ B and MAPK pathway inhibition.[5,10] Clinical trials treating asthmatic patients with 500 mg holy basil three times daily for one month resulted in improved breathing function and reduced asthma attack frequency.[11] The antiviral and immunomodulatory properties mediated through flavonoids demonstrate inhibitory effects against influenza A, herpes simplex viruses, and respiratory syncytial virus.[12,13]

3.2 *Justicia adhatoda* (Vasaka): Mucolytic and Expectorant Properties

Justicia adhatoda demonstrates significant clinical efficacy through potent mucolytic, expectorant, and anti-inflammatory properties.[6, 14] Clinical observational data spanning five years demonstrated that patients with cough, bronchitis, asthma, and violent cough prescribed various *Justicia adhatoda* dilutions showed high recovery rates, with improvement occurring within one to seven days in severe cases, and complete cure achieved in 45% of all age groups.[6] Multiple randomized controlled trials established bromhexine clinical efficacy (the active alkaloid from *Justicia adhatoda*), with a double-blind trial of 242 patients receiving either bromhexine 5 mg three times daily or placebo demonstrating that frequent cough was significantly less prevalent in active treatment (8.6%, $p < 0.02$) versus placebo (15.2%).[14] A cross-sectional double-blind study of 48 chronic respiratory patients receiving bromhexine 8 mg three times daily showed significantly higher clinical improvement with increased expectoration ($p < 0.05$), improved auscultatory findings ($p < 0.004$), and improved peak expiratory flow rate ($p < 0.02$).[14]





WISELEAF SCIENTIFIC VENTURES

3.3 *Piper longum* (Long Pepper):

Piper longum contains bioactive amide piperlongumine (PL) demonstrating potent anti-inflammatory and anti-asthmatic properties through sophisticated molecular mechanisms. Ovalbumin-induced mouse asthma models showed that piperlongumine pretreatment reduced airway inflammatory cell infiltration, Th2 cytokine expression (IL-4, IL-5, IL-13) in bronchoalveolar lavage fluid and lung tissues, serum IgE levels, pro-inflammatory cytokines (TNF- α , IL-6), and intercellular adhesion molecule expression, while reducing NF- κ B activation. Piperlongumine mitigated OVA-induced goblet cell metaplasia, inhibited mucus protein secretion, reduced airway fibrosis, and downregulated fibrosis marker expression.[7] The anti-inflammatory mechanism involves direct NF- κ B pathway inhibition, with in vitro studies demonstrating PL inhibition of TNF- α -induced inflammatory cytokine expression and NF- κ B activation in bronchial epithelial cells through direct p65 subunit nuclear translocation inhibition and κ B DNA-binding activity reduction.[7,15]

3.4 *Glycyrrhiza glabra* (Licorice): Immunomodulatory Effects

Glycyrrhiza glabra has been widely used for bronchial asthma and respiratory conditions for many years, with major active constituent glycyrrhizin accounting for anti-inflammatory, antiallergic, and antiviral activities through a corticosteroid-like mechanism mimicking cortisol through 11 β -hydroxysteroid dehydrogenase inhibition. In chronic asthma mouse models, glycyrrhizin administration alleviated established long-term histopathologic changes including basement membrane and epithelium thickness reduction, smooth muscle layer thinning, and decreased goblet and mast cell numbers.[8] Glycyrrhizin significantly reduced OVA-induced airway constriction, airway hyperreactivity to methacholine, and lung inflammation including eosinophil infiltration through multiple mechanisms including reduced OVA-specific IgE and Th2 cytokine (IL-4, IL-5) levels while preventing TH1 cytokine and interferon- γ decreases, thereby modulating the TH1/TH2 paradigm.[8,16] Glycyrrhizin inhibited E-selectin, L-selectin, and P-selectin-mediated eosinophil and neutrophil adhesion, eotaxin-1 production via STAT6 in lung fibroblasts, and NF- κ B activity with IL-8 expression reduction in lung epithelial cells.

3.5 *Andrographis paniculata* (Kalmegh): Anti-inflammatory and Antimicrobial

Andrographis paniculata (kalmegh) has long been used for upper respiratory tract infection prevention and treatment in Asian countries and Scandinavia, with andrographolide as the principal bioactive component demonstrating potent anti-inflammatory properties through NF- κ B inhibition.[17,18] In OVA-sensitized and challenged BALB/c mice, andrographolide





WISELEAF SCIENTIFIC VENTURES

dose-dependently inhibited OVA-induced increases in total cell count, eosinophil count, and IL-4, IL-5, IL-13 levels in bronchoalveolar lavage fluid, while reducing serum OVA-specific IgE.[17] The compound attenuated OVA-induced lung tissue eosinophilia, airway mucus production, reduced E-selectin, chitinase, Muc5ac, and inducible nitric oxide synthase mRNA expression, and attenuated airway hyperresponsiveness to methacholine.[17] In normal human bronchial epithelial cells, andrographolide blocked TNF- α -induced phosphorylation of inhibitory $\text{I}\kappa\text{B}$ kinase- β and downstream $\text{I}\kappa\text{B}\alpha$ degradation, p65 NF- κB phosphorylation, p65 nuclear translocation and DNA-binding activity, directly modulating the critical NF- κB regulatory node.[17,18]

4. Mechanisms of Action of Herbal Compounds

4.1 NF- κB and MAPK Signaling Pathway Modulation

Persistent NF- κB activation associates with asthma and inflammatory airway disease development, with the pathway operating through $\text{I}\kappa\text{B}$ kinase complex activation causing $\text{I}\kappa\text{B}\alpha$ phosphorylation and degradation, enabling NF- κB p65 nuclear translocation and $\text{I}\kappa\text{B}$ DNA-binding with pro-inflammatory gene transcription. Multiple herbal compounds including andrographolide and piperlongumine effectively suppress NF- κB activation through direct IKK β inhibition, preventing downstream phosphorylation and nuclear p65 translocation, thereby reducing pro-inflammatory gene transcription.[7,15,17]

Mitogen-activated protein kinases (ERK1/2, p38, JNK1/2) play critical roles in inflammatory cell activation and downstream signaling, with many herbal medicines improving allergic asthma through MAPK pathway regulation, demonstrating inhibitory properties through multiple herbal sources including *Scutellaria baicalensis*, *Panax ginseng*, and *Artemisia annua*.[17,19]

4.2 Anti-inflammatory Cytokine Modulation and Th1/Th2 Rebalancing

Allergic asthma pathogenesis involves Th2 cytokine shift producing eosinophilic inflammation characteristic of disease, with Th2 cytokines (IL-4, IL-5, IL-13) explaining IgE overproduction, eosinophil presence, and airway hyperresponsiveness development.[2,3] Many herbal compounds modulate this dysregulated immune response through Th2 cytokine suppression and Th1 response enhancement, restoring natural balance between opposing immune cell subsets.[5,7,8] Glycyrrhizin significantly increases regulatory T cell (Treg) populations, crucial immune cells normally inhibiting Th2-mediated allergic responses through anti-inflammatory cytokine IL-10 and transforming growth factor- β production.[8,16]





WISELEAF SCIENTIFIC VENTURES

4.3 Mucolytic and Expectorant Activities

The expectorant mechanism differs across herbal drugs with secretolytic and secretomotoric effects representing important mechanisms, wherein saponins and essential oils trigger watery mucus secretion while reducing mucine production and altering mucine spectrum composition. Herbal preparations demonstrate mucolytic effects through multiple mechanisms including disulfide bond severance linking mucin oligomers, enhanced chloride secretion, and direct polymer hydrolysis. Herbal constituents target membrane channels and receptor systems including β_2 , β_1 adrenoreceptors producing bronchodilation, Taste 2 Receptor activation, and sodium, TRPA1, and chloride channel targeting promoting mucus clearance and airway patency.[19,20] A natural herbal combination containing *Echinacea purpurea*, *Sambucus nigra*, *Glycyrrhiza glabra*, *Vitex trifolia*, and *Zingiber officinale* demonstrated mucolytic activity equivalent to 0.1% N-acetylcysteine at 0.5% concentration with dose-dependent mucus viscosity reduction.[20]

4.4 Antimicrobial and Immunomodulatory Properties

Beyond anti-inflammatory effects, many herbal medicines demonstrate direct antimicrobial properties through bacterial cell membrane disruption, cellular content leakage, and virulence factor inhibition.[18,21] Phytochemicals inhibit multidrug efflux systems of microbes, particularly significant in antimicrobial resistance contexts, with piperine inhibiting *Mycobacterium tuberculosis* putative multidrug efflux pump (Rv1258c) and berberine interrupting bacterial colonization through amyloid protein binding and lipopolysaccharide-TLR4/MD-2 binding competition, inhibiting infection-associated inflammation. Herbal medicines demonstrate immunomodulatory activities through enhanced antiviral interferon responses and natural killer cell upregulation, particularly in viral respiratory infections. Tulsi antiviral properties mediated through flavonoids (orientin, vicenin, eugenol, rosmarinic acid, luteolin) produce inhibitory effects against influenza A, herpes simplex viruses, adenoviruses, coxsackieviruses, and enteroviruses.[12,13]

5. Safety, Drug Interactions, and Quality Control

5.1 Herb-Drug Interactions and Considerations

Herb-drug interactions raise public health safety concerns requiring careful clinical assessment, with certain herbs modulating co-administered drug pharmacokinetics through multiple mechanisms. Pharmacokinetic herb-drug interactions involve cytochrome P450 enzyme





WISELEAF SCIENTIFIC VENTURES

induction or inhibition, with less than 40% of patients notifying physicians of herbal supplement use, though studies of elderly patients found 538 of 1,000 exposed to 1,087 potential interactions with 30 experiencing adverse effects. Specific herb-drug combinations warrant clinical attention including increased warfarin bleeding risk with ginkgo, garlic, dong quai, or danshen; potential serotonin syndrome with serotonin-reuptake inhibitors and St. John's wort; decreased digoxin and theophylline bioavailability with St. John's wort; mania risk in depressed patients combining antidepressants with Panax ginseng; and increased corticosteroid potency with licorice. [22,23]

5.2 Standardization and Quality Control

Primary challenges in herbal medicine include lack of standardized manufacturing processes and quality control measures, with variability in plant species, growing conditions, harvesting methods, and extraction techniques resulting in composition and potency inconsistencies. Establishing standardized cultivation, harvesting, processing, and formulation protocols is crucial for ensuring quality, safety, and efficacy. The World Health Organization provides comprehensive frameworks ensuring safety, efficacy, and quality through all herbal product lifecycle stages, with adherence crucial for minimizing contamination, adulteration, and potency variability risks. Quality control requires raw material identification through botanical examination, morphological and microscopic analysis, and chemical fingerprinting for species identity confirmation and adulteration detection. Standardization involves establishing specific quality parameters ensuring consistent active constituent levels through HPLC, GC, MS, and biological assays determining potency and efficacy. Good manufacturing practices compliance ensures consistency, purity, and potency through facility design, equipment calibration, personnel training, process validation, and quality assurance procedures.[24,25]

6. Clinical Evidence and Efficacy

6.1 Meta-Analytic Evidence

A comprehensive systematic review and meta-analysis of herbal medicines as asthma add-on therapy identified 23 studies with 9 randomized controlled trials in final analysis, revealing that herbal medicine use significantly improved percent predicted FEV₁ (forced expiratory volume in one second) with weighted mean difference of 3.73 (95% CI 1.76-5.70), with no significant heterogeneity ($p=0.56$, $I^2=0.0\%$). [8,26] Subgroup analysis showed substantially higher improvement in adults (WMD 5.16; 95% CI 2.68-7.63) compared to children (WMD=1.27; 95% CI 1.98-4.51). [8][26] A separate meta-analysis evaluating traditional Chinese medicine herbal formulas combined with western pharmacotherapy for COPD with





WISELEAF SCIENTIFIC VENTURES

pulmonary hypertension reviewed 20 randomized control trials with 1,865 patients, revealing TCM herbal formulas significantly reduced pulmonary artery systolic pressure (MD=-4.50 mmHg, 95% CI: -6.04, -2.95) and mean pulmonary artery pressure (MD=-4.47 mmHg, 95% CI: -5.07, -3.88), with improved pulmonary ventilation function and 6-minute walk distance (MD=48.13 m, 95% CI: 39.92, 56.34).[27]

6.2 Clinical Evidence in Respiratory Infections

A randomized double-blind trial examining herbal preparation effects on upper respiratory tract infection symptoms compared to placebo demonstrated significant symptom decrease 20 minutes post-administration ($P=.019$), with sub-population analysis of severe symptom patients (46 participants) showing even more significant treatment-placebo difference ($P=.009$).[28] Herbal spray preparation rapid symptomatic improvement could be explained by anti-inflammatory and analgesic effects, with eucalyptus and mint oil possessing these effects, while menthol and camphor antitussive and carvacrol bronchodilating effects potentially explaining observed rapid relief.[28]

6.3 Evidence for Herbal Adjuvant Therapy

A comprehensive review of hepatoprotective plants for anti-TB drug-induced hepatotoxicity management demonstrated traditionally used medicinal plants serving as phytochemical and secondary metabolite sources capable of restoring hepatic cell function, enzymatic activity, and structure against anti-TB drug hepatotoxicity.[18,21] Medicinal plants demonstrating efficacy in preliminary studies included *Acalypha indica*, *Adhatoda vasica*, *Allium sativum*, *Andrographis paniculata*, and *Cassia sophera*, showing significant antimycobacterial activity against multidrug-resistant TB in vitro.[18] A clinical study evaluating adjunct Ayurvedic therapy with *Ashwagandha* for pulmonary tuberculosis in anti-TB drug recipients demonstrated that *Ashwagandha* modulates immune system function, restores normal serum transaminase levels (SGPT and SGOT), and increases pyrazinamide and isoniazid bioavailability within 28 days.

7. Conclusion

The convergence of ethnopharmacological evidence, traditional medical systems, and contemporary scientific research demonstrates that medicinal plants and their bioactive phytochemical constituents offer genuine therapeutic potential as complementary modalities for respiratory diseases encompassing diverse pathophysiological mechanisms. Herbal medicines including *Ocimum sanctum*, *Justicia adhatoda*, *Piper longum*, *Glycyrrhiza glabra*,





WISELEAF SCIENTIFIC VENTURES

and *Andrographis paniculata* demonstrate multifaceted pharmacological actions encompassing potent anti-inflammatory, antioxidant, bronchodilatory, mucolytic, and immunomodulatory properties mediated through sophisticated molecular mechanisms including NF- κ B and MAPK pathway inhibition, Th1/Th2 cytokine modulation, and regulatory T cell enhancement. Meta-analytic evidence indicates complementary herbal medicine use results in significant lung function and respiratory parameter improvements in asthmatic patients with favorable adverse event profiles compared to standard pharmacotherapy alone. Clinical investigations demonstrate significant improvements in lung function parameters, respiratory symptom resolution, and enhanced quality of life markers with minimal adverse events in patients receiving appropriately selected and standardized herbal preparations. Integration of evidence-based herbal approaches within contemporary respiratory medicine frameworks represents rational therapeutic strategy, emphasizing rigorous clinical research establishing optimal therapeutic protocols and dosing regimens specific to diverse respiratory conditions and patient populations. Adherence to WHO quality control guidelines, standardized manufacturing processes, pharmacologically validated dosing regimens, and comprehensive herb-drug interaction assessment are essential for maximizing efficacy while minimizing safety risks associated with herbal respiratory therapeutics.

REFERENCES

1. Standing S. *Gray's Anatomy: The Anatomical Basis of Clinical Practice*. 41st ed. Edinburgh: Elsevier; 2020.
2. Sinyor B, Banerjee A, Salter M. Pathophysiology of asthma. In: *StatPearls*. Treasure Island (FL): StatPearls Publishing; 2024.
3. Lee KH, Teh JKL, Lim FSS, et al. The role of respiratory viruses in the etiology of bacterial pneumonia. *J Infect*. 2016;73(1):1-14.
4. Sattar SBA, Sharma S. Bacterial Pneumonia. In: *StatPearls*. Treasure Island (FL): StatPearls Publishing; 2024.
5. Aminian AR, Fakhri S, Khan H. The effect of *Ocimum basilicum* L. and its main ingredients on obstructive airway diseases. *Phytomedicine*. 2022;96:153884.





WISELEAF SCIENTIFIC VENTURES

6. Mandal S, Mandal TK, Rath J. Investigation of therapeutically active constituents of *Justicia adhatoda*. *J Pharmacogn Phytochem*. 2019;8(3):2277-2282.
7. Lu C, Zhang X, Ning Z, et al. Piperlongumine reduces ovalbumin-induced asthma and airway inflammation in mice through NF- κ B inhibition. *Int Immunol*. 2019;31(8):503-514.
8. Hocaoglu AB, Karakaya G, Kalyoncu AF, et al. Glycyrrhizin and long-term histopathologic changes in a murine model of chronic asthma. *Ann Allergy Asthma Immunol*. 2011;106(3):199-206.
9. Medscape. Viral Pneumonia: Practice Essentials, Background. 2024. Available at: <https://emedicine.medscape.com/article/300455-overview>.
10. Jamshidi N, Cohen MM. The clinical efficacy and safety of tulsi in humans: A systematic review of the literature. *Evid Based Complement Alternat Med*. 2017;2017:9217567.
11. PeaceHealth. Holy Basil ,Äi Health Information Library. 2024. Available at: <https://www.peacehealth.org/medical-topics/id/hn-4597000>.
12. Azam MS, Srivastava RK, Atkinson TP. Antiviral foods in the battle against viral infections. *Nutrients*. 2023;12(5):1308.
13. Omrani M, Rezvani N, Rahbar E, et al. Potential natural products against respiratory viruses including SARS-CoV-2. *Front Pharmacol*. 2021;11:586993.
14. Zanasi A, Mazzolini M, Tursi F, et al. A reappraisal of the mucoactive activity and clinical efficacy of bromhexine. *Multidiscip Respir Med*. 2017;12:11.
15. Kumari M, Singh P, Prabhu K. Anti-inflammatory activity of two varieties of Pippali (*Piper longum* Linn.). *Indian J Pharmacol*. 2012;44(5):587-591.
16. Fouladi S, Masjedi M, Hakemi MG, Eskandari N. The review of in vitro and in vivo studies over the glycyrrhizic acid as natural remedy option for treatment of allergic asthma. *Iran J Allergy Asthma Immunol*. 2019;18(1):1-11.





WISELEAF SCIENTIFIC VENTURES

17. Pourova J, Macakova K, Mladenka P, Krejcik Z. Proposed mechanisms of action of herbal drugs and their active constituents on expectorant effects in cough and mucus production regulation. *Phytomedicine*. 2023;113:154707.
18. Mangwani N, Srivastava KL, Chakraborti P, et al. Medicinal plants: Adjunct treatment to tuberculosis therapy. *J Ayurveda Integr Med*. 2019;10(2):81-88.
19. Liu F, Berlin CM, Henkel JS. Herbal medicines for asthmatic inflammation. *J Asthma Allergy*. 2016;9:113-125.
20. Wisastra R, Arifin PF. Ex vivo evaluation of the mucolytic effect from a natural herbal combination. *Res J Pharm Biol Chem Sci*. 2020;11(1):109-114.
21. Huang X, Wang Z, Zhang L, et al. Natural products in anti-tuberculosis host-directed therapy. *Biomed Pharmacother*. 2024;171:115957.
22. Brantley SJ, Oberlies NH, Kroll DJ, et al. Herb,Ädrug interactions: Challenges and opportunities for drug discovery and development. *Phytomedicine*. 2015;22(3):273-289.
23. Kroll DJ, Shaw HS, Combs GF. Herb-drug interactions: A critical review and clinical update. *Drugs*. 2014;74(18):1967-1981.
24. IJPCA. WHO guidelines for quality control of herbal medicines. *Int J Pharm Chem Anal*. 2024;11(3):212-225.
25. Wang H, Zhang T, Liu Y, et al. Advancing herbal medicine: Enhancing product quality and safety. *Front Pharmacol*. 2023;14:1231987.
26. Derakhshan A, Samadi F, Salami M, et al. Efficacy of herbal medicines on lung function in asthma: A systematic review and meta-analysis. *Phytother Res*. 2023;37(6):2342-2352.
27. Liang R, Wang Y, Liu S, et al. The efficacy and safety of herbal formulas for adults with chronic obstructive pulmonary disease and pulmonary hypertension: A meta-analysis. *Front Pharmacol*. 2024;15:1451923.





WISELEAF SCIENTIFIC VENTURES

28. Ben-Arye E, Levy R, Shuval J, et al. Treatment of upper respiratory tract infections in primary care: A randomized herbal intervention trial. *J Altern Complement Med.* 2011;17(1):23-30.
29. Physio-pedia. COPD (Chronic Obstructive Pulmonary Disease). 2024. Available at: <https://www.physio-pedia.com/COPD>.
30. Medscape. Asthma: Practice Essentials, Background, Anatomy. 2024. Available at: <https://emedicine.medscape.com/article/296301-overview>.
31. Wikipedia. Chronic Obstructive Pulmonary Disease. Available at: https://en.wikipedia.org/wiki/Chronic_obstructive_pulmonary_disease. Accessed 2024.
32. Medscape. Bronchiectasis: Background, Pathophysiology, Etiology. 2024. Available at: <https://emedicine.medscape.com/article/296961-overview>.
33. Deepayurveda. Pushkarmool in Ayurveda: Benefits, Uses & Safety. 2025. Available at: <https://deepayurveda.com/blog/news/pushkarmool/>. Accessed 2025.
34. Easyayurveda.com. Pushkarmool - Inula racemosa - Benefits, Usage, Dose, Side Effects. 2013. Available at: <https://www.easyayurveda.com/2013/09/18/pushkarmool-inula-racemosa-benefits-usage-dose-side-effects/>. Accessed 2024.
35. Balkrishna A, Sharma A, Bansal N, et al. Exploring the safety, efficacy, and bioactivity of herbal medicines for multiple cardio-metabolic disorders. *Front Integr Neurosci.* 2024;18:1323460.
36. Chen X, Liu Y, Zhang W, et al. Herbacetin inhibits asthma development by blocking the SGK1/NF- κ B pathway. *Front Immunol.* 2024;15:1429536.
37. Barnes PJ. Immunology of asthma and chronic obstructive pulmonary disease. *Nat Rev Immunol.* 2017;18(7):454-466.
38. Busse WW, Lemanske RF. Asthma. *N Engl J Med.* 2001;344(5):350-362.
39. Sin DD, Miravittles M. Chronic obstructive pulmonary disease: An update on definition, epidemiology and pathogenesis. *Curr Opin Pulm Med.* 2017;23(2):117-122





WISELEAF SCIENTIFIC VENTURES

HEALING ROOTS: INTEGRATIVE HERBAL APPROACHES TO CHRONIC ILLNESS

CHAPTER 5- HERBAL APPROACHES TO IMMUNE SYSTEM ENHANCEMENT

Manvi Jha*, Devashish Pal, Annu Yadav, Anchal Goel

Sanskar College Of Pharmacy and Research, Ghaziabad, 201302, Uttar Pradesh, India

Email: jha79497@gmail.com

ABSTRACT

The human immune system serves as the body's primary defense mechanism against infections, pathogens, and disease. In recent decades, rising rates of infectious diseases, autoimmune disorders, and inflammatory conditions have prompted widespread interest in natural immunity-boosting strategies. This review explores how medicinal herbs can strengthen and modulate immune function through multiple biological pathways. Key herbs including Ashwagandha, Tulsi, Turmeric, Amla, and Garlic contain bioactive compounds such as alkaloids, flavonoids, and terpenoids that work to enhance white blood cell production, reduce stress-induced immunosuppression, and provide powerful antioxidant protection. These plants function as immunomodulators by stimulating immune cells like macrophages and natural killer cells while simultaneously reducing harmful inflammation through cytokine regulation. Herbal formulations work synergistically with the body's detoxification systems, particularly by supporting gut health and maintaining intestinal barrier integrity—critical factors since approximately 70% of immune cells reside in gut-associated lymphoid tissue. Beyond traditional use, scientific research increasingly validates the effectiveness of these herbal approaches for managing stress, boosting immunity during health challenges, and promoting overall wellness. This comprehensive overview demonstrates how plant-based remedies offer practical, accessible, and evidence-supported methods for naturally enhancing immune responses and supporting long-term health.

Keywords: Herbal; Medicine; Immunity; Immune System; Herbs.





WISELEAF SCIENTIFIC VENTURES

1. Introduction

1.1 Overview of the immune system

The immune system's purpose is to protect the body from threats, whether they are foreign or harmful. These invaders encompass:

Microorganisms (like bacteria, viruses, and fungi—commonly known as germs)

Parasites (such as worms)

Malignant (cancerous) cells Grafted organs and tissues. [1]

The body has their its own barriers (the skin, intestinal tract, and respiratory tract) from pathogens (like bacteria, viruses, and fungi) using the immune system. This system incorporates many different types of immune cells, various chemical messengers (cytokines), and interconnected communication routes}. The host immune system is functionally split into two parts: the innate and adaptive immunity.

The adaptive immunity possesses immunological memory, which is absent in innate immunity. External influences, like environmental pollutants or harmful microbes (pathogens), continually impact and disrupt human homeostasis (the body's internal balance). The increase in infectious diseases, inflammatory conditions, allergies, cancers and autoimmune disorders in recent decades has caused widespread human sufferings. [2]

1.2 Importance of immunity in human health

The immune system acts as a defense mechanism, offering protection from invading infectious agents such as bacteria, viruses, or fungi.

1. Protection and Defense

The primary function is protection against pathogens. The system detects foreign antigens—including bacteria, viruses, fungi, and parasites—and initiates a precise defense mechanism to eradicate them and fight illness.

2. Discrimination

It possesses the unique ability to distinguish self from non-self. This allows it to attack foreign molecules but tolerate the body's own cells, which prevents destructive autoimmune reactions.

3. Maintenance and Repair

The immune system actively participates in maintaining the body's integrity. It handles the removal of damaged or dead cells to ensure tissue health and stability. Furthermore, its cells monitor for cancerous growths, performing tumour surveillance by identifying and eliminating malignant cells. Finally, it plays a critical role in wound healing by activating necessary inflammatory and cellular responses.

Function

The innate immune system represents the body's first and fastest defense against invasion. It is often called the "non-specific" immune system because it responds identically to all pathogens and foreign substances.





WISELEAF SCIENTIFIC VENTURES

Barriers: Skin and Mucous Membranes

The innate system includes every internal and external surface of the body. The skin and mucous membranes serve as crucial physical barriers, blocking germs from entering. These surfaces also provide chemical protection; substances like mucus, enzymes, and acid prevent bacteria and viruses from growing. Additionally, certain physical actions help flush out invaders, such as the waving action of cilia in the lungs or movements of the intestinal muscles. Other protective bodily fluids, like sweat, tears, and urine (which sanitizes the urinary tract), offer similar effects.

Cellular and Protein Defenses

If bacteria manage to breach the skin or mucous membranes, the innate immune system activates its second line of defense: specific immune system cells and proteins designed to seek and destroy the invaders. [3]

1.3 Factors Affecting Immune function

Factors that affects the immune functions are-

- 1- Stress: stress that goes on for a long time weakens your immune system. Stress releases a lot of the hormone cortisol, which slows down your body's defenses. You can protect your immune system by managing your stress. these are relaxing, exercising, and practicing mindfulness.
- 2- poor diet: A lack of important nutrients in your food makes your immune system weaker. Specifically, if you skip out on key vitamins such as C, D, and E, or important minerals like zinc and selenium, your body struggles to fight off illness. To ensure a healthy immune system, you need to eat a well-rounded diet that includes plenty of fruits, vegetables, lean meats, and whole grains.
- 3- Lack of sleep: Good sleep is essential for a healthy immune system. While you sleep, your body fixes and renews itself. When you don't get enough sleep, the number of immune cells drops, making you more likely to get sick. To keep your immune system strong, you must go to bed at a regular time and get enough rest.
- 4- Excessive alcohol consumption: Consuming large amounts of alcohol can damage your body's defenses. Too much alcohol negatively affects both the creation and the effectiveness of your immune cells. Regular, heavy drinking weakens your ability to fight infections. By controlling how much you drink and avoiding excess, you can maintain a stronger immune system.
- 5- Chronic medical condition: Long-term illnesses such as diabetes, obesity, and autoimmune diseases can weaken your immune system. These conditions often cause inflammation and make your immune system work incorrectly, which means you're more likely to get sick. To support your immune health, it's vital to manage these conditions well with a doctor's help.
- 6-Aging:As people get older, their immune system naturally changes and doesn't work as well. This age-related weakening, called





WISELEAF SCIENTIFIC VENTURES

immunosenescence, means older adults are more exposed to infections and diseases. However, living a healthy lifestyle can help lessen these effects. [4-6]

1.4 Growing interest in Herbal modulators

The use of natural plant-based treatments and health products is quickly growing globally. People in many countries are increasingly choosing these items to manage various health issues within their national health services (according to the WHO, 2004). As the worldwide use of herbal medicines keeps increasing and many new products appear, concerns about their safety and public health impact are also growing.

The demand for herbal medicines surged during the COVID-19 pandemic, a direct result of consumers prioritizing preventive healthcare and immunity-boosting. [7,8]

2. Historical prospective of Herbal immunity boosters

some drugs that affects the immune system in order to treat a disease or illness These drugs are referred to as immunomodulators.

Immunomodulators are used to cure for many different types of illnesses and diseases. These are followings like , a)Cancer b) An autoimmune disorders, including rheumatoid arthritis (RA) multiple sclerosis (MS) , including psoriatic arthritis c) inflammatory bowel diseases d) allergic conditions, asthma ,and eczema infections The process of chemical drug discovery is a long and complicated process. Recently, the use of medicinal plants has appropriately increased, specifically due to their having a more nutritional value. Plant extract , which are the sources of diverse secondary metabolites with perplex action on immune function that results in an immune stimulation.[9]

Historically, herbs were often understood to work by purifying the body, maintaining balance, or strengthening the body's vital essence. Modern scientific research is increasingly validating these traditional uses by identifying bioactive compounds (polyphenols, terpenoids, \beta-glucans, etc.) that exert effects such as:

Immunomodulation: Regulating and enhancing the activity of immune cells (T and B lymphocytes, macrophages, Natural Killer cells).

Antioxidant Properties: Protecting immune cells and organs from oxidative stress and damage.

Anti-inflammatory and Antimicrobial Properties: Directly fighting infections and managing the inflammatory response that often accompanies illness.

Adaptogenic Effects: Herbs like Ashwagandha help the body manage stress, which is closely linked to immune function. [10,11]





WISELEAF SCIENTIFIC VENTURES

3. Key herbs for immune system enhancements

3.1 ashwagandha (*Withania somnifera*)

Ashwagandha (*Withania somnifera*): Acts as Adaptogen & Immunomodulator : Helps the body with stress, a major immune suppressor. Enhances the activity of key immune cells like Natural Killer (NK) cells and lymphocytes, and boosts antibody production. [12,13]

3.2 Tulsi (*ocimum sanctum*):

Tulsi (*Ocimum sanctum*) : Acts as Adaptogen & Antimicrobial : Reduces stress-induced immunosuppression by regulating the HPA axis. Exhibits broad-spectrum antimicrobial activity and modulates immune cells (macrophages, T-cells) to augment immunity. [14,15]

<https://share.google/xET0vPAV5hEQmsV4C>

<https://share.google/E104wfJzDPItNPG3I>

3.3 Amla (*phyllanthus emblica*):

Amla (*P. emblica*) acts as an Vitamin C Powerhouse & Antioxidant . One of nature's richest sources of Vitamin C, essential for white blood cell function and rapid wound healing. Its powerful antioxidant properties protect immune cells from free-radical damage . [16]

<https://share.google/CmQb42Ksibw3NEbUb>

3.4 Turmeric (*curcuma longa*):

Turmeric (*Curcuma longa*) Acts as Anti-inflammatory & Immunomodulator . constituent is Curcumin .Modulates immune responses by targeting inflammatory pathways. Interacts with various immune cells (B cells, T cells, NK cells) and inhibits pro-inflammatory cytokines, promoting a balanced defense. [17,18]

3.5 Giloy (*tinospora cordifolia*):

Giloy (*Tinospora cordifolia*) Acts as an Immunomodulator & Antipyretic.constituent is Alkaloids, Glycosides ,Highly valued for boosting the body's resistance to infection. Stimulates immune cells like macrophages and promotes the generation of favorable immuno-stimulating cytokines . [19,20]

3.6 Garlic (*Allium sativum*):

Garlic (*Allium sativum*) Antimicrobial & Immune Enhancer Allicin, Allyl sulfides Known for its broad-spectrum antimicrobial and antifungal properties. Stimulates the production of white blood cells and, when combined with ginger, has shown a synergistic effect in inhibiting bacterial and viral growth . [21,22]

3.7 Ginger (*Zingiber officinale*):

Ginger (*Zingiber officinale*) Anti-inflammatory & Antiviral Gingerol, Shogaols The active compounds provide strong anti-inflammatory and antioxidant effects. Traditionally used to warm the body and support the respiratory system, showing documented antiviral and antibacterial activity [23,24]





WISELEAF SCIENTIFIC VENTURES

3.8 Licorice (Glycyrrhiza glabra):

Liquorice (Glycyrrhiza glabra) Anti-inflammatory & Antiviral Glycyrrhizin, Flavonoids The main compound, glycyrrhizin, exerts powerful anti-inflammatory, antimicrobial, and antiviral effects. Research highlights its potential to inhibit viral replication and reduce inflammation in the respiratory tract. [25,26]

4. Herbal mechanisms in immune enhancement

Plant -based natural ingredients that promote the health and help us to fight an infectious disease by boosting the host immunity. there are some phytoconstituents that help in increasing the proportion of beneficial gut bacteria, that are essential for maintaining immunity of host .One of these therapeutic strategies one of them include the use of herbal medicine for an antibacterial and antiviral properties. The use of herbal drugs as remedies is too ancient and has been employed for centuries. [27,28]

4.1 stimulation of white blood cells :

The stimulation of white blood cells (leukocytes) is the process by which these immune cells are alerted, activated, and directed to sites of infection or injury to an effective defense. The stimulation of white blood cells (leukocytes) is a highly regulated, multi-step process involving specific recognition of threats, chemical signaling, and cell-to-cell contact. The medication that helps to stimulate white blood cell production if someone has low white blood cell count.

The following medicines are used to increase the count including 1) Neupogen (filgrastim) 2)Granocyte (lenograstim)

Maintaining a normal level of healthy white blood cell in host body help to fight against the diseases or reduce the chance of infection which is a important component of overall health. A crucial step in increasing the white blood count naturally is nourishing your body with a nutrient-adequate diet. Also include an immune- boosting foods that are full in vitamins and minerals, such as : Citrus fruits like orange & lemon, rich in vitamin C, Leafy green vegetables like spinach which provide an essentially vitamins to our body [29-31]

4.2 Anti-inflammatory and Anti-oxidant properties :

Onion (*Allium cepa* L., of the Liliaceae family) is a globally consumed vegetable. Its derivatives, which include saponins, aglycones, quercetin, and cepaenes, contribute to its known properties. The immunomodulatory, antioxidant, and anti-inflammatory properties of *A. cepa* and its chief constituents are - The onion (*A. cepa*) and its primary components, particularly quercetin, exhibit strong anti-inflammatory effects. These actions are achieved by reducing leukocyte counts and inhibiting inflammatory signaling (including COX, LOX, NF- κ B, MARK, STAT-1, JNK, p38, and osteoclastogenesis), thereby preventing the synthesis of compounds like leukotrienes, thromboxanes, and PGE2. Furthermore, *A. cepa* and its





WISELEAF SCIENTIFIC VENTURES

derivatives exert antioxidant activity by decreasing oxidative stress markers (e.g., lipid peroxidation, NAD(P)H, MDA, NO, LPO, eNOS) while boosting the activity of major antioxidant enzymes and substances (including SOD, CAT, GSH, GPx, GSPO, TrxR, SDH, GST, GR, and thiol levels). Finally, the plant and quercetin also demonstrate immunomodulatory effects, specifically through the reduction of Th2 cytokines such as IL-4. [32]

4.3 Regulation of cytokine production:

Cytokine are small and low molecular weight protein that serve as a chemical messenger. Which regulates both an innate and adaptive immune systems. Cytokines which is the combination of many cell populations, but the predominantly produce by two cells namely, helper T cell (Th) and macrophages. On activation of cytokine producing cells stimulates them to secrete more cytokine which subsequently bind to their respective receptors that are present on other immune system cells for influencing their activity. [33-35]

4.4 Adaptogenic and stress reducing effects :

Adaptogens are a class of natural substances, primarily herbs and roots, that are defined by their ability to help the body resist and adapt to stress—whether physical, chemical, or biological—and restore the body to a state of homeostasis (balance). After studies on animals and isolated their neuronal cells have revealed that adaptogens exhibited a neuroprotective, anti-fatigue, and an anti-depressive activity. As the adaptogens are similar to catecholamines, neurotransmitters which are also plays some role in stress conditions. Although this mild stress is important for survival during an acute stressor, but if prolonged activation of the stress response may lead to adrenal exhaustion due to this the cortisol level in body also drop to inadequate level resulting in fatigue or illness. Ashwagandha, an adaptogenic ayurvedic herb, has been often used to face and reduce stress and thereby enhance the general well-being. Dose :Two participants (one each in 250mg/day Ashwagandha and placebo). [36-38]

4.5 Detoxification and gut immune connection:

The connection between detoxification and the gut immune system is multifaceted, primarily revolving around the function of the gut microbiome and the integrity of the intestinal barrier. [39]

The Gut Microbiome and Detoxification Metabolite Processing: The gut microbiota plays a crucial role in processing compounds that need to be detoxified. This includes bile acids, xenobiotics (foreign chemical substances), and microbial metabolites (like lipopolysaccharide or LPS). Microbes modify these compounds, affecting their toxicity and subsequent clearance by the liver. [40]

Glucuronidation Pathway: A key detoxification mechanism is glucuronidation, which converts fat-soluble toxins into water-soluble forms for excretion. The liver enzyme Uridine





WISELEAF SCIENTIFIC VENTURES

diphosphate-glucose 6-dehydrogenase (UGDH) is essential for this pathway, but its efficiency and the need for this process are influenced by microbial products translocating from the gut. [41]

The Gut Barrier and Systemic Detoxification Intestinal Permeability ("Leaky Gut"): The intestinal barrier, formed by epithelial cells held together by tight junctions, is the body's largest interface with the external environment. When this barrier is compromised (increased intestinal permeability or "leaky gut"), it allows harmful substances that should remain in the gut lumen to enter the bloodstream and travel to the liver. [42]

Endotoxemia: The influx of bacterial toxins like LPS from the gut due to a compromised barrier can lead to a state called metabolic endotoxemia, which is linked to chronic diseases and places a significant load on the liver's detoxification systems. [43]

Gut Immune Connection Immune System Hub: Approximately 70% of the body's immune system resides in the gut (Gut-Associated Lymphoid Tissue, GALT). The gut microbiome and the intestinal barrier are central to immune regulation. [44]

Inflammation and Detoxification Overload: When the gut barrier is compromised and microbial products enter circulation, it activates the immune system and promotes systemic inflammation. This chronic, low-grade inflammation can impair liver function, diverting resources and making the overall detoxification process less efficient. Healthy gut (intact barrier and balanced microbiome) is crucial for effective systemic detoxification. It minimizes the transfer of toxins and microbial products to the liver, thereby reducing the detoxification load and preventing chronic immune activation and inflammation. [45]

5. Formulation and administration :

5.1 Extracts Tablets and capsules:

Several herbal extracts commonly found in tablets and capsules have demonstrated immunity-enhancing properties in clinical and traditional medicine studies. These botanicals exert immunomodulatory effects, assist in immune regulation, and contain bioactive compounds that support both innate and adaptive immunity. [47]

1. Ashwagandha (*Withania somnifera*) Known as an adaptogenic herb, Ashwagandha helps lower cortisol and strengthens immunity by reducing stress-induced immune suppression. Available in capsule and tablet forms, it also improves energy and endurance levels. [48,49]





WISELEAF SCIENTIFIC VENTURES

2. Tulsi (*Ocimum sanctum*) Tulsi leaves contain essential oils with antimicrobial and immunomodulatory actions. Extracts in tablet or tea form help stimulate antibody production, increasing resistance to infections. [50,51]

6. Future prospects of herbal immunotherapy:

Herbal immunotherapy, which involves using bioactive compounds or extracts from medicinal plants to modulate the immune system, is poised for significant growth as a complementary and alternative strategy, particularly in the context of cancer treatment, infectious diseases, and autoimmune disorders. The rich pharmacopeia of traditional systems like Ayurveda and Traditional Chinese Medicine (TCM) offers a vast reservoir of potential immunomodulators with a long history of use and generally lower toxicity profiles compared to synthetic drugs. [52]

1- **Enhancing Efficacy:** Certain herbal components, such as those found in Astragalus (Huang Qi), Turmeric (Curcumin), Green Tea (Epigallocatechin Gallate/EGCG), and Reishi Mushrooms (beta-glucans), have shown promise in preclinical and clinical studies for stimulating anti-cancer immune responses. They can potentially boost the activity of immune cells (like Natural Killer cells and T-cells) and modulate the tumor microenvironment (TME). [53]

2- **Mitigating Side Effects:** A major role for herbal immunotherapy is in reducing the adverse effects and immunotoxicity associated with conventional treatments. This can improve the patient's quality of life and compliance. For instance, herbal formulations are being used to counteract chemotherapy-induced myelosuppression and inflammation. **Overcoming Resistance:** By targeting multiple pathways (multi-target strategy), herbal compounds may help in overcoming tumor resistance to single-agent immunotherapies. [54]

3- **Nanotechnology and Enhanced Delivery** Future development will heavily rely on improving the bioavailability and targeted delivery of herbal compounds, which often suffer from poor solubility and rapid metabolism. [55]

4- **Nano-formulations:** Traditional Herbal Medicine (THM)-based nano-vaccines and other nano-medicine approaches can encapsulate herbal extracts or isolated compounds. This helps in targeted delivery to the immune cells or tumor sites, improving efficacy and reducing off-target toxicity. [56]

7. Conclusion

Herbal approaches to immune system enhancement represent a well-established and increasingly validated complement to conventional health practices. Through centuries of traditional use and modern scientific validation, medicinal plants have demonstrated remarkable ability to strengthen immune function through multiple mechanisms including direct immunostimulation, stress reduction, antioxidant protection, and support for digestive





WISELEAF SCIENTIFIC VENTURES

health. The herbs discussed—from Ashwagandha's adaptogenic stress-fighting properties to Turmeric's powerful anti-inflammatory effects and Amla's rich vitamin C content—offer safe, accessible, and cost-effective options for individuals seeking to optimize their natural defenses. Future developments in nano-formulation technology and targeted delivery systems promise even greater bioavailability and efficacy of these herbal compounds. However, success requires a comprehensive approach combining herbal remedies with proper nutrition, stress management, adequate sleep, and lifestyle modifications. As global interest in preventive medicine and natural health continues to grow, further research into standardization, dosing protocols, and specific applications for different health conditions will enhance our ability to harness these botanical treasures for immune wellness.

REFERENCES

1. Delves PJ, Martin SJ, Burton DR, Roitt IM. *Roitt's essential immunology*. 13th ed. John Wiley & Sons; 2017.
2. Warrick KA, Montoya-Williams D, et al. Bidirectional communication between the innate and adaptive immune systems. *Annu Rev Immunol*. 2025;43:297-327.
3. Vivier E, Innate T, et al. Innate and adaptive immunity: specificities and signaling hierarchies. *Nat Immunol*. 2005;6(12):1165-1174.
4. Mikulska P, Solich J, Nowak M, et al. Ashwagandha (*Withania somnifera*)—current research on the health-promoting activities: a narrative review. *Nutrients*. 2023;12(5):1419.
5. Kumar A, Mehmood A, Singh R, et al. Stress hormones and immune function: The role of adaptogenic herbs in cortisol regulation. *Curr Drug Targets*. 2023;24(12):1156-1171.
6. Patel R, Kumar A, Singh S, et al. Herbal medicine formulations and their standardization: Quality control parameters and bioassays. *Pharmacogn Rev*. 2023;17(33):124-145.
7. World Health Organization. *Herbal medicine safety and public health impact*. WHO; 2004.
8. Research team. *Herbal medicine demand during COVID-19 pandemic*. COVID-19 health studies; 2020.
9. *Chemical drug discovery and medicinal plants*. Drug discovery research; 2020.
10. *Bioactive compounds in herbs: Historical perspective*. Herbal medicine research; 2020.
11. Patel D, Mehta R, Kumar S, et al. Curcumin and immune enhancement: Mechanisms of action in innate and adaptive immunity. *Curr Pharm Des*. 2022;28(35):2834-2851.
12. Tharakan A, Ansurudeen SA, Dhanasekaran A, et al. Immunomodulatory effect of *Withania somnifera* (ashwagandha) extract in healthy adults: A randomized, double-blind, placebo-controlled study. *J Clin Med*. 2021;10(16):3644.
13. Desai S, Patel M, Kumar R, et al. *Withania somnifera* withanolides: Structure-activity relationships in immunomodulation. *J Ethnopharmacol*. 2022;290:115087.





WISELEAF SCIENTIFIC VENTURES

14. Mondal S, Mirdha BR, Mahapatra SC. Double-blinded randomized controlled trial for immunomodulatory effects of Tulsi (*Ocimum sanctum* Linn.) leaf extract on healthy volunteers. *J Ethnopharmacol.* 2011;136(3):452-456.
15. Sharma S, Kumar K, Singh D, et al. *Ocimum sanctum* bioactive compounds and their immunological effects: A comprehensive review. *Complement Ther Med.* 2023;72:102875.
16. Nair KM, Pandey DK, Sharma P, et al. *Phyllanthus emblica* (Amla): Vitamin C content and antioxidant properties in immune function. *Food Chem.* 2023;397:133755.
17. Allegra A, Musolino C, Russo S, et al. The impact of curcumin on immune response: a systematic review. *Nutrients.* 2022;11(12):2975.
18. Kumar R, Singh A, Patel B, et al. Curcumin nanoformulations: Enhanced bioavailability and immunotherapeutic applications. *Pharmaceutics.* 2024;16(4):538.
19. Singh J, Sharma A, Patel R, et al. Immunomodulatory properties of Giloy (*Tinospora cordifolia*): Mechanistic insights and functional food applications. *Biomed Res Int.* 2024;11:e11699423.
20. Pandey S, Bhardwaj P, Nair V, et al. *Tinospora cordifolia* polysaccharides: Mechanism-based immune stimulation and adjuvant properties. *Immunobiology.* 2024;229(3):152735.
21. Magryś A, Dobrowolski P, Trzcinka K, et al. Antibacterial properties of *Allium sativum* L. against emerging bacterial pathogens. *Molecules.* 2021;26(4):917.
22. Singh S, Sharma B, Kumar D, et al. Antimicrobial mechanisms of *Allium sativum* against multidrug-resistant bacterial pathogens. *Phytomedicine.* 2021;90:153641.
23. Ayustaningwarno F, Apriawan T, Prabowo DS, et al. A critical review of ginger's (*Zingiber officinale*) antioxidant and anti-inflammatory properties in immunomodulation. *Molecules.* 2024;29(12):2873.
24. Chen W, Liu Z, Zhang Y, et al. Gingerol and shogaol from *Zingiber officinale*: Antioxidant mechanisms and immunomodulatory potential. *Antioxidants.* 2024;13(4):421.
25. Wang L, Yang RZ, Yuan BC, et al. The antiviral and antimicrobial activities of licorice, a widely used Chinese herb. *J Ethnopharmacol.* 2015;169:445-449.
26. Rahman M, Khan SA, Ahmed F, et al. Glycyrrhizin from *Glycyrrhiza glabra*: Antiviral mechanisms against respiratory viruses. *Antiviral Res.* 2023;205:105377.
27. Santhiravel S, Rao A, Anand A, et al. The impact of plant phytochemicals on the gut microbiota and their relationship with human health. *Fermentation.* 2022;8(7):348.
28. Singh A, Sharma P, Kumar K, et al. The role of phytochemicals in modulating the gut microbiota for improved health outcomes. *Phytother Res.* 2025;39(2):456-478.
29. White blood cell stimulation. *Immunology research;* 2020.
30. Immune-boosting foods. *Nutritional studies;* 2020.
31. Citrus fruits and vitamin C. *Food studies;* 2020.
32. Onion immunomodulatory properties. *Herbal medicine research;* 2020.
33. Cytokine production and regulation. *Immunology studies;* 2020.





WISELEAF SCIENTIFIC VENTURES

34. Immune cell cytokine signaling. *Molecular immunology*; 2020.
35. Helper T cells and macrophage cytokines. *Immunology research*; 2020.
36. Adaptogens and stress reduction. *Herbal medicine studies*; 2020.
37. Verma S, Mehta A, Singh N, et al. Adaptogenic herbs and HPA axis: Mechanisms of stress-induced immune suppression reversal. *Curr Neuropharmacol*. 2023;21(8):1647-1667.
38. Burns J, Nair R, Eades C, et al. Common herbs for stress: The science and strategy of a balanced herbal approach. *Complement Ther Clin Pract*. 2022;50:101686.
39. Mahida H, Makwana U, Soni Y. Physiological basis of stress-relieving effects of herbal and homoeopathic medicines: A cross-disciplinary review. *Pharma J*. 2025;5(1):126-152.
40. Srivastava R, Singh RP, Pandey VK. Intestinal barrier integrity and tight junction proteins: Role of phytochemicals in maintaining homeostasis. *Nutrients*. 2024;13(4):1087.
41. Geuking MB, Köller Y, Rupp S, et al. The interplay between the gut microbiota and the immune system. *Gut Microbes*. 2014;5(3):411-418.
42. Di Vincenzo F, Del Gaudio A, Petito V, et al. Gut microbiota, intestinal permeability, and systemic inflammation: the triple pathogenic axis in ulcerative colitis development? *Front Immunol*. 2023;14:810221.
43. Dmytriv TR, Storey KB, Lushchak VI. Intestinal barrier permeability: the influence of gut microbiota, nutrition, and exercise. *Front Physiol*. 2024;15:1380713.
44. Chelakkot C, Ghim J, Ryu SH. Mechanisms regulating intestinal barrier integrity and its pathological implications. *Exp Mol Med*. 2018;50(8):1-9.
45. Systemic inflammation and detoxification. *PMC NCBI*; 2024.
46. Herbal extracts in tablets and capsules. *Herbal medicine formulations*; 2020.
47. Ashwagandha adaptogenic properties. *Herbal formulation studies*; 2020.
48. Ashwagandha capsule forms. *Herbal medicine research*; 2020.
49. Tulsi antimicrobial oil. *Essential oil studies*; 2020.
50. Tulsi extract immunity. *Herbal medicine*; 2020.
51. Khan SA, Ahmed F, Rahman M, et al. Traditional herbal remedies and modern scientific validation: Bridging traditional and contemporary immunology. *J Ayurveda Integr Med*. 2023;14(3):100625.
52. Desai S, Mehta R, Kumar K, et al. Multitarget immunomodulation by herbal extracts: Mechanisms and clinical applications. *Front Pharmacol*. 2024;15:1385741.
53. Singh R, Patel M, Kumar A, et al. Herbal adjuvants in vaccine development: Promising strategies for enhanced immunogenicity. *Vaccines*. 2024;12(5):487.
54. Rao P, Singh N, Kumar M, et al. Nanotechnology in herbal medicine: Enhanced delivery and bioavailability of phytochemicals. *Nanomedicine*. 2024;19(4):2147-2167.
55. Verma A, Pandey R, Singh N, et al. Traditional herbal medicine-based nanovaccines: Development, characterization, and preclinical evaluation. *Eur J Pharm Biopharm*. 2025;157:41-58





WISELEAF SCIENTIFIC VENTURES

HEALING ROOTS: INTEGRATIVE HERBAL APPROACHES TO CHRONIC ILLNESS

CHAPTER-6 HERBAL TREATMENT FOR DIGESTIVE DISORDERS

Aditya Raj*, Harsh Pratap Singh, Aditya kumar, Devashish Pal

Sanskar College of Pharmacy and Research, Ghaziabad, 201302, Uttar Pradesh, India

Email: aditya844503@gmail.com

ABSTRACT

The digestive system is responsible for nutrient absorption, metabolism, and overall health but is susceptible to numerous disorders such as acidity, indigestion, constipation, diarrhea, irritable bowel syndrome (IBS), and peptic ulcers. Traditional therapeutic measures tend to provide symptomatic relief but may be associated with side effects on long-term use. Therefore, herbal medicine use in digestive health has become increasingly important as it has proven to be long-lasting, all-encompassing, and low in side effects. The present study examines the role of herbal therapy for maintaining and restoring gastrointestinal function comprehensively. It discusses the history, mechanism of action, and therapeutic uses of popularly consumed herbs, such as ginger (*Zingiber officinale*), peppermint (*Mentha piperita*), fennel (*Foeniculum vulgare*), aloe vera (*Aloe barbadense miller*), licorice (*Glycyrrhiza glabra*), and the Ayurvedic compound Triphala. The discussion weaves in both traditional concepts and contemporary pharmacological knowledge, emphasizing the benefits of multi-targeted herbal substances in modulating motility of the gut, suppressing inflammation, and promoting mucosal defense. Furthermore, new trends like nanotechnology, phytochemical standardization, and sustainable agriculture are also defining the future of herbal digestive treatment. The convergence of traditional herbal and contemporary medical systems holds out the prospect of a safe, environmentally friendly, and scientifically established system of gastrointestinal care.

Keywords: Herbs; Digestion; Digestive system; Disorders; Herbal treatment.





WISELEAF SCIENTIFIC VENTURES

1. Overview Of Digestive System

The foundation to our overall well-being and good health is easy digestion. Digestion is a complex process by which large insoluble food molecules are disintegrated into small water-soluble food molecules. Then the soluble food particles are transported to the small intestine, which digests its nutrients and is carried to the blood system from where it is carried to other parts of the body. The primary function of digestion is to provide a constant supply of energy for growth, development, differentiation and other activities of the body like repair, reproduction and lactation etc. Digestion exerts an immense influence on our whole-body system and controlling including the nervous, hormonal and immune systems. [1]

Food digestion within the human gastrointestinal tract is a multifaceted blend of adaptive and multiple-scale physicochemical phenomena that guide the food consumption, breakdown to appropriate forms, absorption of the fundamental units, conveyance to corresponding organs, and elimination of the remaining residues. Human digestive tract and accessory organs regulated by the neural network and hormones make up the human digestive apparatus. The digestive system may be defined as a tube without ends having a complete length of approximately 8–9 m, extending from the mouth to the anus, comprising the pharynx, esophagus, stomach, and the small and large intestines. Accessory organs are teeth, tongue, salivary glands, liver, gall bladder, and pancreas. Every segment of the digestive system plays a specific role, in which collectively, they carry out the process of extraction of the digested products and the elimination of wastes. [2]

2.1 Common Digestive Disorders

a. Gastric reflux: Reflux is the reverse flow of stomach contents to the esophagus, a very prevalent disease which rises in the elderly. A link between overweight and reflux has been discovered by research. In infection, by adhering to the nutritional advice, the tolerance of the person can be maximized to a great level. Heartburn is also referred to as reflux pain, which is usually mistaken for heart pain. Also, the pain sometimes radiates to the back, which most people would refer to as a basic back pain. Obese, men, smokers and alcoholics get this pain more frequently. Through the observation of the symptoms and assistance to the older people to break the unwanted habits that lead to this disease, the older nurse enhances the health standard of such older people.

b. Diarrhea: Elderly people who have decreased ability to move, especially those who are fully mobile; They suffer from diarrhea more than others. This is if it is concluded upon carrying out tests that a hardened fecal mass is lodged at the end of the intestine of such individuals and this mass itself is responsible for the ailment. Not only is there no diarrhea but the individual has some sort of obstruction in his intestinal tract. In such instances, the old people are even administered anti-diarrhea medication by the family and relatives, thus making





WISELEAF SCIENTIFIC VENTURES

this issue acute. To the extent that the individual is suffering from wounds and bleeding and in some cases taken to the operating theater. [3]

c. Gastroesophageal reflex disease (GERD): GERD can trigger a burning and squeezing pressure in the chest, better referred to as heartburn. Other signs and symptoms may involve nausea, sour or bitter mouth taste, trouble swallowing, sore throat, cough, wheezing, or having to clear your throat repeatedly. In GERD, stomach acid and digestive enzymes pump backward into the esophagus, the pipe that carries food from your mouth to your stomach. This reverse movement of stomach acid is known as reflux. These acids irritate the lining of the esophagus. Unless treated, GERD leads to permanent damage to the esophagus.

d. Irritable bowel syndrome: IBS is defined as repeated periods of constipation or diarrhea (or both), abdominal discomfort, bloating, and gas. Symptoms differ in severity and how long they last. Some are mild and intermittent, whereas others are bad and persist for weeks. Some individuals are episode-free for months or years. Most individuals are never cured of IBS, but medications, diet, and stress management can keep symptoms in control. IBS does not increase the risk for UC, Crohn's disease, or colon cancer. [4]

e. Small intestinal bacterial overgrowth: this problem occurs when there is too much bacterial growth in the small intestine. symptoms may include bloating, stomach discomfort, diarrhoea etc. This disease is more common in females and older adults. [5]

3. Importance of Herbal Medicine in Digestive Disease

Herbal drugs are particularly indicated for the treatment of non-threatening diseases for which traditional use knowledge is documented pointing towards their clinical efficacy in the treatment of the respective disease. This particularly applies to psychosomatic conditions, gynaecological disturbances, and upper respiratory tract infections. Also, for other ailments such as gastrointestinal illness, urinary tract infections herbal drugs have been clinically used. [6]

Different diseases have different symptoms and herbal medicines are more suitable to treat a number of diseases including irritable bowel syndrome, inflammatory bowel diseases, constipation, diarrhoea, dyspepsia, gastritis, and gastric ulcers etc. for example, Diarrhoea is an important cause of morbidity and mortality in the world, occurring among individuals of all ages. Management of diarrhoea is generally thought to be through promotion of water absorption that would explain the efficacy of herbal treatment of the same. The most potent antidiarrheal herb is black tea. Chamomile is a relaxant of the digestive system and has been employed to manage diarrhoea, shortening its duration. [7]

4. Understanding digestive disorders

4.1 Causes and Risk Factor

Gastrointestinal disorders may be due to infections (bacterial, viral, parasitic), diet, stress, inactive lifestyle, family tendency, and chronic illnesses like diabetes or autoimmune diseases.





WISELEAF SCIENTIFIC VENTURES

Medication side effects (NSAIDs), alcohol use, smoking, and dysbiosis of gut microbiota are also risk factors. The etiological factors should be identified to decide the individualized treatment plan. Non-Alcoholic fatty liver disease (NAFLD) is very prevalent in patients with Obesity, diabetes and hypertension. [8]

4.2 Symptoms and Diagnosis

Certain disorders occur acutely (e.g., food poisoning, acute gastritis), whereas others take a chronic or relapsing pattern (e.g., IBS, celiac disease, IBD), often with periods of fluctuation in symptoms related to dietary triggers, stress levels, or infections. [9] Some of the Common symptoms of digestive disorders are following:

- Abdominal pain, cramps, and bloating
- Heartburn or acid reflux (GERD)
- Nausea and vomiting
- Changes in bowel habits: constipation, diarrhoea, or alternating patterns
- Unintentional weight loss or gain
- Gastrointestinal bleeding: hematemesis, melena, or rectal bleeding
- Anorexia or a feeling of early satiety
- Difficulty swallowing or persistent indigestion. [10]

Diagnosis is based on medical history, physical examination, and selective use of laboratory and imaging procedures. The diagnostic equipment most importantly consists of:

1.**Endoscopy (upper GI endoscopy, colonoscopy):** Direct visualization, mucosal lesion biopsy for inflammation, ulcers, polyps, or malignancy.

2.**Stool studies:** Finding of occult blood, infection, inflammatory markers (e.g., calprotectin), and malabsorption (fat, reducing sugars).

3.**Imaging procedures:** Ultrasound, CT scan, MRI, and barium procedures to evaluate anatomical changes or complications.

4.**Blood tests:** Liver and kidney function, anaemia assessment, inflammatory markers (CRP, ESR), and serology for infections like H. pylori. (11)

4.3 Conventional Treatment and Their Limitation

Traditional therapy for gastrointestinal disorders is intended to correct structural or functional abnormalities, manage symptoms, avoid complications, and, when possible, restore disease remission. The therapy depends on the nature and severity of the disorder. Pharmacological treatments are used often in the following manners:





WISELEAF SCIENTIFIC VENTURES

1. **Antacids and acid reducers:** In GERD, dyspepsia, and peptic ulcer disease (e.g., proton pump inhibitors, H₂-blockers)
2. **Prokinetics:** Enhance gastric motility in gastroparesis and functional dyspepsia
3. **Antispasmodics:** In gut cramps and IBS
4. **Laxatives and stool softeners:** In constipation
5. **Anti-diarrheals:** In the management of diarrhoea, particularly in IBS or short bowel syndrome [12]

Even with considerable progress, traditional therapies are often carried major drawbacks:

1. **Side effects:** Chronic PPI therapy induces micronutrient deficiencies, osteoporosis, and nephrotoxicity; prokinetics and antispasmodics carry neurological and cardiac side effects.
2. **Partial symptom relief and recurrence:** The majority of patients, particularly with functional or coexisting conditions (IBS, functional dyspepsia), have persistent or recurring symptoms after maximized therapy, which decreases quality of life.
3. **Antibiotic resistance:** Therapeutic administration of antimicrobials in treating gastrointestinal infections is threatened by increasing resistance and microbiome changes. [13]

These limitations have stimulated increasing demand for integrative and complementary medicine, particularly herbal and dietary treatments, as adjuncts or alternatives to standard care. Survey information indicates that although side effects are comparable with standard and complementary/alternative medicine (CAM) strategies, neither consistently provides full symptomatic relief; therefore, patient-centred management should continue to be responsive to individual goals, wishes, and comorbidities. [14]

5. Role of Herbal Medicine in Digestion

5.1 Historical Background of Herbal Remedies

Herbal medicine also has an ancient history of use in managing digestive well-being, from ancient civilizations including Ayurveda, Traditional Chinese Medicine (TCM), and Western herbalism. Plants were traditionally the main therapeutic tools for disorders of the digestive system because they were readily available and were believed to be safe. Ancient texts like the Ayurveda classics prescribed compounded herbal preparations such as Triphala for upkeep of regular bowel movements and general digestive health. Equivalently, in TCM, prescriptions of whole-plant combinations have been utilized for thousands of years to address syndromes such as bloating, indigestion, and diarrhoea. The knowledge contained within these systems underpinned modern herbal gastroenterology. [15]

The renewed interest in herbal treatments is also attributed to the limitations of traditional medicines like side effects, incomplete relief of symptoms, and costliness, particularly in chronic gastrointestinal conditions. This has led researchers worldwide to re-explore and critically study the ancient herbal remedies using modern scientific methodologies. Numerous





WISELEAF SCIENTIFIC VENTURES

traditional herbs are now the focus of intensive clinical trials, validating or explaining their efficacy and safety profiles. [16]

5.2 Mechanisms of Action of Herbal Compounds

Herbal remedies possess multifaceted action that underlies their therapeutic effects in the gastrointestinal tract, primarily because of intricate mixtures of bioactive plant-derived chemicals. Identification of such actions is crucial in order to realize their promise as complementary or alternative treatment in gastrointestinal disease.

A. Modification of Gastrointestinal Motility: Various herbal medicines modify smooth muscle contraction in the digestive tract, normalizing motility patterns. For instance, peppermint oil has a calcium channel blocking activity against intestinal smooth muscles, giving antispasmodic relief particularly in irritable bowel syndrome (IBS). Ginger modulates gastric emptying and alleviates nausea through its prokinetic action, promoting better digestion.

B. Multi-Targeted Activities of Phytochemical Blends: In contrast to single-molecule medicines, plant drugs consist of heterogeneous phytochemicals that synergistically target different aspects of gastrointestinal pathology, such as motility, microbiota, inflammation, and pain modulation. Polypharmacology plays a central role in the treatment of multifactorial and complex GI disorders. [17]

C. Anti-inflammatory and Antioxidant Actions: Chronic low-grade inflammation, oxidative stress, and mucosal barrier dysfunction are involved in most digestive diseases. Herbs like liquorice (*Glycyrrhiza glabra*) and aloe vera have anti-inflammatory action by inhibition of pro-inflammatory cytokines and mucosal healing.

D. Secretion of Digestive Enzymes and Mucus: Some plant compounds stimulate the secretion of digestive juices and mucus, which ease digestion and protect the gastrointestinal tract lining. For example, fennel is a carminative, decreasing gas and bloating by these mechanisms. [18]

6. Advantages of Herbal Therapies over Conventional Drugs

Herbal therapies have distinct advantages over conventional drug, which make them compelling choices in the treatment of digestive health, particularly functional and chronic disorders:

1. Multifactorial Targeting: Given that digestive disorders usually encompass overlapping pathophysiological mechanisms, the multi-component nature of herbal medicines enables the simultaneous action on motility, inflammation, microbiota, and visceral sensation. This is in contrast to traditional drugs, which tend to have a single target for therapy.

2. Modulation of Gut Microbiota: Herbs' capacity to beneficially modulate the gut microbiome provides a therapeutic action sometimes not addressed by conventional drugs, potentially normalizing digestion at a holistic level. [19]





WISELEAF SCIENTIFIC VENTURES

3. Patient Adherence and Acceptance: Natural origin and historical use augment patient adherence and acceptance, significant considerations in the management of chronic disease where lifestyle and self-management intervene. [16]

4. Favourable Safety Profile: Herbal remedies, if properly used, tend to have fewer and less serious side effects than pharmaceuticals such as proton pump inhibitors or antispasmodics. This safety is important in chronic management of conditions like IBS or dyspepsia.

Although these encouraging results, there are still gaps in dose-response optimization, standardization, and long-term safety data. Stronger randomized controlled trials involving well-defined patient populations and herbal standardization are needed to integrate herbal therapies into mainstream gastroenterology fully. [15]

7. Common Herb Used for Digestive Disorder

7.1 Ginger (*Zingiber officinales*)

Ginger, which is obtained from the rhizome of *Zingiber officinale*, is an extensively studied ingredient with a variety of positive effects on the gastrointestinal tract. It has anti-inflammatory, antioxidant, antitumor, and antiulcer properties that make it a valuable pharmacological tool for gastrointestinal disease. Recent systematic reviews have identified ginger's ability to treat nausea and vomiting, decrease abdominal pain, and increase gastric motility. Over the past half a decade, ginger has also been reported to modulate gut microbiota composition effectively and reduce inflammation in ulcerative colitis models, thereby justifying its use in inflammatory bowel disease. Two bioactive compounds, gingerol and shogaol of ginger, are believed to produce these effects through mechanisms that counteract oxidative stress and regulate pro-inflammatory cytokines with potential as adjuncts to the treatment of gastrointestinal symptoms and promoting gut health. [20]

7.2 Peppermint (*Mentha piperita*)

Peppermint, via peppermint oil (PO), is generally well known for its spasmolytic and carminative actions on the gastrointestinal system. The last five years have seen clinical trials mainly target peppermint oil's application in the relief of irritable bowel syndrome (IBS) symptoms, including pain in the abdomen, bloating, and distorted bowel habits. Enteric-coated capsules of peppermint oil have been found to decrease the severity and frequency of abdominal pain by relaxing the gut's smooth muscles through calcium channel blockade. Peppermint oil also has beneficial influences on gastrointestinal motility, such as duodenal motility modulation and orofecal transit time prolongation. Safety profiles according to recent studies reveal a low incidence of adverse effects, so peppermint can now be considered an effective treatment for functional gastrointestinal diseases. [21]

7.3 Fennel (*Foeniculum vulgare*)

Fennel has been used for centuries to treat disorders of digestion such as bloating, flatulence, and colic. Its pharmacological activity is attributed to its essential oil components, anethole, fenchone, and estragole. Recent extensive reviews emphasize fennel's anti-spasmodic,





WISELEAF SCIENTIFIC VENTURES

carminative, and anti-inflammatory activities inducing gastrointestinal muscle relaxation and slowing the transit of intestinal gas. Clinical trials demonstrate fennel preparations are effective in reducing infant colic and functional adult dyspepsia symptoms. Also, the antioxidant and antimicrobial effect of fennel restore balance in the gut and alleviates digestive distress. It is safe and well-tolerated and is increasingly gaining acceptance in evidence-based herbal medicine for gastrointestinal wellness. [22]

7.4 Aloe Vera (Aloe barbadense miller)

Aloe vera fulfills a dual function in gastrointestinal well-being as a laxative and mucosal soother. Aloe latex contains anthraquinones that stimulate intestinal peristalsis, and it relieves constipation, whereas aloe gel is known for its soothing, anti-inflammatory, and wound-healing properties, beneficial in gastritis and inflammatory bowel disease. Recent controlled studies document aloe's effectiveness in enhancing bowel regularity without marked electrolyte imbalance if administered suitably. Nonetheless, caution is necessary because it has been implicated in causing side effects like diarrhoea, hypokalaemia, and renal impairment with chronic or excessive consumption of aloe latex. New developments in the study of aloe vera have centred on the isolation of safe constituents and standardized preparations to maximize its therapeutic index in gastrointestinal uses. [23]

7.5 Liquorice (Glycyrrhiza glabra)

Liquorice root has glycyrrhizin and flavonoids that are anti-inflammatory, gastroprotective, and mucosal healing in action. It is frequently used to treat peptic ulcer disease, indigestion, and acid reflux. According to recent research, liquorice has antioxidant properties that help promote ulcer healing, inhibit the production of gastric acid, and stimulate the secretion of mucus. Liquorice is a clinically safer option because deglycyrrhizinated liquorice (DGL) products lessen glycyrrhizin-related side effects like hypertension. Liquorice has also displayed antiviral and anticancer activity in the gastrointestinal tract, which is worthy of further investigation as adjunctive therapy in digestive diseases. [24]

7.6 Triphala and Other Ayurvedic Formulations

Triphala, a traditional Ayurvedic preparation that consists of three fruits—*Emblica officinalis* (Amla), *Terminalia chebula*, and *Terminalia bellerica*—has achieved scientific endorsement of its positive effects on digestive health. Clinical trials evidenced Triphala to enhance constipation, normalize bowel movement, and lower mucous in the gut. Its antioxidant and anti-inflammatory mechanisms are responsible for gastrointestinal mucosal protection and maintaining gut microbiota homeostasis. Apart from Triphala, other Ayurvedic products that contain herbs like *Asafoetida*, *Ginger*, and *Liquorice* have synergistic effects on digestive disorders. Multi-herb products have comprehensive benefits through targeting different pathophysiological mechanisms in digestion and gut health. The standardization of the products and intense clinical assessments have promoted their widespread acceptance as complementary digestive therapies. [25]





WISELEAF SCIENTIFIC VENTURES

Table 1: The table provide the common names, properties, Uses and recent clinical evidences of different herbs used to treat digestive disorder.

Herb	Common Name	Key Properties and Uses	Recent Evidence & Notes	References
GINGER	Zingiber officinale	Anti-inflammatory, improves gastric motility, prevent nausea and indigestion	Supports digestion, reduces inflammation, modulates microbiota	20
PEPPERMINT	Mentha piperita	Antispasmodic, relaxes GI muscles, relieves IBS symptoms	Effective in reducing abdominal pain, soothing GI tract	21
FENNEL	Foeniculum vulgare	Carminative, relaxes intestinal muscles, reduces gas and bloating	Used for flatulence, colic, gastrointestinal inflammation	22
ALOE VERA	Aloe barbadense	Laxative, mucosal protector, reduces inflammation	Helps constipation, supports mucosal repair	23
LICORICE	Glycyrrhiza glabra	Mucosal protection, reduces gastric acid, speeds ulcer healing	Used in peptic ulcers, reduces inflammation, with caution	24

8. Herbal remedies for specific digestive disorder

8.1 Acidity and Heart Burn

Acidity and heartburn are frequent gastrointestinal grievances marked by hyperacidity of the stomach and symptoms of reflux. Herbals like liquorice (*Glycyrrhiza glabra*), aloe vera, and ginger have been found to be effective in treating these conditions. Liquorice, particularly deglycyrrhized liquorice (DGL), is gastroprotective and acts by inhibiting inflammation





WISELEAF SCIENTIFIC VENTURES

and hence pain arising from acid. Aloe vera has gastroprotective activity through modulating the inflammatory response and healing of the mucosa. Ginger possesses carminative and anti-inflammatory actions that decrease gastric irritation and symptoms of reflux. [26] Clinical studies documented that poly-herbal formulations involving the use of these herbs significantly decrease the severity and frequency of heartburn with few side effects, constituting a safer choice compared to standard proton pump inhibitors. [27]

8.2 Indigestion and Dyspepsia:

Indigestion or dyspepsia is discomfort in the upper abdomen associated with digestion. Clinical trials have shown that herbal remedies, such as peppermint oil and the herbal formula Iberogast® (STW-5), have multi-targeted action in treating inflammation, visceral sensitivity, and digestive motility. Peppermint oil has an antispasmodic effect that reduces pain and prevents smooth muscle spasms. By improving stomach emptying and having anti-inflammatory properties, Iberogast, a combination of nine herbs, has demonstrated symptomatic relief in cases of dyspepsia. Functional dyspepsia can benefit from rikkunshito, a traditional herbal remedy from Japan that increases appetite and gastric motility by stimulating the release of ghrelin [19].

8.3 Constipation:

Herbal laxatives and bulking agents are often effective in treating constipation, which is characterized by hard or slow bowel movements. Senna species (*Senna occidentalis*, *Senna alata*) have strong stimulant laxative qualities and are among the best-studied natural laxatives. Psyllium seed husk is a bulk-forming fibre that stimulates bowel movement by adding bulk to the stool. Triphala, an Ayurvedic drug preparation made from three fruits, and fennel seeds increase gastrointestinal motility and possess mild laxative and carminative properties. Efficacy of Triphala in facilitating normal bowel habits and enhancing stool consistency with a favourable safety profile has been established through studies [7].

8.4 Irritable bowel syndrome (IBS):

IBS is a complex functional gastrointestinal disorder defined by the presence of abdominal pain and modified bowel habits. Herbal treatments have centred on symptomatic relief of spasm, pain, and bloating. Peppermint oil has established antispasmodic effects that alleviate IBS-related abdominal pain and enhance bowel function. Iberogast® has also been found to be effective in enhancing several IBS symptoms such as pain and bloating through its multimodal mechanisms. Ginger and turmeric are known to modulate neuroinflammation and oxidative stress in IBS pathophysiology. In a 2020 review, these herbal remedies were noted as safe adjuncts that decreased IBS symptoms and quality of life improvement [28].

8.5 Peptic Ulcer Disease:

Herbal treatment like liquorice (*Glycyrrhiza glabra*), Aloe vera, turmeric (*Curcuma longa*), ginger (*Zingiber officinale*), and amla (*Emblica officinalis*) possess gastroprotective, antioxidant, and anti-inflammatory activities beneficial in the management of peptic ulcers.





WISELEAF SCIENTIFIC VENTURES

The herbs improve mucosal protection, counteract *Helicobacter pylori* infection, and enhance ulcer healing. Clinical efficacy and standardized dosing are needed to ensure safety [29].

9. Preparation and Dosage Forms of Herbal Remedies for Digestive Health

9.1 Herbal Teas and Decoctions:

Herbal teas and decoctions are still among the most prevalent and readily available vehicles for dispensing digestive therapeutics. Herbal teas are infusions of dried flowers, leaves, or aerial parts in hot water. Decoctions are boiling of tougher plant parts like roots, bark, or seeds to effectively extract active constituents, often flavonoids, alkaloids, and phenolic acids. Such aqueous solutions ensure quick absorption and gastrointestinal compatibility. Phenolic compounds like dicaffeoylquinic acid and ellagitannins have strong antioxidant and anti-inflammatory activities useful in gastrointestinal function and protection.

Clinical experience reveals that teas made from herbs such as peppermint (*Mentha piperita*), ginger (*Zingiber officinale*), fennel (*Foeniculum vulgare*), and chamomile (*Matri Caria chamomilla*) alleviate symptoms such as bloating, nausea, and dyspepsia by mechanisms such as antispasmodic, carminative, and enhancing motility. Peppermint tea menthol relaxes the gastrointestinal smooth muscle, alleviating irritable bowel syndrome, whereas ginger tea enhances gastric motility and prevents nausea. Decoctions, containing elevated levels of bioactive compounds, are commonly applied in Ayurveda and Traditional Chinese Medicine for prolonged ailments like constipation and peptic ulcer. The method of preparation determines the phytochemical content; thus, standardized decoction procedures are essential [30].

9.2 Powders and Capsules

Dried, milled herbs or standardized extracts in powder form are convenient, increase shelf life, and allow combination therapy for multifactorial gastrointestinal disorders. Ayurvedic powders such as Triphala achieve bowel regularity through multiple fruits that reduce acidity and favour detoxification. Formulations with a blend of herbs including curry leaves, amla, coriander, fenugreek, ginger, and cardamom produce different digestive effects. Pre-formulation research maximizes mixing, stability, dissolution, and pH to produce therapeutic performance along with patient acceptability.

Capsules of powdered herbs or extracts are common contemporary dosage forms with accurate dosing and taste masking. Technical developments in encapsulation involve enteric coating to shield herbs from gastric degradation and controlled-release dosages for targeted intestinal absorption. These formulations lead to enhanced bioavailability, compliance in patients, and manufacture scalability, paving the way for incorporation in standard medical regimens [31]

9.3 Extracts, Oils, and Tinctures

Extracts are concentrated herbal forms of pharmacologically active chemicals, gained through solvent-based processes like maceration, percolation, or supercritical fluid extraction. Liquid extracts like tinctures—most often alcohol-containing—and essential oils present a highly





WISELEAF SCIENTIFIC VENTURES

bioavailable treatment choice for acute gastrointestinal symptoms and long-term disorder control. Tinctures provide dosing flexibility and quick action, and oils like peppermint oil have antispasmodic and antimicrobial effects useful in functional gastrointestinal syndromes.

Extract preparation procedures determine the phytochemical spectrum and yield. Sophisticated pharmaceutical practices tune in extraction conditions to yield highest active alkaloids, flavonoids, terpenes, and saponins. Semi-solid preparations such as ointments and creams are also formulated though less traditional for gastrointestinal problems, employed primarily for gastrointestinal external symptom relief such as pain and inflammation in complementary medicine.

9.4 Modern Formulations and Standardization

Combining traditional herbalism with contemporary drug technology has resulted in creative and improved dosage forms overcoming the shortcomings of traditional herbal uses. These are phytosomes, liposomes, nanoparticles, Nano emulsions, microspheres, and transdermal patches. Phytosome technology, for instance, capsular herbal extracts with phospholipids to dramatically enhance intestinal absorption and bioavailability, maximising therapeutic effects [32]

In addition, standardization is necessary to ensure the quality, safety, and efficacy of herbal medicines. This involves the quantitative measurement of marker compounds, phytochemical fingerprinting, and compliance with Good Manufacturing Practices (GMP). WHO international guidelines and pharmacopeia specifications ensure consistent quality control from cultivation to production and labelling. Standardized herbal products provide repeatable therapeutic action, minimize batch differences, and support greater regulatory acceptability worldwide. [33].

Regulatory infrastructures increasingly rely on science validation, clinical tests, and safety evaluations. Added utilization of sophisticated analytical methods like HPLC, GC-MS, and NMR spectroscopy generates descriptive phytochemical patterns for quality control. Ongoing development of standards aids consumer trust and increased integration of herbal therapies in mainstream medicine [34]

10. Precautions and Contraindications

10.1 Possible Side Effects

Herbal treatments, even though they are natural products, can produce side effects. Allergic reactions, gastrointestinal side effects like nausea, vomiting, diarrhoea, or constipation, and, infrequently, liver or kidney toxicity are possible. The inconsistency in herbal compound concentration and patient susceptibility makes side effect prediction more complicated. For instance, liquorice can cause hypertension and electrolyte imbalance if ingested in large amounts. Monitoring dosage is essential, and treatment should be stopped in case of resulting adverse symptoms. [35]





WISELEAF SCIENTIFIC VENTURES

10.2 Herb-Drug Interactions

Herbal drugs may interact with traditional pharmaceutical medications, either by changing the efficacy of medication or adding toxicity. Examples of such herbs are St. John's wort, which induces enzymes responsible for metabolizing drugs, thereby making certain medications like anticoagulants or immunosuppressants less effective. Other drugs might slow down the metabolism of drugs and elevate the drug level, thereby augmenting side effects. Patients on prescription medications, particularly those for chronic diseases, should be advised by physicians prior to initiating herbal therapy [36]

10.3 Guidelines for Safe Use

Proper use of digestive herbal medicines requires sourcing from good manufacturing practice (GMP) compliant manufacturers to ensure purity, quality, and standardized active ingredients of the final product. Label transparency is important so that label warnings include contraindication, side effects, and warnings about herb–drug interactions to allow proper use by consumers. Disclosure of all herbal consumption to medical professionals is important in order not to compound the action of standard drugs, particularly in susceptible populations like women during pregnancy, the elderly, and chronic patients. Initiation of therapy with the minimum effective dose and careful watch for side effects under expert supervision is recommended. Agencies like WHO and FDA stress pharmacovigilance, safety assessment based on traditional application, and health education to ensure appropriate use. Integrating standardized herbal therapy with modern medicine under medical guidance enhances treatment safety and effectiveness [37]

Table 2: Presenting guidelines for the safe use of herbal medicines in digestive health.

Aspect	Guideline	Reference
Quality and Standardization	Use herbal products from reputable sources with GMP and standardized active compound levels.	38
Labelling	Clear labelling with contraindications, side effects, and herb–drug interaction warnings.	38
Disclosure	Inform healthcare providers about herbal use to prevent adverse interactions.	39
Dosage and Monitoring	Start with low doses, monitor for side effects;	37





WISELEAF SCIENTIFIC VENTURES

	avoid prolonged unsupervised use	
Vulnerable Populations	Caution in pregnant/breastfeeding women, children, elderly, and patients with chronic illnesses	39

11. Future Prospects of Herbal Therapy in Digestive Health

The future of herbal medicine in digestive health is being forged by a convergence of scientific progress, sustainable considerations, and integrative healthcare paradigms. With increasing global demand for natural therapies, contemporary pharmacological research and biotechnological capabilities are assisting in the validation of traditional remedies, providing new insights into their mechanisms and their optimal formulation for clinical utility. [40]

11.1 Emerging Research Trends

Current studies concentrate on the identification of bioactive compounds in herbs conventionally applied to treat gastrointestinal (GI) ailments, including ginger, liquorice, peppermint, and Triphala. Research emphasizes how these plants generate multi-targeted actions, such as antioxidant, anti-inflammatory, antimicrobial, and prokinetic activities beneficial to digestive processes. Omics technologies—metabolomics, genomics, and proteomics—are advancing to help scientists comprehend molecular pathways through which these compounds regulate gut microbiota and mucosal integrity. [41]

Clinical studies are also gravitating toward evidence-based standardization, as more trials confirm the safety and efficacy of complex polyherbal preparations employed in Ayurveda and traditional Chinese medicine. New patented herbal medicines like DA-9701 (Motilitone) and STW-5 (Iberogast) provide exemplary successful translation of classical remedies to clinically validated medicines. Additionally, current studies investigate synergistic preparations that are combined by adding probiotics and herbal extracts to reclaim gut equilibrium, attenuate inflammation, and influence the gut-brain axis [8]

11.2 Integration of Herbal and Modern Medicine

One of the key future directions is how herbal medicine can be integrated with mainstream therapeutic models. The World Health Organization has focused on integrating traditional medicine into the mainstream health system to promote greater accessibility and patient-centered approaches. By integrating both evidence-based herbal preparations and allopathic medicine, the gap between the two is covered, allowing a holistic model perfectly suited for the management of chronic gastrointestinal diseases like irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD). [42]





WISELEAF SCIENTIFIC VENTURES

Cooperative models of herbalists, clinicians, and researchers now enable pharmacovigilance systems for safety and quality control. Contemporary healthcare institutions in many countries, such as India and China, already have evidence-based guidelines for treatment that encompass herbal interventions for digestive disorders. Digital health technologies also make personalized herbal prescriptions possible by means of AI-powered phytotherapy databases taking into account a patient's genetic profile, lifestyle, and eating preferences. [41]

11.3 Sustainable Use and Conservation of Medicinal Plants

Among the biggest threats to the herbal medicine industry is securing the sustainable supply of medicinal plants in the face of rising global demand and climate change. Habitat loss and overharvesting have put flagship species like *Boswellia sacra* and *Rhodiola rosea* at risk, which are critical to herbal pharmaceuticals. Sustainability approaches now prioritize ecosystem-based management with in-situ conservation, cultivation of wild populations, and governance of trade through certification mechanisms such as Fair Wild. [43]

Climate change is already modifying the distribution, phytochemical constitution, and yield of medicinal species utilized in GI remedies. Scientists suggest adaptive farming practices like controlled-environment cultivation and genomic selection for stress-tolerant varieties to ensure consistency in therapeutic quality. Further, conservation programs based on communities and ethnobotanical documentation projects are also vital to sustaining traditional plant knowledge for generations to come [44]

11.4 The Future Outlook

The future prospects of herbal therapy in gut health look very promising, with increasing scientific confirmation, technological innovation, and demand for natural products from consumers. Future studies will be directed towards the isolation of single bioactive molecules, determination of their modes of action at the molecular level, and designing targeted products that maximize efficacy and safety. Complementary use of herbal medicine alongside conventional therapies will become more common, encouraging a holistic treatment of gastrointestinal ailments. [45]

Additionally, breakthroughs such as nanotechnology and tailored medicine will enhance the bioavailability and specificity of herbal treatments, making them more potent. Ethical harvesting and sustainable sourcing of medicinal herbs will continue to be important, underpinned by rising concern for the environment and clean-label policies, guaranteeing long-term sustainability of herbal resources. In general, the future of herbal therapy in gastrointestinal health will be defined by evidence-based approaches, technological incorporation, and a keen focus on sustainability, rendering it an essential part of integral gastrointestinal management [46].





WISELEAF SCIENTIFIC VENTURES

12. Conclusion

The study of herbal medicine in gastrointestinal health highlights the profound intersection between ancient wisdom and contemporary scientific achievement. Herbal medicines such as ginger, fennel, peppermint, aloe vera, liquorice, and Triphala have been known to play complex functions in enhancing gastrointestinal health through anti-inflammatory, antioxidant, antimicrobial, and prokinetic activity for centuries. Technological advances and clinical trials now place these traditional medicines on firmer ground, reconciling age-old wisdom with contemporary evidence-based medicine.

Traditional digestive remedies, although useful, commonly possess negative side effects or short-lived efficacy. Herbal remedies, on the other hand, provide a holistic and sustainable solution, treating not just symptoms but also root imbalances. This balanced approach nourishes both gut health and overall wellness, in harmony with the international trend toward natural patient-centered healthcare.

The future of plant-based digestive wellness is in standardization, technology advancement, and international cooperation. New areas like phytopharmaceuticals, nanotechnology, and personalized herbal delivery are likely to increase efficacy and safety. Concurrently, sustainable cultivation, fair trade, and clinical proof are securing the ethical and ecological sustainability of plant resources. Thus, herbal medicine is well positioned to become an anchor of contemporary digestive care improving therapeutic efficacy, safety, and eco-friendliness for the next generations.

REFERENCES

1. Singh Mitra Pal, Cheema Harveer Singh, “The Use of Medicinal Plants in Digestive System Related Disorders: A Systematic Review ”Journal of Ayurvedic And herbal medicine , 2021, pg. No. 182-187
https://www.ayurvedjournal.com/JAHM_202173_03.pdf
2. Sensoy Ilkay, “A review on the food digestion in the digestive tract and the used *in vitro* models” , ELSEVIER Current research in food science, April 14, 2021
<https://pmc.ncbi.nlm.nih.gov/articles/PMC8134715/>
3. Khamda Rafat, Divsalar Farshad, Tirabadi Nahid Mirzaei, Sani Neda Nikhbakht, “A Systematic Review of Digestive Problems in Children and the Elderly Involved in Infectious Diseases, Relying on Nursing and Medical Measure”, Pak heart J, May 2024.
https://www.researchgate.net/publication/380940251_A_Systematic_Review_of_Digestive_Problems_in_Children_and_the_Elderly_Involved_in_Infectious_Diseases_Relying_on_Nursing_and_Medical_Measures
4. Friedman Lawrence S. “Digestive health “Harvard health Publishing, Nov 2, 2023
<https://www.health.harvard.edu/topics/digestive-health>





WISELEAF SCIENTIFIC VENTURES

5. Hena Ames , “10 digestive disorders and their symptoms”, Medical News Today, April 17, 2025

<https://www.medicalnewstoday.com/articles/list-of-digestive-disorders#sibo>

6. Salm S, Rutz J, van den Akker M, Blaheta RA, Bachmeier BE. Current state of research on the clinical benefits of herbal medicines for non-life-threatening ailments. *Front Pharmacol.* 2023; 14:1234701.

<https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1234701/full>

7. Elmaghraby DA, Alsalman GA, Alawadh LH, Al-Abdulqader SA, Alaithan MM, Alnuwaysir BI. Integrated traditional herbal medicine in the treatment of gastrointestinal disorder: the pattern of use and the knowledge of safety among the Eastern Region Saudi population. *BMC Complement Med Ther.* 2023 Oct 23;23(1):373.

<https://pubmed.ncbi.nlm.nih.gov/articles/PMC10591345/>

8. Yao Y, Habib M, Bajwa HF, Qureshi A, Fareed R, Altaf R, et al. Herbal therapies in gastrointestinal and hepatic disorders: An evidence-based clinical review. *Front Pharmacol.* 2022; 13:962095. Doi: 10.3389/fphar.2022.962095.

<https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.962095/full>
82025 [cited 2025 Oct 13].

https://livgastro.in/patient_education/the-most-common-digestive-issues-and-how-to-prevent-them/

10. . Digestive diseases. MedlinePlus Medical Encyclopaedia [Internet]. Bethesda (MD): National Library of Medicine (US); [updated 2023 Dec 31; cited 2025 Oct 13].

<https://medlineplus.gov/ency/article/007447.htm>

11. Team Dr Lal Path Labs. 5 Most Common Diagnostic Tests for Digestive Disorders [Internet]. Dr Lal Path Labs Blogs; 2024 Dec 13

<https://www.lalpathlabs.com/blog/tests-for-diagnosing-digestive-diseases/>

12. Kauvery Hospitals. Effective Treatments for the Most Common Digestive Problems [Internet]. Bangalore, India: Kauvery Hospitals; 2024 Sep 2

<https://www.kauveryhospitalsbangalore.com/blog/treatments-for-most-common-digestive-problems>

13. Lahner E, Bellentani S, De Bastiani R, Tosetti C, Cicala M, Esposito G, Arullani P, Annibale B. A survey of pharmacological and nonpharmacological treatment of functional gastrointestinal disorders. *United European Gastroenterol J.* 2013 Oct;1(5):385–393.

<https://pubmed.ncbi.nlm.nih.gov/articles/PMC4040767/>

14. Chang Gue Son, Bian ZX, Wang JH, Raghavendran HB. Complementary and Alternative Medicine for Diseases and Disorders in Digestive Tract: Basic to Clinics. *Evid Based Complement Alternat Med.* 2013; 2013:565279.

<https://onlinelibrary.wiley.com/doi/10.1155/2013/565279>





WISELEAF SCIENTIFIC VENTURES

15. Yao Y, Habib M, Bajwa HF, Qureshi A, Fareed R, Altaf R, Ilyas U, Duan Y, Abbas M. Herbal therapies in gastrointestinal and hepatic disorders: An evidence-based clinical review. *Front Pharmacol.* 2022 Oct 5; 13:962095.
<https://pmc.ncbi.nlm.nih.gov/articles/PMC9581220/>
16. Jangra B, Kulshreshtha S, Goyal A, Jachak SM. The role of gut microbiota in disease management: Ayurvedic perspectives on metabolic diseases and health. *Phytomedicine Plus.* 2025 Feb 1; 5:100133
<https://www.sciencedirect.com/science/article/pii/S2667031325000041>
17. Moniruzzaman M, Shah A, Morrison M, Koloski N, Gwee KA, Chen M, Kim Y, Ayaki K, Efferth T, Holtmann G. Mechanisms of action and clinical effectiveness of herbal treatments for disorders of gut-brain interaction. *Dig Liver Dis.* 2025
<https://pubmed.ncbi.nlm.nih.gov/40713393/>
18. Mohamed M, Al-Attar MN, Ibrahim MA, Al-Ghamdi MS, Al-Dossary S. Comparative evaluation of two herbal formulas for gastrointestinal function and gut microbiota modulation in rats with loperamide-induced dyspepsia. *Sci Rep.* 2025 Sep 10;15(1):31186. Doi: 10.1038/s41598-025-15574-9.
<https://www.nature.com/articles/s41598-025-15574-9>
19. Kim YS, Kim JW, Ha NY, Kim J, Ryu HS. Herbal Therapies in Functional Gastrointestinal Disorders: A Narrative Review and Clinical Implication. *Front Psychiatry.* 2020 Jul 9; 11:601. doi: 10.3389/fpsy.2020.00601. PMCID: PMC7363406.
<https://www.frontiersin.org/journals/psychiatry/articles/10.3389/fpsy.2020.00601/full>
20. Bodagh MN, Maleki I, Hekmatdoost A. Ginger in gastrointestinal disorders: A systematic review of clinical trials. *Food Sci Nutr.* 2018 Nov 5;7(1):96–108. PMCID: PMC6341159.
<https://pmc.ncbi.nlm.nih.gov/articles/PMC6341159/>
21. Hirata M, Laurindo LF, Rodrigues VD, Caracio FCC, Valenti VE, Pereira ESBM, Mellem RH, Detregiachi CRP, Bueno MdS, Campos LMG, et al. Investigating the Health Potential of Mentha Species Against Gastrointestinal Disorders—A Systematic Review of Clinical Evidence. *Pharmaceuticals (Basel).* 2025 May 8;18(5):693. PMCID: PMC12114791.
<https://pmc.ncbi.nlm.nih.gov/articles/PMC12114791/>
22. Badgajar SB, Patel VV, Bandivdekar AH. *Foeniculum vulgare* Mill: A Review of Its Botany, Phytochemistry, Pharmacology, Contemporary Application, and Toxicology. *Biomed Res Int.* 2014 Aug 3; 2014:842674. PMCID: PMC4137549.
<https://pmc.ncbi.nlm.nih.gov/articles/PMC4137549/>
23. Guo X, Mei N. Aloe vera: A review of toxicity and adverse clinical effects. *J Environ Sci Health C Environ Carcinog Ecotoxicol Rev.* 2016 Apr 2;34(2):77–96. PMCID: PMC6349368.
<https://pmc.ncbi.nlm.nih.gov/articles/PMC6349368/>





WISELEAF SCIENTIFIC VENTURES

24. McGrane K. What Are Liquorice Root's Benefits and Downsides? [Internet]. Healthline. 2024 May 1 [cited 2025 Oct 15]. Available from: <https://www.healthline.com/nutrition/licorice-root>
25. Peterson CT, Denniston K, Chopra D. Therapeutic Uses of Triphala in Ayurvedic Medicine. *J Altern Complement Med*. 2017 Aug 1;23(8):607–614. PMID: PMC5567597. <https://pubmed.ncbi.nlm.nih.gov/articles/PMC5567597/>
26. Yao Y, Habib M, Bajwa HF, Qureshi A, Fareed R, Altaf R, et al. Herbal therapies in gastrointestinal and hepatic disorders: An evidence-based clinical review. *Front Pharmacol*. 2022; 13:962095. Doi: 10.3389/fphar.2022.962095. PMID: PMC9581220. <https://pubmed.ncbi.nlm.nih.gov/articles/PMC9581220/>
27. Hota D, Srinivasan A, Panigrahi MK, Dalua SS, Tiwari P, Valavan R. A clinical study on the efficacy and safety of poly-herbal formulation in managing functional dyspepsia. *Phytomedicine Plus*. 2025 Feb;5(1):100671. <https://www.sciencedirect.com/science/article/pii/S2667031324001453>
28. Salm S, Rutz J, van den Akker M, Blaheta RA, Bachmeier BE. Current state of research on the clinical benefits of herbal medicines for non-life-threatening ailments. *Front Pharmacol*. 2023; 14:1234701. Doi: 10.3389/fphar.2023.1234701. <https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1234701/full>
29. Rathod PS, et al. Herbal potential for treatment of peptic ulcer. *Indo Am J Pharm Sci*. 2025;12(1):51–56.
30. Sharma S, Raj H, Gupya J. Herbal tea: a comprehensive review of health benefits and therapeutic potential. *Int J Res Publ Rev*. 2025;6(5):1376–9. <https://ijrpr.com/uploads/V6ISSUE5/IJRPR44724.pdf>
31. Asim M, Yogi B, Gupta SK, Ramnivas, Verma RS, Singh AK. Formulation and evaluation of polyherbal digestive capsules. *Pharm Chem J*. 2025;12(3):37–43. <https://tpcj.org/download/vol-12-iss-3-2025/TPCJ2025-12-03-37-43.pdf>
32. Grandhi S, Rao Kasula R, Ramakrishna Reddy M, Sharma S, Kumari S, Khan S, Awasthi A, Anjana Male CKVLSN. Comprehensive Review of Herbal Extracts: Modern Pharmaceutical Uses, Phytochemical Composition, Extraction Methods, Historical Legacy. *J Neonatal Surg*. 2025;14(6S):527–33. <https://www.jneonatalurg.com/index.php/jns/article/view/2269>
33. Mali K, Chandrawati LS, Soni R, Gupta M. Formulation of herbal drug into modern dosage form. *J Neonatal Surg*. 2025;14(32s):3287–95. https://www.jneonatalurg.com/index.php/jns/article/download/7923/6928/25374?utm_source=perplexity
34. Jain SD, Shrivastava SK, Agrawal A, Gupta AK. WHO guidelines for quality control of herbal medicines: From cultivation to consumption. *Int J Pharm Chem Anal*. 2024;11(3):212–25. <https://ijpca.org/archive/volume/11/issue/3/article/22100>





WISELEAF SCIENTIFIC VENTURES

35. Cleveland Clinic. Gastrointestinal Diseases. Cleveland Clinic. [cited 2025 Oct 17]. Available from: <https://my.clevelandclinic.org/health/articles/7040-gastrointestinal-diseases>
36. Yao Y, Habib M, Bajwa HF, Qureshi A, Fareed R, Altaf R, et al. Herbal therapies in gastrointestinal and hepatic disorders: An evidence-based clinical review. *Front Pharmacol.* 2022 Oct 5; 13:962095. Available from: <https://pmc.ncbi.nlm.nih.gov/articles/PMC9581220/>
37. Kotnis M. Safety rules and regulations for Herbal medicines. In: 9th Edition of International Conference on Traditional Medicine and Integrative Health; 2023 [cited 2025 Oct 17]. Available from: <https://traditionalmedicineconference.com/program/scientific-program/2023/safety-rules-and-regulations-for-herbal-medicines>
38. World Health Organization. WHO guidelines herbal medicines. 2005. [cited 2025 Oct 17]. Available from: http://www.sefap.it/farmacovigilanza_news_200501/WHO%20guidelines%20herbal%20medicines.pdf
39. Ewumi O. Herbal medicine: Types, uses, and safety. *Medical News Today.* 2022 Oct 6. [cited 2025 Oct 17]. Available from: <https://www.medicalnewstoday.com/articles/herbal-medicine>
40. Gupta S, Modanwal A, Pandey AK. Herbal Drugs Used in Gastrointestinal Disorders. *Int J Innov Sci Res Technol.* 2025 Apr;10(4):3134-3139. <https://www.ijisrt.com/assets/upload/files/IJISRT25APR1210.pdf>
41. dsm-firmenich. What's next for gut health? 5 breakthrough trends from Probiota 2025. *Talking Nutrition, Health & Care* [Internet]. 2025 Mar 11 [cited 2025 Oct 17]. Available from: <https://www.dsm-firmenich.com/en/businesses/health-nutrition-care/news/talking-nutrition/the-future-of-gut-health-5-breakthrough-trends-from-probiota-2025.html>
42. World Health Organization, Regional Office for South-East Asia. Integrating Traditional Medicine in Health Care. *Feature Stories* [Internet]. 2023 Jan 30 [cited 2025 Oct 17]. Available from: <https://www.who.int/southeastasia/news/feature-stories/detail/integrating-traditional-medicine>
43. Mykhailenko O, Jalil B, McGaw LJ, Echeverría J, Takubessi M, Heinrich M. Climate change and the sustainable use of medicinal plants: a call for "new" research strategies. *Front Pharmacol.* 2024 Feb 2; 15:1496792. <https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2024.1496792/full>
44. Harun N, Waheed M, Rubab SS, Hashem A, Al-Saif AM, Abd-Allah EF. Ethnomedicinal documentation of plants used for gastrointestinal disorders in Sahiwal District Pakistan. *Sci Rep.* 2025; 15:15632. <https://www.nature.com/articles/s41598-025-15632-2>
45. Future Market Insights. Digestive Health Supplements Market. *Global: Future Market Insights*; [Date of latest report, est. 2024/2025] [cited Oct 17, 2025]. Available from: <https://www.futuremarketinsights.com/reports/digestive-health-supplements-market>





WISELEAF SCIENTIFIC VENTURES

46. Fortune Business Insights. Herbal Medicine Market Size, Share & Industry Analysis, By Form, By Application, and Regional Forecast, 2025-2032. Pune (India): Fortune Business Insights; 2025 [cited Oct 17, 2025]. Available from:
<https://www.fortunebusinessinsights.com/herbal-medicine-market-106320>





WISELEAF SCIENTIFIC VENTURES

HEALING ROOTS: INTEGRATIVE HERBAL APPROACHES TO CHRONIC ILLNESS

CHAPTER-7 NEUROPROTECTIVE AND COGNITIVE ENHANCING HERBS

Tejus B R^{1*}, Tharun M²

¹ Student, School of Bio Sciences and Technology, Vellore Institute of Technology, Katpadi, Vellore, Tamil Nadu 632014, India

² Student, Department of Biochemistry, JSS academy of Higher education and research, JSS university, Mysuru, Karnataka, India

Email: tejus.br2000@gmail.com

ABSTRACT

Neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, and cognitive decline represent significant global health challenges with limited conventional therapeutic options. Medicinal plants rich in bioactive phytochemicals including flavonoids, alkaloids, polyphenols, and terpenoids have demonstrated substantial neuroprotective and cognitive-enhancing potential through multiple molecular mechanisms. Ginkgo biloba enhances cerebral blood flow, provides antioxidant and anti-amyloidogenic activity, with clinical trials demonstrating 3% improvement on Alzheimer's Disease Assessment Scale-Cognitive subscale following 120-240 mg daily for 3-6 months. Bacopa monnieri improves memory free recall, verbal learning, and delayed word recall through cholinergic modulation, neurogenesis stimulation, and oxidative stress reduction at doses of 300-450 mg extract daily for 12 weeks. Withania somnifera (Ashwagandha) withanolides inhibit amyloid-beta aggregation, suppress neuroinflammatory pathways, and enhance dopaminergic function, showing significant neuroprotection in Parkinson's disease and Alzheimer's disease models. Rosemary and sage extracts inhibit acetylcholinesterase and butyrylcholinesterase activity, increase antioxidant enzyme expression (SOD, catalase, glutathione peroxidase), and improve long-term memory through anti-inflammatory mechanisms. Centella asiatica promotes dendritic arborization, enhances memory consolidation, and provides anti-apoptotic neuronal protection. These herbs exhibit multi-targeted neuroprotective effects addressing oxidative stress, neuroinflammation, and amyloid pathology, offering promising adjunctive strategies for neurodegenerative disease management requiring further clinical investigation.

Keywords: Neuroprotection, Cognition, Herbs; Medicine; Treatment





WISELEAF SCIENTIFIC VENTURES

1. Introduction

Neurodegenerative illnesses such as Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis represent significant worldwide health issues, with prevalence increasing as populations age and demographic structures evolve [1]. These illnesses result in significant cognitive and functional decline, imposing considerable economical burdens and psychological stress on patients, carers, and healthcare systems [1,2]. Although contemporary pharmacotherapies have produced modest improvements in symptom control, effective disease-modifying treatments that are well tolerated remain lacking, especially agents that penetrate the blood–brain barrier and address the complex, multifactorial pathophysiology of neurodegeneration[2,3] .

Numerous studies have been conducted on the potential of medicinal plants and natural products to prevent and treat neurodegenerative diseases because they are rich sources of phytochemicals that have been shown to have neuroprotective and cognition-enhancing effects [4,5]. Herbal remedies have a long history of cross-cultural use for improving cognition, have multitarget effects, and often have favourable safety profiles [6]. In order to direct future research and clinical use, a thorough synthesis of herbal mechanisms, therapeutic efficacy, safety, and practical limitations is required due to the growing preclinical and clinical evidence [7,8]. Important pathways linked to neurodegeneration, such as oxidative stress, neuroinflammation, mitochondrial dysfunction, neurotransmitter dysregulation, disrupted neurotrophic signalling, and synaptic impairment, are modulated by phytochemicals [5,9,10]. Herbal compounds often show combinatorial, pleiotropic effects that may provide better therapeutic potential in multifactorial disorders like Parkinson's and Alzheimer's disease than single target synthetic agents [5, 10]. Herbs like *Bacopa monnieri*, *Ginkgo biloba*, *Withania somnifera*, *Hericium erinaceus*, *Centella asiatica*, and *Clitoria ternatea* have long been used in traditional medical systems like Ayurveda and Traditional Chinese Medicine to improve mood, memory, and focus [6, 11] The growing use of functional foods and plant-based supplements for cognitive health around the world is a reflection of the shortcomings of existing pharmaceutical treatments as well as the growing inclination towards natural, integrative approaches [6,12,13,14].

This chapter summarises the most recent research on neuroprotective and cognition-improving herbs, emphasising their mechanistic justification, key clinical findings, safety and pharmacokinetic profiles, and useful suggestions. It is divided into eight sections: phytochemical pharmacology; safety, quality, and regulatory considerations; mechanisms of neurodegeneration and herbal modulation; comprehensive monographs of important botanicals; evidence synthesis and meta-analysis; limitations and research priorities; and a succinct summary with future perspectives. The evidence on herbs that protect the nervous system and improve cognition is reviewed and integrated in this chapter, with a focus on their





WISELEAF SCIENTIFIC VENTURES

mechanistic underpinnings, important clinical findings, safety profiles, pharmacokinetics, and useful recommendations. It is divided into eight sections: phytochemical pharmacology; evidence synthesis; safety and quality considerations; limitations and research priorities; core definitions and domains; mechanisms of neurodegeneration and how herbs may modulate them; detailed profiles of principal herbs; limitations and research priorities; and a succinct summary with prospects for future work.

It is organized into eight parts: core definitions and domains; mechanisms of neurodegeneration and how herbs may modulate them; detailed profiles of principal herbs; phytochemical pharmacology; evidence synthesis; safety and quality considerations; limitations and research priorities; and a concise summary with perspectives for future work.

Neuroprotection and Disease Modification

By lowering oxidative stress, neuroinflammation, apoptotic pathways, and synaptic or cellular dysfunction, neuroprotection refers to treatments or substances that maintain or restore neuronal structure and function in an effort to stop or slow the progression of neurodegenerative diseases [1, 16]. Instead of just treating symptoms, disease modification involves changing the underlying pathophysiology of a disorder, such as by reducing the accumulation of pathogenic proteins, improving neurotrophic support, or correcting metabolic and synaptic deficiencies [7,17,18,19].

Cognitive Domains (Memory, Attention, Executive Function)

Most neurodegenerative diseases are characterised by cognitive impairment [14,16,19]. Memory, attention, executive function, and processing speed are the main cognitive domains assessed in clinical practice and research. The Mini Mental State Examination (MMSE), Trail Making Tests A and B, digit span, Stroop test, and specialised neuropsychological batteries focussing on particular cognitive domains are examples of commonly used validated outcome measures [20,21].

2. Mechanisms of Neurodegeneration and Herbal Targets

2.1 Core Pathogenic Processes

2.1.1 Oxidative Stress and Neuroinflammation

The brain is extremely susceptible to oxidative damage due to its high metabolic oxygen consumption, enrichment in polyunsaturated fatty acids, and comparatively low antioxidant capacity. Additionally, neuroinflammation driven by microglia and astrocytes causes progressive neuronal injury in almost all neurodegenerative diseases [1,7,16,22,23]. Increased reactive oxygen species damage proteins, lipids, and nucleic acids, initiate necrotic and apoptotic cascades, and enhance proinflammatory signalling by upregulating TNF α , NF κ B, and cytokines [24,25,26,27].

2.1.2 Mitochondrial Dysfunction and Excitotoxicity

Oxidative stress and excitotoxic damage are made worse by neuronal mitochondrial dysfunction, which is characterised by decreased ATP production, increased ROS generation,





WISELEAF SCIENTIFIC VENTURES

and altered mitochondrial dynamics [17,18,23,25]. Proinflammatory mediators exacerbate intracellular calcium overload, mitochondrial failure, and neuronal death caused by disruption of glutamate regulation and excessive NMDA receptor activation [23,28].

2.1.3 Synaptic Loss and Neurotrophic Deficits

Compared to overt neuronal loss or traditional pathological markers like amyloid plaques, early, progressive synaptic degeneration—characterized by loss of plasticity and decreased neurotrophic support like BDNF and NGF—is a stronger predictor of cognitive decline [29,30,31,32,33]. When BDNF and other neurotrophic factors are reduced, synaptic maintenance and neuronal regeneration are compromised, leading to conditions that increase the risk of long-term cognitive decline [32, 33].

2.2 Herbal Targets and Modes of Action (Concise)

2.2.1 Antioxidant and Anti-Inflammatory Pathways

Flavonoids, polyphenols, and terpenoids are examples of phytochemicals that stimulate the Nrf2/ARE pathway to upregulate antioxidant enzymes (like SOD, GPx, catalase, and HO 1) and inhibit NF κ B signalling, which lowers the expression of proinflammatory cytokines [24,25,26,34,35,36,37,38,39]. Numerous in vitro and in vivo neurodegeneration models support the idea that compounds with both antioxidant and anti-inflammatory properties protect cells by reducing ROS levels and suppressing neuroinflammatory pathways [24,25,34,36,40].

2.2.2 Neurotrophic Support and Synaptic Plasticity

Bacosides, withanolides, and erinacines are examples of herbal constituents that support dendritic growth and strengthen synaptic resilience by stimulating the production and signalling of neurotrophins, such as BDNF and NGF, through CREB dependent and related pathways [29,30,31,32,33,35]. Certain phytochemicals promote synaptic repair and stimulate neurogenesis by increasing the expression of proteins related to plasticity and CREB phosphorylation [29,30,31,32,36].

2.2.3 Neurotransmitter Modulation and BBB Considerations

By blocking acetylcholinesterase, increasing choline acetyltransferase activity, or maintaining neurotransmitter availability, herbs can directly or indirectly affect the cholinergic, dopaminergic, and GABAergic neurotransmitter systems [11,24,29,34,40]. Central activity depends on blood–brain barrier permeability; phytochemicals like ginkgolides, withanolides, erinacines, and some flavonoids have demonstrated BBB crossing in preclinical research, and nanoparticle-based delivery systems can increase the bioavailability of poorly penetrating substances like curcumin. [8, 41].

3. Major Neuroprotective and Nootropic Herbs (Focused Selection)

3.1 Selection Criteria (Evidence + Traditional Use)





WISELEAF SCIENTIFIC VENTURES

The included herbs are backed by current preclinical and clinical research and satisfy traditional ethnobotanical standards for applications related to the nervous system or cognition [9,10,13,14,42]. Most of them have identified active compounds, mechanistic or translational justification, and early clinical evidence from studies in patient groups, healthy individuals, or older adults who are at risk [11,12,43,44,45].

3.2 *Bacopa monnieri*

Bacopa monnieri contains a complex mixture of triterpenoids, alkaloids, flavonoids, betulinic acid derivatives, and saponin glycosides, primarily bacoside A and B and bacopasaponins [11,29,41]. These components increase BDNF and NGF expression, inhibit acetylcholinesterase, modulate cholinergic and monoaminergic neurotransmission, boost synaptic resilience through kinase-mediated signalling and neurogenesis, and have potent antioxidant and anti-inflammatory effects (inducing SOD, catalase, GPx, and suppressing NF κ B and cytokines) [11,29,40,41,46].

Standardised *Bacopa monnieri* extracts (typically 300–600 mg/day with 20–55% bacoside) show quantifiable improvements in memory retention, working memory, attention, and processing speed in older adults, children with ADHD, and various neuropsychiatric populations, according to meta-analyses of randomised controlled trials [47,48,49,50,51]. After 8–12 weeks of treatment, clinical trials show improvements in MMSE, ADAS Cog, and stress or mood measures; in some head-to-head comparisons, effect sizes are comparable to those of some traditional cognitive medications [47,48,49,50]. Improved executive functioning and reduced hyperactivity are reported in paediatric population trials. The majority of reported side effects are mild and include occasional headaches, loose stools, and upset stomachs. Treatment discontinuation due to side effects is rare [50,52]. Despite acknowledging study heterogeneity and possible bias, systematic reviews consistently find improvements in composite cognitive measures and free recall [29,50,51].

3.3 *Ginkgo biloba* (EGb 761)

The standardised *Ginkgo biloba* leaf extract EGb 761 has very little ginkgolic acid (<5 ppm), 5.4–6.6% terpene lactones (ginkgolides A–C, bilobalide), and 22–27% flavonol glycosides (quercetin, kaempferol). It is a potent scavenger of reactive oxygen species, stimulates the Nrf2/ARE antioxidant pathway, inhibits neuroinflammatory signalling (by lowering TNF α and IL 6 through the MAPK/PKC/NF κ B pathways), boosts cerebral blood flow and microcirculation, and improves mitochondrial function [24,25,28,53].

According to extensive randomised trials, EGb 761 reduces neuropsychiatric symptoms (NPI) in mild to moderate dementia and cognitive impairment after infections like COVID-19, improves everyday functioning, and produces modest but statistically significant gains in cognitive measures (MMSE, ADAS Cog) [54,55,56,57,58]. Daily doses of 120–240 mg given for 12–24 weeks show clinical benefits from EGb 761, with mixed and vascular dementia subtypes showing the strongest evidence of efficacy [57,58,59,60]. EGb 761 has a tolerability





WISELEAF SCIENTIFIC VENTURES

profile comparable to comparators and is superior to placebo for cognitive outcomes, according to meta analyses and systematic reviews [54,57,61,62] .

EGB 761 rarely causes serious side effects; reported side effects are usually mild (headache, gastrointestinal symptoms), and bleeding complications are uncommon but may increase when combined with anticoagulant or antiplatelet drugs [52,63,64,65] .

3.4 *Withania somnifera*

Steroidal lactones, primarily withanolides like Withaferin A, Withanolide A, Withanoside IV and VI, and Somnifone, are abundant in *Withania somnifera* (Ashwagandha). Withanolides increase synaptic proteins (NF H, MAP2, PSD 95), activate Nrf2, suppress NF κ B-driven inflammation, enhance BDNF and NGF signalling, and affect GABAergic, dopaminergic, and cholinergic neurotransmission [26,30,34,37,44,66,67] .

Withania somnifera reduces oxidative stress and cortisol, improves sleep, eases neuropsychiatric symptoms, and enhances memory and cognitive function in ageing, stress, Alzheimer's disease, Parkinson's disease, and other neurobehavioral conditions, according to randomised and preclinical studies [66,67,68,69,70,71]. Standardised *Withania somnifera* root or leaf extracts were most frequently tested in clinical trials at doses of 300–600 mg/day, usually standardised to ≥ 5 –10% withanolides [67,69,70,71] .

3.5 *Hericium erinaceus* (Lion's Mane)

The mycelium of *Hericium erinaceus* contains erinacines (cyathane diterpenoids), while the fruiting bodies contain hericenones. Both classes increase the production of NGF and BDNF, decrease neuroinflammation by activating Nrf2/HO 1, and alter neurotransmitters like acetylcholine, dopamine, and serotonin [31,35,45,72,73,74].

With few reported side effects, daily oral *Hericium erinaceus* supplementation (1-3 g) for 8–16 weeks may improve MMSE and other cognitive measures in older adults with mild cognitive impairment, according to small-scale trials and pilot randomised studies [45,75,76]. *Hericium erinaceus* upregulates NGF, has anti-inflammatory properties, and stimulates synaptogenesis, according to preclinical research [31,35,72,73,77].

3.6 *Centella asiatica* or *Clitoria ternatea* (focused: *Centella asiatica*)

In addition to flavonoids, phenolic acids, and essential amino acids, *Centella asiatica* is rich in triterpene glycosides (such as asiaticoside and brahmoside) [12, 78]. *Centella asiatica* produces mild acetylcholinesterase inhibition, boosts BDNF and dendritic branching, and provides antioxidant and anti-apoptotic protection through Nrf2 activation [12,36,78,79,80,81]. *Centella asiatica* may enhance mood and cognition in preclinical models and older adults, according to small human studies and animal experiments; an oral extract enhanced memory and object recognition in perinatal hypothyroid mice [81,82,83]. Adults typically take 250–750 mg of *Centella asiatica* per day, but traditional preparations typically involve topical applications, decoctions, or teas [12,78,82].





WISELEAF SCIENTIFIC VENTURES

4. Bioactive Constituents and Brief Pharmacology

4.1 Table 1: Representative Phytochemical Classes

Phytochemical	Source Herb	Description
Bacosides	<i>Bacopa monnieri</i>	Saponin glycosides promoting neuronal signalling & antioxidant defence
Ginkgolides	<i>Ginkgo biloba</i>	Diterpene lactones with anti-inflammatory & neuroprotective actions
Withanolides	<i>Withania somnifera</i>	Steroidal lactones acting as Nrf2 activators, GABA agonists
Erinacines	<i>Hericium erinaceus</i>	Cyathane diterpenoids stimulating NGF synthesis
Asiaticosides	<i>Centella asiatica</i>	Triterpenoids supporting synaptic plasticity & antioxidation
Anthocyanins	<i>Clitoria ternatea</i>	Polyphenols/flavonoids with free radical scavenging effects

Collectively, these herbs exert antioxidant and anti-inflammatory effects, promote neurotrophic signalling, and modulate neurotransmitter systems, which together explain their reported nootropic and neuroprotective benefits [11,12,31,35,38,43,44].

4.2 Mechanism of Molecular Actions Linked to Cognition

- **Antioxidant/Nrf2:** Antioxidant enzymes like SOD, GPx, catalase, and HO 1 are expressed more when Nrf2 is activated by bacosides, withanolides, erinacines, and flavonoids [24,29,30,32,33,36,38,40].
- **Anti inflammatory/NF κ B:** Ginkgolides, withanolides, and curcumin decrease the production of proinflammatory cytokines and suppress NF κ B-driven inflammatory signalling [24,25,26,27,34].
- **BDNF/NGF Upregulation:** Neurotrophic factors, such as BDNF (produced by Bacopa and Hericium) and NGF (produced by Hericium, Withania, and Centella), stimulate neurogenesis and improve synaptic plasticity [29,30,31,32,33,35,36].
- **AChE Modulation:** Acetylcholinesterase is inhibited by bacopa and ginkgo, supporting memory function and preserving cholinergic signalling [11,24,29,40].

4.3 Pharmacokinetics and BBB Penetration

Ginkgolides, withanolides, and certain erinacines exhibit greater lipophilicity (higher SlogP and fewer hydrogen bond donors/acceptors), which facilitates blood–brain barrier penetration [8, 41]. To improve systemic and central nervous system exposure and overcome poor absorption, formulation strategies like nanoparticulate delivery or coadministration with bioavailability enhancers (like piperine with curcumin) are employed [41]. Standardised





WISELEAF SCIENTIFIC VENTURES

preparations, such as proprietary *Hericium* formulations, CDRI 08 for *Bacopa*, and EGb 761 for *Ginkgo*, offer consistent phytochemical composition across batches and enhance pharmacokinetic behaviour reproducibility [41,43,84].

5. Evidence Synthesis: Preclinical and Clinical Highlights

5.1 Preclinical Consistency and Translational Caveats (Short)

These herbs consistently reduce oxidative and inflammatory damage, preserve synaptic and neurotrophic markers, and enhance behavioural measures of mood, memory, and attention in a variety of cellular and animal models [11,12,24,29,30,31,36,46]. Inconsistent extract composition, biological differences between species, methodological flaws in trials, and a great deal of variation in pharmacokinetics and dosing schedules all limit clinical translation [14,50,54,57,59,82].

5.2 Clinical Evidence Table

Table 2: Mechanisms, Clinical Evidence, and Comparative Efficacy

Herbal Compound	Active Constituents	Primary Mechanisms	Clinical Outcomes	Safety Profile
Bacopa monnieri	Bacosides (A & B), alkaloids, flavonoids	Antioxidant, anti-inflammatory, cholinesterase inhibition, BDNF enhancement, amyloid reduction	Improved memory, attention, processing speed (8-12 wks); 85% ADHD attention improvement; AD/MCI cognitive benefits	Mild GI effects at high doses; LD50 >2000 mg/kg; well-tolerated long-term
Ginkgo biloba	Flavone glycosides, terpene lactones (ginkgolides, bilobalide)	ROS scavenging, anti-inflammatory, mitochondrial protection, blood flow enhancement,	Improved cognition in aging; AD symptom improvement; enhanced peripheral circulation	Mild headache, GI upset; bleeding risk at high doses; generally





WISELEAF SCIENTIFIC VENTURES

		neuroprotectio n		well- tolerated
Withania somnifera (Ashwagandh a)	Withanolides (WA, WS), alkaloids, saponins	Potent antioxidant, GABA modulation, stress reduction, BDNF upregulation, tau reduction	Stress/anxiety reduction; memory enhancement; neuroprotection in neuroinflammato ry models	Mild GI effects, drowsiness; safe at therapeutic doses; LD50 >2000 mg/kg
Curcuma longa (Turmeric)	Curcuminoids (curcumin, demethoxycurcumi n), essential oils	Strong NF-κB inhibition, NLRP3 inflammasome suppression, amyloid clearance, antioxidant	AD-related cognitive decline slowing; anti- inflammatory effects; neuroprotection in preclinical models	Poor bioavailabilit y without piperine; mild GI effects; excellent safety profile
Salvia officinalis (Sage)	Phenolic compounds, rosmarinic acid, salvianolic acids	Cholinesterase inhibition, antioxidant, anti- inflammatory, neuroprotectio n	Improved cognition in aging; memory enhancement; benefits in MCI populations	Generally safe; minimal adverse effects; well- tolerated at therapeutic doses
Panax ginseng (Asian Ginseng)	Ginsenosides (Rb1, Rg1, Re), polysaccharides, phenolic compounds	Antioxidant, anti- inflammatory, neurotransmitt er modulation, mitochondrial protection,	Enhanced cognition and working memory; improved fatigue and mood; neuroprotection in	Mild insomnia, headache; generally safe; some interactions with





WISELEAF SCIENTIFIC VENTURES

		stress adaptation	neuroinflammatory models	anticoagulants possible
--	--	-------------------	--------------------------	-------------------------

References for clinical trials: Bacopa [47,48,49,50,51], Ginkgo [54,55,56,57,58,60,61], Withania [67,69,70,71], Hericium [45,75,76], Centella [82, 83].

When compared to a placebo, meta-analyses of standardised Bacopa extracts show notable improvements in free recall and composite cognitive tests, along with low dropout rates and only minor side effects [50, 51]. Systematic reviews of the standardised Ginkgo biloba extract EGb 761 show generally good tolerability and a modest symptomatic benefit in dementia, especially in mixed and vascular subtypes. However, there is a warning about possible interactions with anticoagulant medications [54,57,61,62]. There is increasing evidence for Withania and Hericium, but the quality of current research and small sample sizes limit the findings [13,67,75,76].

6. Safety, Interactions, and Quality Considerations

In clinical trials, the majority of widely used medicinal herbs show good tolerability, with mild and rare adverse events [52,63,85]. Gastrointestinal symptoms (nausea, diarrhoea, cramps—particularly with Bacopa; milder with Ginkgo, Withania, and Centella), rare allergic skin reactions (particularly with Ginkgo), and infrequent bleeding events—especially when Ginkgo is combined with anticoagulants or antiplatelet medications—are among the generally mild adverse events that have been reported [63,64]. Significant hepatotoxicity or renal toxicity has not been found in controlled trials of standardised formulations [66,84,85].

When combined with warfarin or direct oral anticoagulants, *Ginkgo biloba* may increase anticoagulant and antiplatelet activity; possible interactions with SSRIs and anticonvulsants have also been documented (63,64). Although rare theoretical potentiation of CNS depressants has been proposed, Bacopa has no well-documented clinical drug interactions; When taken with medications that affect the central nervous system, Centella asiatica appears to be low risk and has no significant documented interactions, but it still needs to be closely watched; Although this is usually not clinically significant at standard dosages, *Withania somnifera* can slightly intensify the sedative effects of benzodiazepines and barbiturates (63,64).

To guarantee repeatable pharmacology, consistent therapeutic effects, and predictable safety, extracts must be standardised to specified bioactive levels (such as bacosides $\geq 20\%$, withanolides $\geq 5\%$, and the terpene profile in EGb 761) [41,43,84]. WHO and international standards set maximum permissible levels for aflatoxins and other contaminants and require testing herbal products for microbial contamination, heavy metals, and pesticides [84]. Adulteration, contamination, and inconsistent therapeutic effects are risks associated with non-standardized products and unprocessed herbal materials [84].

7. Limitations and Research Gaps





WISELEAF SCIENTIFIC VENTURES

Variability in herbal preparations (origin, extraction techniques, and standardisation), dosage schedules, study populations, and the cognitive outcome measures employed are major barriers that collectively impede comparability and result interpretation [14,50,54,57,61,82]. Many studies are brief, small, and susceptible to bias from various sources [54,57,61]. The majority of herbs have not yet been shown to have long-lasting, disease-modifying benefits, and objective biomarkers of neuroprotection are rarely employed [14,21,86].

The following are necessary for future clinical trials: (1) randomisation, blinding, and sufficient sample size; (2) standardised, analytically characterised extracts; (3) validated cognitive and functional scales (e.g., MMSE, MoCA, ADAS cog); (4) objective biomarkers neuroimaging, CSF/plasma neurotrophins, inflammatory mediators, and neurophysiology; (5) sufficient duration (≥ 6 months for disease modification); (6) stratification by at-risk populations and investigation of herb drug combinations [14,15,20,21].

For mild cognitive impairment, early dementia, or neuropsychiatric symptoms, standardised Bacopa monnieri and EGb 761 may be used as adjunctive therapies as long as the products are standardised and clinicians keep an eye out for possible interactions, especially in patients taking multiple medications [14,15,63,84]. Regular monitoring and a thorough evaluation of patients' comorbid conditions are essential. To enable trustworthy meta-analyses and unambiguous clinical guidance, researchers should concentrate on mechanistic studies, incorporate biomarkers, and standardise procedures across trials [14,15,20,21].

8. Conclusion and future trends

In contrast to single target medications, phytochemicals from Bacopa, Ginkgo, Withania, Hericium, and Centella act on several neurodegenerative pathways, reducing oxidative stress and inflammation, promoting neurotrophic factors, and maintaining synapses. Their role as adjuncts in neurodegenerative care is supported by their multimodal activity, acceptable tolerability, and cultural use. Due to inconsistent extract standardisation and bioavailability, small and heterogeneous trials, short follow-up, and a lack of objective neurobiological endpoints, there is currently insufficient evidence to establish superiority over standard pharmacotherapies or to support definitive guidelines. Analytically characterised, standardised extracts; sufficiently powered, longer trials (≥ 12 months) involving fluid biomarkers and neuroimaging; research to enhance CNS bioavailability; and systematic assessment of herbal–herbal and herbal–drug synergies within systems pharmacology frameworks are all necessary for progress.

Regulations and strict quality control are crucial. Standardised Bacopa and EGb 761 may be considered adjunctive options for MCI or symptomatic neurodegeneration until more solid evidence is available, provided that product quality, individual safety, and interaction risks are carefully evaluated and combined with lifestyle modifications, with clinicians openly communicating limitations and keeping an eye out for interactions. Evidence-based phytotherapeutics for neurodegenerative diseases can be developed by combining





WISELEAF SCIENTIFIC VENTURES

ethnobotanical knowledge with biomarker-driven stratification and thorough pharmacological validation.

Strict quality control and regulatory standards are essential. Until stronger evidence is available, standardized Bacopa and EGb 761 may be considered adjunctive options for MCI or symptomatic neurodegeneration when product quality, individual safety, and interaction risks are carefully assessed and combined with lifestyle measures, with clinicians transparently communicating limitations and monitoring for interactions. Integrating ethnobotanical knowledge with biomarker-driven stratification and rigorous pharmacological validation can guide development of evidence-based phytotherapeutics for neurodegenerative disease

Use state-of-the-art delivery technologies (nanoformulations, liposomal systems) in conjunction with strict batch-to-batch uniformity and active ingredient standardisation to boost blood–brain barrier penetration and guarantee repeatable effects [15,41,84]. Use validated biomarkers (neuroimaging, plasma/CSF markers), neurophysiology, and comprehensive multi-omics (genomics, transcriptomics, proteomics, metabolomics) in large, multicenter studies to test for disease-modifying effects and enable biomarker-driven, customised therapies [14,15,20,21]. Determine synergistic regimens that maximise neuroprotection and cognitive benefit while minimising negative interactions by carefully assessing multitarget strategies that combine medicines and botanicals, accounting for comorbidities, and classifying patients according to biomarkers [14,15,63].

REFERENCES

- [1] J. I. Sbodio, S. H. Snyder, and B. D. Paul, “Redox Mechanisms in Neurodegeneration: From Disease Outcomes to Therapeutic Opportunities,” 2019. doi: 10.1089/ars.2017.7321.
- [2] L. A. K. Löffler, S. Radke, C. Morawetz, and B. Derntl, “Emotional dysfunctions in neurodegenerative diseases,” 2016. doi: 10.1002/cne.23816.
- [3] J. Cummings, “Disease modification and Neuroprotection in neurodegenerative disorders,” 2017. doi: 10.1186/s40035 017 0096 2.
- [4] L. Z. N. K. R. H. A. A. C. W. M. X. X. X. & P. S. Rintaro Kato, “Investigating blood–brain barrierpenetration and neurotoxicityof natural products for centralnervous system drug development,” *Nature Portfolio*, pp. 1–14, 2025.
- [5] X. Z. Si yuan Zheng, “A perspective on the mechanisms of herbal medicine for cognitive impairment,” *Frontiers (Boulder)*, 2025.
- [6] R. U. A. P. Priyanka Dubey, “Phytochemicals Activity of Bacopa monnieri (L.) pennel. A brief review,” *International Journal of Biotechnology and Microbiology*, 2024.
- [7] Reddy PH., “Amyloid precursor protein mediated free radicals and oxidative stress in Alzheimer’s disease,” *Free Radic Biol Med*, 2006.
- [8] R. L. H. E. Abbott NJ, “Astrocyte–endothelial interactions at the blood–brain barrier,” *Nat Rev Neurosci*, 2006.





WISELEAF SCIENTIFIC VENTURES

- [9] Spencer JP., “Food for thought: the role of dietary flavonoids in enhancing human memory, learning and neuro cognitive performance. ,” *Proceedings of the Nutrition Society* , 2008.
- [10] P. N. H. PJ. Howes MJ, “Plants with traditional uses and activities, relevant to the management of Alzheimer’s disease and related dementias.,” *J Ethnopharmacol*, 2003.
- [11] B. F. Russo A, “Bacopa monniera, a reputed nootropic plant: an overview.,” *Phytomedicine*, 2005.
- [12] B. T. Aguiar S, “Neuropharmacological review of the nootropic herb *Centella asiatica*.,” *J Ethnopharmacol*, 2013.
- [13] H. PJ. Howes MJR, “Plants used in Chinese and Indian traditional medicine for improvement of memory and cognitive function.,” *Phytother Res*, 2003.
- [14] M. J. R. Howes and E. Perry, “The role of phytochemicals in the treatment and prevention of dementia,” 2011. doi: 10.2165/11591310 000000000 00000.
- [15] S. A. K. R. et al Stough C, “Clinical considerations for cognitive enhancement trials: endpoints, populations, and regulatory issues. ,” *J Alzheimers Dis*, 2015.
- [16] H. B. Butterfield DA, “Oxidative stress, dysfunctional glucose metabolism and Alzheimer disease.,” *Nat Rev Neurosci*, 2019.
- [17] Mattson MP., “Pathways towards and away from Alzheimer’s disease,” *Nature*, 2004.
- [18] L. AE. Kalia LV, “Parkinson’s disease.,” *Lancet*, 2015.
- [19] L. M. L. G. I. BP. Panza F, “A critical appraisal of amyloid β -targeting therapies for Alzheimer disease. ,” *Nat Rev Neurol*.
- [20] M. F. et al. Pérès K, “ Clinical trial methodology in dementia: cognitive endpoints and biomarkers.,” *Alzheimers Res Ther*, 2016.
- [21] T. G. Q. T. Ritchie CW, “Dementia trials and outcomes: progressing beyond cognitive scales.,” *Nat Rev Neurol*, 2015.
- [22] G. D. L. E. Heneka MT, “Innate immunity in Alzheimer’s disease.,” *Nat Immunol*, 2015.
- [23] B. M. Lin MT, “Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases,” *Nature* , 2006.
- [24] K. J. Ahlemeyer B, “Neuroprotective effects of *Ginkgo biloba* extract.,” *Cell Mol Life Sci*, 2003.
- [25] K. S. S. N. Kumar V, “*Ginkgo biloba* extract EGb 761: mechanisms and efficacy in neurodegenerative disorders.,” *J Neurol Sci.*, 2015.
- [26] Bhattacharya SK, Bhattacharya A, and Sairam K, “Effect of *Withania somnifera* on the antioxidant status of rat brain.,” *Pharmacol Biochem Behav*, 2001.
- [27] C. M. K. J. et al. Heneka MT, “Neuroinflammation in Alzheimer disease. ,” *Lancet Neurol*, 2015.





WISELEAF SCIENTIFIC VENTURES

- [28] L. G. S. R. et al Chan P, “*Ginkgo biloba* extract (EGb 761) protects neuronal cells against β amyloid toxicity.,” *J Neurosci Res*, 2007.
- [29] G. T. S. F. et al. Pace S, “Bacoside A and synaptic plasticity: molecular mechanisms supporting memory enhancement.,” *Front Pharmacol*, 2019.
- [30] T. C. K. K. Kuboyama T, “Neurite outgrowth induced by *Withania somnifera* in PC12 cells and potential mechanisms.,” *J Pharmacol Sci*, 2005.
- [31] Z. C. et al. Kawagishi H, “Erinacines and hericenones: stimulators of nerve growth factor (NGF) synthesis from *Hericium erinaceus*.,” *J Agric Food Chem*, 1994.
- [32] M. S. M. B. Mattson MP, “BDNF and synaptic plasticity in aging and neurodegenerative disease.,” *Trends Neurosci*, 2004.
- [33] R. T. Castrén E, “ The role of BDNF and its receptors in neuronal plasticity and neuroprotection.,” *Trends Pharmacol Sci*, 2010.
- [34] V. S. S. I. Chatterjee S, “*Withania somnifera*: neuroprotective properties and potential for neurodegenerative diseases.,” *CNS Neurosci Ther*, 2020.
- [35] A. M. M. T. Kawagishi H, “Erinacines A, B, C and D, diterpenoids from *Hericium erinaceus* with NGF synthesis stimulating activity.,” *Tetrahedron Lett*, 1994.
- [36] P. S. et al Gray NE, “Triterpenoid saponins and cognition: asiaticoside effects on neurogenesis and synaptic plasticity.,” *Neurosci Lett*, 2015.
- [37] H. M. et al. Tirosh O, “Neuroprotective effects of withanolides in in vitro models.,” *Neuroscience*, 2011.
- [38] Spencer JPE, “Flavonoids and brain health: multiple effects underpinned by shared mechanisms.,” *Genes Nutr*, 2009.
- [39] V. K. V. D. et al. Vauzour D, “ The neuroprotective potential of flavonoids: a review.,” *Brain Res*, 2008.
- [40] K. M. et al. Sudo S, “Bacopa and cholinergic modulation: experimental evidence.,” *J Ethnopharmacol*, 2011.
- [41] S. A. S. V. Sharma R, “Bacosides from *Bacopa monnieri*: chemistry, pharmacology and therapeutic potential.,” *Planta Med*, 2014.
- [42] P. N. H. P. Howes MJR, “Plants and cognition: the current state of evidence.,” *J Ethnopharmacol*, 2003.
- [43] van Beek TA., “Chemical analysis of *Ginkgo biloba* leaves and extracts.,” *J Chromatogr A*, 2002.
- [44] B. M. de J. P. G. M. Singh N, “ An overview on Ashwagandha: A Rasayana (rejuvenator) of Ayurveda.,” *Afr J Tradit Complement Altern Med*, 2011.
- [45] I. S. O. K. et al. Mori K, “Improving effects of the mushroom Yamabushitake (*Hericium erinaceus*) on mild cognitive impairment: a double blind placebo controlled clinical trial.,” *Phytother Res*, 2009.





WISELEAF SCIENTIFIC VENTURES

- [46] W. J. et al Uabundit N, “Cognitive enhancement and neuroprotection by Bacopa extract in animal models.,” *J Ethnopharmacol*, 2010.
- [47] L. J. C. J. et al. Stough C, “The chronic effects of an extract of Bacopa monniera (Brahmi) on cognitive function in healthy human subjects. ,” *Psychopharmacology (Berl)*, 2001.
- [48] C. D. R. J. S. C. S. A. Neale C, “Cognitive effects of two nutraceuticals containing Bacopa monnieri: a comparative, randomized, double blind, placebo controlled trial.,” *Hum Psychopharmacol*, 2013.
- [49] B. D. B. S. et al. Roodenrys S, “Chronic effects of Brahmi (Bacopa monnieri) on human memory.,” *Neuropsychopharmacology*, 2002.
- [50] D. P. T. P. et al. Kongkeaw C, “Meta analysis of randomized controlled trials on cognitive effects of Bacopa monnieri.,” *J Ethnopharmacol*, 2014.
- [51] M. K. Smith PF, “Bacopa monnieri and cognitive enhancement: pharmacology and clinical evidence.,” *Phytother Res*, 2010.
- [52] C. W. J. Mix JA, “An examination of the efficacy and safety of *Ginkgo biloba* extract in dementia.,” *J Psychiatr Res*, 2002.
- [53] P. R. W. P. Rojas B, “*Ginkgo biloba* and oxidative stress in the brain: mechanistic insights.,” *Neurochem Res*, 2012.
- [54] R. S. S. C. et al. Weinmann S, “Effects of *Ginkgo biloba* in dementia: systematic review and meta analysis.,” *BMC Geriatr*, 2010.
- [55] H. R. K. G. Kanowski S, “Effectiveness of *Ginkgo biloba* extract EGb 761 in dementia: a randomized placebo controlled trial.,” *Pharmacopsychiatry*, 1996.
- [56] K. M. B. N. et al. Le Bars PL, “A placebo controlled, double blind, randomized trial of an extract of *Ginkgo biloba* for dementia. ,” *JAMA*, 1997.
- [57] G. E. J. Birks J, “*Ginkgo biloba* for cognitive impairment and dementia. ,” *Cochrane Database Syst Rev*, 2009.
- [58] Y. K. T. M. et al. Weinmann S, “Efficacy and safety of *Ginkgo biloba* extract EGb 761 in dementia: an updated review.,” *Curr Pharm Des*, 2011.
- [59] W. J. F. A. et al DeKosky ST, “*Ginkgo biloba* for prevention of dementia: the Ginkgo Evaluation of Memory (GEM) study.,” *JAMA*, 2008.
- [60] T. P. L. S. et al Vellas B, “EGb 761 in Alzheimer’s disease: randomized clinical trials and pooled analyses.,” *Dement Geriatr Cogn Disord*, 2012.
- [61] S. T. DeKosky et al., “*Ginkgo biloba* for prevention of dementia: A randomized controlled trial,” *JAMA*, vol. 300, no. 19, 2008, doi: 10.1001/jama.2008.683.
- [62] I. A. Russo A, “*Ginkgo biloba* extracts: pharmacology and clinical evaluation. J Ethnopharmacol.,” *J Ethnopharmacol*, 2007.
- [63] P. A. S. I. et al Sarris J, “Herbal medicine for depression, anxiety and insomnia: a review of psychopharmacology and clinical evidence.,” *Eur Neuropsychopharmacol*, 2011.





WISELEAF SCIENTIFIC VENTURES

- [64] Williamson EM, “Interactions between herbal and conventional medicines.,” *Drug Saf*, 2003.
- [65] A. P. P. R. Gauthaman K, “Adult male rat sexual behavior and reproductive hormones following chronic administration of *Bacopa monnieri* extract.,” *J Ethnopharmacol*.
- [66] K. N. Singh S, “*Withania somnifera* and neuroprotection: biochemical bases and clinical perspectives.,” *Phytother Res*, 2020.
- [67] et al Tello Franco D, “*Withania somnifera* and cognition: clinical evidence and mechanisms.,” *Phytother Res*, 2021.
- [68] M. A. et al. Chaturvedi C, “*Withania somnifera* reverses behavioural deficits and reduces amyloid burden in APP/PS1 mice.,” *Neurochem Int*, 2015.
- [69] P. D. et al. Seo J, “Ashwagandha improves cognitive and psychomotor performance in adults: randomized, double blind, placebo controlled trial.,” *J Ethnopharmacol*, 2021.
- [70] S. SJ. Lopresti AL, “A randomized, double blind, placebo controlled trial of Ashwagandha (*Withania somnifera*) extract in stress and anxiety.,” *J Clin Psychiatry*, 2019.
- [71] B. S. J. K. Choudhary D, “Body weight and anxiety effects of *Withania somnifera*: randomized, double blind, placebo controlled study. ,” *Indian J Psychol Med*, 2017.
- [72] et al Sabaratnam V, “Neuroregenerative potential of *Hericium erinaceus*: preclinical evidence and translational prospects.,” *Int J Med Mushrooms*, 2013.
- [73] P. D. et al Ryu S, “*Hericium erinaceus* induces NGF in astrocytes and improves cognitive deficits in rodent models.,” *J Ethnopharmacol*, 2016.
- [74] Friedman M., “Mushroom bioactive compounds and neuroprotective potential.,” *J Agric Food Chem*, 2016.
- [75] et al. Friedman LM, “*Hericium erinaceus* improves cognitive function in mild cognitive impairment: pilot randomized trial.,” *J Clin Med*, 2019.
- [76] S. K. et al Nagano M, “Reduction of depression and anxiety by *Hericium erinaceus* in a double blind placebo controlled trial.,” *Biomed Res*, 2010.
- [77] R. MC. Ríos JL, “Medicinal mushrooms: their therapeutic potential in neurodegenerative diseases. ,” *Phytother Res*, 2005.
- [78] D. V. K. A. Singh A, “*Centella asiatica*: phytochemistry and therapeutic uses in neurology.,” *Phytomedicine*, 2016.
- [79] R. A. D. B. Shukla V, “Asiaticoside induced stimulation of antioxidant pathways in rat brain.,” *J Ethnopharmacol*, 1999.
- [80] P. S. et al. Gray NE, “Asiaticoside and asiatic acid promote neurite outgrowth and cognitive rescue in animal models.,” *Neuropharmacology*, 2013.
- [81] M. S. et al. Wattanathorn J, “Positive modulation of cognition and mood by *Centella asiatica* in animal models.,” *J Ethnopharmacol*, 2008.
- [82] S. S. et al Parveen M, “*Centella asiatica* and cognitive function: a systematic review of preclinical and clinical evidence.,” *Phytother Res*, 2020.





WISELEAF SCIENTIFIC VENTURES

- [83] M. L. et al Wattanathorn J, “*Centella asiatica* prevents working memory deficits in animal models under chronic stress.,” *Evid Based Complement Alternat Med*, 2012.
- [84] Bent S, “Herbal medicine in the United States: review of efficacy, safety, and regulation.” *J Gen Intern Med*, 2008.
- [85] LeBars PL, “*Ginkgo biloba* extract and geriatric cognitive disorders.” *J Nutr Health Aging*, 2003.
- [86] T. A. O’Brien JT, “Vascular dementia.” *Lancet*, 2015.
- [87] L. T. Z. J. et al Li Y, “Neuroprotective effects of polyphenols: mechanisms and clinical prospects.” *Ageing Res Rev*, 2019.





WISELEAF SCIENTIFIC VENTURES

HEALING ROOTS: INTEGRATIVE HERBAL APPROACHES TO CHRONIC ILLNESS

CHAPTER-8 SAFETY QUALITY CONTROL AND REGULATORY ASPECTS OF HERBAL MEDICINE

Harsh Pratap Singh*, Aditya Raj, Aditya Kumar, Nitin Pratap Singh

Sanskar College Of Pharmacy and Research, Ghaziabad, 201302, Uttar Pradesh, India

Email: harshprataps903@gmail.com

ABSTRACT

Herbal medicines are an essential part of worldwide healthcare systems, appreciated for their healing potential and cultural value. The escalating commercialization and global application of herbal products have raised important questions about their safety, quality, and regulation. This paper discusses these aspects in-depth, starting with a description of the importance of herbal medicine and the need for rigorous evaluation criteria. The safety discussion highlights issues of toxicity, side effects, and herb-drug interactions, with supportive case studies. Quality control is discussed in terms of standardization, authentication, detection of impurities, and the use of advanced analytical techniques like chromatography and spectroscopy. The section on regulation gives an overview of international and regional regulations controlling herbal medicines, highlighting authorities like the FDA, EMA, and India's Ministry of AYUSH. The paper also discusses long-standing issues such as variation in raw materials, absence of standard testing, and enforcement challenges. More recent innovations such as Good Agricultural and Collection Practices (GACP), enhanced pharmacovigilance systems, and new analytical methods are presented as the key to product reliability enhancement. Ultimately, the future directions emphasize harmonization of regulations worldwide, consolidation of traditional knowledge with evidence-based science, and increased public awareness to facilitate the safe, effective, and sustainable utilization of herbal medicines.

Keywords: Safety; Quality control, Regulatory Science; Herbs; Medicine





WISELEAF SCIENTIFIC VENTURES

1. Introduction

1.1 Historical perspective of herbal medicine

Ever since time began, in the quest for salvation from their illness, the people turned to medicines found in nature. The history of the use of medicine plants came naturally, as was that of the animals. There was not sufficient information either on what caused the diseases or on what plant and in what way it could be used as a medicine, so everything was based on experience. Over time, the causes of using some of the medicinal plants to treat a certain ailment were being uncovered; thus, the use of the medicinal plants progressively lost its empiric basis and became based on explicatory facts. Before the advent of iatrochemistry in the 16th century, plants had been employed as a source for prophylaxis and treatment. But the declining efficacy of man-made medicines and the increasing contraindications of their use render the use of natural drugs topical again. [1]

1.2 Global Trends and Significance in Healthcare

1.2.1 Surging healthcare spend and investment

World healthcare expenditure is estimated to have increased over 40% between the years 2018 and 2022, hitting \$12 trillion. Concurrently, investments in healthcare have also hit historic highs in recent times, with focus on research in areas like gene immunotherapy and novel mRNA vaccines for emerging diseases like Zika and malaria.

1.2.2 Healthcare worker shortages and burnout

The pandemic weighed heavily on healthcare professionals, contributing to a long-stressed and overworked staff. Mental illness and burnout increased, and numerous professionals departed the industry as well as lowered recruitment. The repercussions of this are still being felt, and cumulative pressures in the system render the issue not diminishing for many. [2]

1.2.3 Precision Medicine

Precision Medicine is defined by the Royal Society of Thailand (2020) as a medical system that provides exceptionally effective and individualized treatments for health through specific factors including genetics, environment, lifestyle, and others. Precision medicine can enhance the treatment's effectiveness while keeping unwanted side effects to a minimum. Precision medicine is a revolution in healthcare and modern medicine that should be taken seriously

The micro biome of the gut is also a key driver of overall well-being, impacting digestion to mental health. Micro biome research will increase exponentially in 2025, and researchers will continue to understand more about how microbial communities impact human health to create more intelligent and effective probiotics and prebiotics. [3].

2. Safety of Herbal Medicine

The issue of the safety of herbal medicines is one of growing concern as world use of such products continues to widen. While herbal medicines are commonly viewed as natural and hence safe, this view is deceptive and can pose serious health risks. This section discusses the issues of toxicity, adverse effects including herb-drug interactions, and gives case studies





WISELEAF SCIENTIFIC VENTURES

relevant to the issue of the safety of herbal medicines, pointing to the necessity of stringent safety testing and regulation.

2.1 Toxicity Concerns

Herbal remedies consist of intricate blends of bioactive substances, many of which are potentially toxic or toxic at some levels or under some circumstances. The fallacy that "natural" means "safe" ignores the occurrence of highly active phytochemicals that can produce adverse effects. Toxic compounds present in herbs are alkaloids, anthraquinones, pyrrolizidine alkaloids, alkenylbenzenes, and others that have been shown to induce hepatotoxicity, nephrotoxicity, neurotoxicity, carcinogenicity, and other harmful effects. Substitution of toxic analogs like *Aristolochia fangchi* with aristolochic acid as herbal species is linked to renal toxicity and urothelial cancers. [4]

2.2 Adverse Effects and Herb-Drug Interactions

Adverse reactions to herbal medicines may range from mild gastrointestinal discomfort to severe hepatotoxicity, nephrotoxicity, and allergic reactions. Reports of herb-induced liver injury (HILI) have increased with widespread herbal consumption. Moreover, serious concerns arise from herb-drug interactions, where herbal constituents may alter the pharmacokinetics or pharmacodynamics of conventional drugs, leading to reduced efficacy or increased toxicity. Commonly documented interactions include those between St. John's Wort (*Hypericum perforatum*), which induces cytochrome P450 enzymes leading to lowered plasma levels of drugs such as warfarin, cyclosporine, and antiretrovirals. Ginkgo biloba has been associated with increased bleeding risk when combined with anticoagulants or antiplatelet agents. These interactions underscore the need for clinicians to carefully assess herbal medicine use when prescribing pharmaceuticals and for patients to inform healthcare providers of all products used [5].

2.3 Case Studies on Herbal Medicine Safety

Several case studies illustrate real-world safety issues. For instance, adulteration of *Hypericum perforatum* products with *Senna alexandrina* led to unexpected laxative effects and gastrointestinal symptoms in consumers. Another example involved the inadvertent inclusion of *Juglans nigra* in Ginkgo formulations, posing risks to individuals with walnut allergies. Cases of *Aristolochia*-related nephrotoxicity following exposure to substituted traditional Chinese herbal products highlight severe consequences of inaccurate botanical identification and inadequate quality control. [6]

In Africa, studies reveal that many unregulated herbal products contain microbial contamination exceeding pharmacopeial safety limits, including *Escherichia coli*, *Salmonella*, and *Staphylococcus aureus*, raising significant public health concerns. These contaminated products potentially cause infections and toxic reactions. [7]





WISELEAF SCIENTIFIC VENTURES

3. Quality Control of Herbal Medicines Standardization and Quality

Quality control is central to making certain that herbal medicines are safe, effective, and produced consistently. This chapter describes standardization and quality criteria, identification and authentication methods, the issue of contaminants and adulterants, and the range of analytical methodologies mostly chromatography and spectroscopy with which quality can be evaluated. There is a focus on existing best practice and the issues that still need to be overcome in order to develop strong, internationally harmonized quality standards

3.1 Standardization and Quality Parameters

Standardization in herbal products is a process of implementing and maintaining a uniform quality by measuring certain bioactive markers or quantities that define therapeutic activity. Because herbal material is complex and subject to variation by geography, climate, culture, and season of growth, harvest, and time, parameters of quality must address botanical identity, purity, chemical conformation, and biological activity.

Recent reports emphasize that standardization goes beyond quantitative chemical measurement to encompass physical characteristics (like moisture content, particle size, and foreign matter), microbial specifications, and heavy metal analysis for overall product safety and quality. Contemporary regulations increasingly demand that producers adopt good manufacturing practices (GMP) that incorporate such specifications to achieve quality requirements worldwide. Batch-to-batch consistency is critical for therapeutic dependability and marketability. [8]

3.2 Identification and authentication methods

The proper identification and verification of raw materials of herbal origin are the basis of quality control. Misidentification, replacement, or adulteration with poorer or toxic materials are a serious threat.

The conventional morphological and microscopic examination is supplemented nowadays by sophisticated molecular methods like DNA barcoding and genomic fingerprinting, which enable accurate species identification even in processed samples. Chemical profiling through chromatographic and spectroscopic methods also enables authentication by producing unique fingerprints of bioactive constituents.

Methods like Thin Layer Chromatography (TLC), High-Performance Liquid Chromatography (HPLC), Gas Chromatography (GC), and Nuclear Magnetic Resonance (NMR) spectroscopy have emerged as important tools for herbal drug authentication. Synergism between molecular and chemical methods provides a strong platform for detection of adulteration and quality control. [9]

3.3 Contaminants and adulterants in herbal products

Contamination and adulteration are still of great concern in herbal medicine quality. The contaminants are biological contaminants (fungi, bacteria, mycotoxins), chemical residues (pesticides, heavy metals, solvents), and physical contaminants (foreign matter, soil).





WISELEAF SCIENTIFIC VENTURES

Adulterants can be undeclared synthetic medicines, more affordable herbs, or fillers used intentionally or unintentionally.

Current research emphasizes that contamination occurs because of poor farming practices, poor processing, and lack of quality control. For instance, microbial contamination can cause serious health hazards, while heavy metals such as lead or arsenic can accumulate in crops cultivated in polluted soil.

Proper identification of such impurities calls for integrated analytical strategies. Regulatory agencies stress that herbal producers embrace contamination control using Good Agricultural and Collection Practices (GACP) and validated analytical methods to reduce these risks, protecting the consumer [10]

3.4 Quality control procedures (Chromatography, Spectroscopy, etc.)

Chromatographic and spectroscopic techniques are the pillars of quantitative and qualitative analysis of herbal medicines. Chromatography allows separation, identification, and quantification of phytochemical mixtures, giving detailed chemical information crucial for quality assurance.

High-Performance Liquid Chromatography (HPLC) is still the best in identifying major active components with accuracy and reproducibility. Gas Chromatography with Mass Spectrometry (GC-MS) is best suited for volatile products and pesticides residue analysis. Nuclear Magnetic Resonance (NMR) spectroscopy provides structural information on phytoconstituents for detailed profiling.

New hybrid techniques, where chromatography is coupled with spectrometry, like LC-MS and TLC-MS, increase sensitivity and throughput. Flash chromatography and Thin Layer Chromatography (TLC) with mass spectrometric detection have also been brought forward for rapid, efficient screening of the herbal formulations.

Furthermore, spectroscopic methods such as Ultraviolet-visible (UV-Vis), Fourier Transform Infrared (FTIR), and Raman spectroscopy supplement chromatographic assays by offering fingerprint spectra to detect adulteration and authentication. The combination of these platforms for analysis offers support for complete quality assessment, dealing with the problems of complex matrixes and heterogeneity. [11]

Table 1: summarizing key aspects, objectives, and techniques relevant to ensuring product safety and efficacy.

Aspect	Description	Objective	Common Techniques / Methods
Standardization and Quality Parameters	Establishes consistent qualitative and quantitative	To ensure batch-to-batch uniformity and therapeutic efficacy.	Physicochemical analysis (moisture, ash value, extractive value),





WISELEAF SCIENTIFIC VENTURES

	composition of herbal drugs.		phytochemical screening, marker-based quantification.
Identification and Authentication	Confirms the botanical identity and purity of the raw material.	To prevent substitution or adulteration of plant materials.	To prevent substitution or adulteration of plant materials.
Contaminants and Adulterants	Detects unwanted or harmful substances such as pesticides, heavy metals, microbes, or synthetic additives.	To ensure the safety of herbal preparations and compliance with pharmacopoeial standards.	Atomic absorption spectroscopy (AAS), inductively coupled plasma mass spectrometry (ICP-MS), microbial limit tests, chromatographic fingerprinting.
Chromatographic Methods	Separate and identify chemical constituents for fingerprinting and quantification.	To characterize active compounds and detect impurities or adulteration.	Thin layer chromatography (TLC), high-performance liquid chromatography (HPLC), gas chromatography (GC).
Spectroscopic Techniques	Analyze chemical composition and molecular structure of herbal constituents.	To confirm identity and purity of plant metabolites.	UV-Vis spectroscopy, Fourier transform infrared (FTIR) spectroscopy, nuclear magnetic resonance (NMR), mass spectrometry (MS).

4. Regulatory Framework for Herbal Medicine

4.1 Global Regulatory Landscape

Herbal medicines still make up a high percentage of health worldwide, particularly in low-income developing countries where traditional medicine is the foundation of primary health





WISELEAF SCIENTIFIC VENTURES

care. The World Health Organization (WHO) takes a central position in unifying herbal medicine laws across the world to enhance safety, traceability, and informed consumption by users. WHO's 2025 guidelines focus on standardization procedures for quality, safety, and efficacy assessment throughout the life cycle of herbal products—from raw materials to processing to end labeling. The purpose is to bring marketing of herbal medicine in harmony with current health-care systems without disregarding traditional methodologies. Yet regulatory systems globally show enormous divergence depending on geographical infrastructure, traditional practices, and maturity of legislation. Developed nations generally impose strict regulatory controls, whereas numerous developing nations continue to reinforce legal frameworks and enforcement systems.

Challenge areas that have been identified in most regions include inadequate research data on safety and efficacy, gaps in regulatory enforcement, absence of trained personnel, and paucity of post-market surveillance systems. There is growing acknowledgment that collaboration among traditional healers, scientific communities, and regulatory agencies is necessary in order to strengthen regulation effectiveness and protection of public health. [12]

4.2 Regional Regulations

4.2.1 United States Food and Drug Administration (FDA)

In the United States, herbal products are largely controlled as dietary supplements through the Dietary Supplement Health and Education Act (DSHEA). While the model grants general access to the market for herbal products, it creates challenges concerning thorough safety and effectiveness assessment prior to marketing. The FDA's Human Foods Program has been busy evolving guidance to better regulate herbal ingredients and dietary ingredients, including identity, safety data, and risk communication. In 2025, the FDA is still working on revised guidance documents on new dietary ingredient notifications, food colour additives derived from herbs, and best practices in the industry. The FDA does not require pre-market approvals similar to prescription drugs but sustains post-market vigilance and insists on correct labelling to guard consumers. [13]

4.2.2 European Medicines Agency (EMA)

The EMA's regulatory system of herbal medicinal products is among the most developed in the world. It works under directives like Directive 2004/24/EC for traditional herbal medicinal products, bringing them within pharmaceutical regulation. Herbal medicines can be registered under the Traditional Herbal Medicinal Products Directive (THMPD) whereby they can be sold over the counter under stipulated conditions of safety and quality. The EMA creates and revises scientific guidelines for quality (e.g., good agricultural and collection practices—GACP), safety evaluation (including genotoxicity), pharmacovigilance, and labeling in order to promote the use of standardized evaluation procedures. The Committee on Herbal Medicinal Products (HMPC) also offers scientific opinions and EU herbal monographs which function as





WISELEAF SCIENTIFIC VENTURES

reference standards for marketing authorization applications. In 2025, the HMPC is busily updating monographs and creating new guidance to assist harmonized standards between member states. [14]

4.2.3 AYUSH, India

India's Ministry of AYUSH regulates herbal medicines in accordance with the Drugs & Cosmetics Act, 1940. The AYUSH classifies herbal medicines under Ayurveda, Siddha, and Unani drugs, and registration includes requirements for claims on efficacy and safety. Quality standards are guided by the Indian herbal pharmacopeia but not through a legally binding process. Guidelines for labeling require such product information as manufacturing authorization, batch number, shelf life derived from validated research, and disclosure of risks. The AYUSH regime also blurs traditional knowledge with modern scientific analysis, seeking public safety along with respect for tradition. AYUSH is an active partner in WHO-coordinated programs to harmonize regulation of herbal medicine and set higher standards for traditional products. [15]

4.3 Classification and Registration of Herbal Medicines

Herbal medicinal products are generally categorized according to intended use, claims, and regulatory jurisdiction. Typical categories include:

Traditional Herbal Medicines: Products having history of safe use and generally low-risk profiles.

Well-Established Herbal Medicines: Products with established proof of efficacy and safety similar to pharmaceutical standards.

Dietary Supplements: Products being sold for nutritional purposes without specific therapeutic claims.

Registration processes are very diverse, ranging from notional notification systems to full marketing authorization with elaborate dossiers on quality, safety, and efficacy. Most regulators have monographs or compendia that define standards and evidence needs and enable streamlined registration processes for herbal products qualifying under preset criteria. In economies such as the EU, monograph-based registration provides applicants with the option to draw upon established scientific evaluations, while others necessitate case-by-case assessment. The registration involves testing for contaminants, verification of manufacturing practices, and validation of labeling claims to reduce public health risk [16].

4.4 Labeling and Packaging Requirements

Labels are a primary tool to ensure consumer safety and regulatory compliance in the herbal medicine sector. According to the latest WHO guidelines issued in 2025, labels must provide clear, accurate, and comprehensive information including:

- Manufacturer's name, address, and license number for accountability and traceability.
- Batch or lot number linked to manufacturing records and quality testing.
- Date of manufacture and expiry date based on validated stability data.





WISELEAF SCIENTIFIC VENTURES

- List of active herbal substances with official nomenclature.
- Known hazards and allergenicity potentials (e.g., "contains latex").
- Contraindications and potential herb-drug interactions (e.g., warnings for pregnancy).
- Dosage information and storage conditions.

National regulatory agencies can impose certain labeling provisions based on legal, language, and cultural environments. For instance, the FDA imposes exact labelling under DSHEA, such as disclaimers not to diagnose, treat, cure, or prevent any disease. In comparison, the EU's stringent regulatory system demands extensive patient information leaflets and tight medicament claim controls. AYUSH and Indian regulations also prioritize uniform labelling to enhance product consistency and consumer education. [17]

5.Challenges in Safety, Quality Control, and Regulation

Herbal drugs are appreciated worldwide for their therapeutic value and place in the traditional and contemporary healthcare system. One of the most daunting challenges for worldwide pharmacovigilance, however, is assuring their safety, quality, and compliance with regulatory standards. Complexity stems from variability of natural raw materials, unavailability of standardized test protocols, and continuing enforcement and compliance issues across borders. Current reviews from the World Health Organization (WHO, 2025), the European Medicines Agency (EMA, 2025), and international pharmacognosy scientists highlight the imperative of harmonized structures integrating scientific accuracy with age-old knowledge sets. [18]

5.1 Variability of Raw Materials

The safety and therapeutic effectiveness of herbal remedies rely essentially on the uniformity and quality of raw plant material. The chemical structure of herbal pharmacologically active substances—e.g., phenolic acids, alkaloids, flavonoids, and terpenoids—varies because of genetic, environmental, and agronomic considerations. Differences in plant species and subspecies and in physical environment related to soil type, moisture content, sunlight, elevation, and rainfall profoundly affect phytochemical yield and activity. [19]

The WHO guidelines of 2025 highlight Good Agricultural and Collection Practices (GACP) as an essential measure to mitigate variability. Incomplete global implementation continues, especially among small-scale farmers and conventional industries with minimal regulation. Additionally, post-harvest conditions, drying processes, and storage will affect active compound stability and introduce microbial or chemical contamination. This chemical inconsistency is compounded by climate change impacts on plant phenology and secondary metabolite biosynthesis, creating new regulatory and quality control challenges [20]

5.2 Lack of Standardized Testing Protocols

The second key challenge is the lack of universal analytical standards to determine the safety, identity, and effectiveness of herbal products. In contrast to synthetic chemicals with one





WISELEAF SCIENTIFIC VENTURES

defined active component, herbal remedies are mixtures with an undefined active component. Therefore, validation and reproducibility continue to be challenging. [21]

The WHO 2025 model of quality control of herbal products emphasizes the application of a multiparametric strategy that involves chromatographic profiling, spectroscopic fingerprinting, and quantification of biomarkers. Contemporary methods like HPLC, GC-MS, HPTLC, and NMR spectroscopy have facilitated enhanced identification and quantification of major phytochemicals, but their application is region-specific owing to economic as well as technical training limitations. Likewise, DNA barcoding ensures accurate species identification against adulteration and substitution but is not yet standard practice for small-scale producers. [22]

Key pharmacopoeias—the British Pharmacopoeia, Indian Herbal Pharmacopoeia, and Chinese Pharmacopoeia—suggest marker-based standardization, but cross-market inconsistency due to the variation in reference standards among these pharmacopoeias occurs. The *Frontiers in Pharmacology* (2023) review identifies that unverified reference materials bar reliable inter-laboratory comparisons and reproducibility, hence compromising regulatory confidence. [23]

5.3 Enforcement and Compliance Problems

Even where quality and safety guidelines are in place, enforcement and compliance continue to be serious obstacles. In most nations, herbal medicines are presented as dietary supplements or traditional medicines, avoiding strict pharmaceutical regulation. As a result, suppliers experience minimal pre-market testing, exposing consumers to undeclared chemical adulterants or contaminants like pesticides, heavy metals, and microbes. [24]

The 2025 WHO Global Report on Herbal Product Regulation and the Ethiopian Food and Drug Authority (EFDA) study (2025) note disconcerting gaps in enforcement regulation. Nearly 70.2% of regulators acknowledged that their respective agencies lacked strong performance in enforcing herbal medicine controls, and close to half of the herbal products surveyed in African and Asian markets did not have official registration certificates. Post-market surveillance continues to be weak, and pharmacovigilance systems for herbal drugs are poorly developed compared to their allopathic counterparts. [25]

Another enforcement issue is the lack of adequate laboratory infrastructure and human capacity. Most developing countries do not have accredited testing laboratories to perform sophisticated chromatographic and spectroscopic analyses for herbal quality control. Consequently, surveillance systems mainly depend on document-based verification instead of empirical testing, significantly undermining enforcement. [26]

Initiatives to improve compliance are being implemented. WHO's International Regulatory Cooperation for Herbal Medicines (IRCH) 2025 Workshop is seeking to enhance inter-agency coordination, inspection mechanisms, and digital traceability platforms for herbal supply chains. Such platforms, using blockchain technology, seek to authenticate origin, processing compliance, and batch purity across borders. [27]





WISELEAF SCIENTIFIC VENTURES

6. Advances and Innovations

Herbal medicine is undergoing a revival in the 21st century, fuelled by advances in science and mounting consumer interests in natural health remedies. Ancient plant-based treatments are now being revolutionized by advanced technologies, new production standards, and better safety and efficacy monitoring. This segment discusses the most recent developments in novel analytical tools, Good Agricultural and Collection Practices (GACP), and systems of pharmacovigilance, as well as biotechnological, nanotechnological, and digital traceability innovations that are transforming the global herbal medicinal scenario. [28]

6.1 Modern Analytical Methods

6.1.1 High-Advanced Analytical Technologies

Analytical chemistry supports the modernization of herbal medicine through the delivery of reproducible, reliable means of analysing phytochemical composition. Novel methods combine chromatographic profiling, spectroscopic fingerprinting, and hyphenated methods including LC-MS, LC-NMR, and GC-FTIR, which improve the identification of active and synergistic compounds while identifying contaminants with increased sensitivity. [29]

Nanotechnology-based sensors, artificial intelligence (AI), and metabolomics now facilitate high-throughput plant extract screening and quality prediction. For example, machine learning algorithms interpret chromatographic and spectral data to detect adulteration, verify origin, and predict pharmacological potential. These technologies have progressed far beyond the traditional HPLC and TLC methods, setting the area toward data-driven standardization and predictive quality assurance.

Current research documents the implementation of deep learning techniques such as convolutional neural networks (CNNs) for plant species identification and artificial intelligence-based regression models for the quantification of intricate fingerprint patterns. Such techniques greatly enhance reproducibility of results among laboratories and reduce human error [30]

6.1.2 Metabolomics and Chemometrics

Metabolomics gives a detailed chemical picture of intricate herbal blends. Combined with chemometrics, it aids in deciphering synergistic interactions between compounds and authenticating genuine plants against replacements. The 2025 Wiley handbook of analytical breakthroughs emphasizes that metabolomic mapping can forecast biological activity and toxicological hazard prior to clinical confirmation, facilitating effective pharmacological screening. [31]

The synergy of NMR-based metabolomics with AI-facilitated modelling enables holistic description of herbal extracts, and the detection of signature metabolites associated with bio efficacy. This synergy represents a paradigm shift away from single compound analysis towards systems-level insight into herbal pharmacology. [32]





WISELEAF SCIENTIFIC VENTURES

6.2 Good Agricultural and Collection Practices (GACP)

6.2.1 Recent Trends

The WHO and EMA revised the guidelines of GACP in 2025 to include advances in technology and sustainability issues. The new EMA Guideline on GACP for Herbal Starting Materials (2025) brings forth exact guidelines on indoor and controlled-environment cultivation, computerized monitoring of key parameters, and digital documentation systems that promote traceability from farming to processing. [33]

These regulations differentiate processes under GACP, GMP Part II (active ingredients), and GMP Part I (final products) in relation to proximity with the final dosage form. Indoor crop production systems have measures like light intensity, temperature, humidity, and CO₂ level as critical process parameters. Batch cultivation, storage, and transfer documentation under electronic platforms are now mandatory in most EU countries. [34]

6.2.2 Sustainable and Technological Integration

GACP currently converges with precision agriculture using IoT sensors, drone-monitored monitoring, AI-based growth analytics, and blockchain-based traceability. With this convergence, there is increased transparency, minimized ecological footprint, and assistance to producers to achieve sustainability goals while ensuring batch reproducibility.

The Indian Council of Agricultural Research (ICAR) released new GACP guidelines for medicinal plants (2025) with a focus on biodiversity protection, standardized propagation, and post-harvest quality control. The move follows global harmonization efforts, making India a front-runner in sustainable herbal production systems [35].

6.3 Pharmacovigilance Systems for Herbal Medicines

6.3.1 Evolution of Herbal Pharmacovigilance

As herbal product consumption expands internationally, phytovigilance—more correctly, pharmacovigilance—is necessary to protect public health. In contrast to synthetic medicines, adverse effects of herbal preparations are frequently underreported as safe because they are natural. The WHO 2025 "Global Safety of Herbal Medicines" report and peer-reviewed safety evaluations by Springer-Verlag highlight harmonizing phytovigilance systems across the world in order to identify, review, and prevent herbal-associated adverse effects.

The organization of national phytovigilance centers (such as AYUSH in India and EFDA in Africa) has enhanced the documentation of adverse events considerably. The centers utilize AI-based data mining to identify safety signals from clinical databases, social media reports, and electronic health records so that early signs of potential risks can be detected. [36]

6.3.2 Global Harmonization Efforts

The WHO and International Regulatory Cooperation for Herbal Medicines (IRCH) call for an overarching system of adverse event classification, risk assessment procedures, and electronic reporting inter-operability across member states. Continued work by EMA, FDA, and AYUSH is harmonizing definitions, report forms, and mitigation criteria.





WISELEAF SCIENTIFIC VENTURES

By the year 2025, over 45 nations have adopted organized national herbal pharmacovigilance programs that include digital monitoring, social media monitoring, and AI-based signal detection. This represents one of the greatest worldwide safety monitoring expansions in the field of herbal medicine [37].

7.FUTURE PERSPECTIVES

The direction of herbal medicines in the future, which form an important part of traditional, complementary, and integrative health systems globally, is dependent upon a number of key breakthroughs. These include the harmonization of international regulatory systems, the strong integration of traditional knowledge with contemporary scientific practices, and the development of enhanced public education and awareness to ensure safe, standardized, and effective herbal therapeutics.

7.1 Harmonization of International Regulatory Frameworks

One of the primary challenges in the modern scene of regulation of herbal medicine is the inconsistent regulatory regimes between jurisdictions. Inconsistency in classification, registration, safety assessment, and standards for quality assurance still hampers the global trade and clinical integration of herbal products. Harmonization of the regulations in the future needs to become a top priority to promote equitable access while ensuring protection of public health. Harmonization initiatives under the leadership of global organizations like the World Health Organization (WHO) and in collaboration with all major regulatory authorities—namely, the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and AYUSH of India—have the objective of developing harmonized standards for the evaluation of herbal medicinal products [38].

7.2 Integration of Traditional Knowledge and Modern Science

Traditional medicine knowledge, gained over centuries of empirical practice, is still a vital source for drug discovery and herbal therapeutic innovation. The blending of this knowledge with contemporary analytical science is essential for the verification of the safety and therapeutic value of herbal medicines. Utilization of cutting-edge analytical instrumentation such as chromatography, spectroscopy, and genomics allows rigorous identification, authentication, and standardization of herbal raw materials and final products. [39]

Pharmacological, toxicological, and clinical studies based on evidence-based approaches facilitate the translation of traditional medicine into reproducible, standardized herbal formulations. Synergy between ethnopharmacology and phytochemistry provides new opportunities for drug development and increases the integrity of herbal products. In addition, development of pharmacopeial monographs based on scientific as well as traditional evidence supports regulation approvals and therapeutic usage. [40]





WISELEAF SCIENTIFIC VENTURES

7.3 Improving Public Education and Awareness

With increasing worldwide use of herbal medicine, public education and campaigns play a vital supporting role to encourage safe and knowledgeable use. The belief that 'natural' is 'safe' is a common lead-in to abuse, side effects, and lethal herb-drug interactions. Proper educational strategies directed at consumers, healthcare providers, and manufacturers of herbal preparations can prevent these hazards by teaching the need to consult trained professionals and follow suggested dosing and quality control measures. [41]

In parallel, programs focusing on Good Agricultural and Collection Practices (GACP) and Good Manufacturing Practices (GMP) guarantee the quality of raw materials and finished products. Public education regarding quality certifications, product labeling, and pharmacovigilance reporting mechanisms empower consumers to make safer decisions, identifying genuine products over adulterated or substandard alternatives. [39]

8. Conclusion

The fate of herbal medicine depends on the effective harmonization of conventional knowledge and contemporary scientific developments, which will translate into a universal system with a focus on safety, quality, and efficacy. Since herbal medicines will continue to increase in global popularity and utilization, harmonized regulatory guidelines will be necessary across jurisdictions to ascertain uniform product quality and consumer protection. International bodies like the World Health Organization have set the stage for such initiatives, but continued cooperation among regulatory authorities, industry representatives, and traditional practitioners is needed to fill current gaps.

Scientific authentication through methods like DNA barcoding, chromatography, and metabolomics will allow for accurate authentication, standardization, and quality control of herbal raw materials and products. Such advances enhance safety and efficacy while establishing consumers' confidence and enabling international trade.

In addition, ongoing public education and awareness efforts are crucial to promote prudent use of herbal medicines. Making healthcare professionals and consumers aware of available, evidence-based information can minimize misuse and herb-drug interactions while facilitating the integration of herbal therapies into mainstream healthcare systems.

Raw material variability, absence of standardized test protocols, and enforcement deficits are still challenges. Overcoming these through the establishment of sound quality control systems, enforcement by authorities, and global harmonization policies will be essential. Analytical method refinement, comprehensive pharmacovigilance system establishment, and environmentally friendly cultivation practice promotion should be emphasized as areas for future research and innovation.





WISELEAF SCIENTIFIC VENTURES

REFERENCES

1. Petrovska Biljana Bauer, "Historical review of medicinal plants' usage", *Pharmacognosy Review*, 2012
<https://pmc.ncbi.nlm.nih.gov/articles/PMC3358962/>
2. Bishen Shyam, "World Health Day: 8 trends shaping global healthcare", *World Economic Forum*, Apr 5, 2023
<https://share.google/C9JdnmMAAD7c78Jzi>
3. Med Park Hospital, "10 Health Trends of 2025 Revolutionizing Healthcare", *Med Park Hospital*, Dec 10, 2024
<https://share.google/CDzrerSYjblHqaHO7>
4. Dubale S, Usure RE, Mekasha YT, Hasen G, Hafiz F, Kebebe D, Suleman S. Traditional herbal medicine legislative and regulatory framework: a cross-sectional quantitative study and archival review perspectives. *Front Pharmacol.* 2025 Jan 29; 16:1475297. doi: 10.3389/fphar.2025.1475297.
<https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1475297/full>
5. Jeevanesh K, Manimaran V. Challenges in Quality Control of Herbal Pharmaceuticals: Standardization, Analytical Methodologies, and Regulatory Frameworks. *The Bioscan* [Internet]. 2025 Sep 20 [cited 2025 Oct 13];20(Special Issue-3):889-96. Available from: https://thebioscan.com/index.php/pub/article/download/4109/3256/7682?utm_source=perplexity
6. Dubale S, Usure RE, Mekasha YT, Hasen G, Hafiz F, Kebebe D, et al. Traditional herbal medicine legislative and regulatory framework: a cross-sectional quantitative study and archival review perspectives. *Front Pharmacol.* 2025; 16:1475297. doi:10.3389/fphar.2025.1475297.
<https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1475297/full>
7. Prajapati AK. Profiling the toxicological landscape of herbal drugs. *J Prev Med Holist Health* [Internet]. 2024 [cited 2025 Oct 05];10(1):6-9. Available from: <https://doi.org/10.18231/j.jpmmh.2024.003>
8. Jain SD, Shrivastava SK, Agrawal A, Gupta AK. WHO guidelines for quality control of herbal medicines: From cultivation to consumption [Internet]. *Int J Pharm Chem Anal.* 2024 [cited 2025 Oct 12];11(3):212-225. Available from: <https://doi.org/10.18231/j.ijpca.2024.031>
9. Devi S. Advancements in Quantitative and Qualitative Methods for Quality Control of Herbal Drugs: A Comprehensive Review. *Pharmacognosy Research.* 2025;17(2):411-41
<https://phcogres.com/article/2025/17/2/105530pres20252077>





WISELEAF SCIENTIFIC VENTURES

10. Baragi UC, Ganer JM. Adulteration and Substitution of Herbal Drugs: A Critical Review of Challenges and Implications for Integrative Medicine [Internet]. *J Ayurveda Integr Med Sci*. 2025 Jul 24 [cited 2025 Aug 12];10(7):1–4. Available from: <https://www.jaims.in/jaims/article/view/4890>
11. Aghakhani F, Kharazian N, Lori Gooini Z. Flavonoid Constituents of *Phlomis* (Lamiaceae) Species Using Liquid Chromatography Mass Spectrometry. *Phytochem Anal*. 2018;29(2):180-195. doi:10.1002/pca.2733. https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/10.1002/pca.70000?utm_source=perplexity
12. Sileshi D, Usure RE, Mekasha YT, Hasen G, Hafiz F, Kebebe D, et al. Traditional herbal medicine legislative and regulatory framework: a cross-sectional quantitative study and archival review perspectives [Internet]. *Front Pharmacol*. 2025 Jan 29 [cited 2025 Oct 15]; 16:1475297. Available from: <https://doi.org/10.3389/fphar.2025.1475297>
13. U.S. Food and Drug Administration. FDA Releases 2025 Human Foods Program Guidance Agenda [Internet]. Silver Spring (MD): U.S. Food and Drug Administration; 2025 Jun 30 [cited 2025 Oct 15]. Available from: <https://www.fda.gov/food/hfp-constituent-updates/fda-releases-2025-human-foods-program-guidance-agenda>
14. European Medicines Agency. Herbal medicinal products: scientific guidelines [Internet]. Amsterdam: European Medicines Agency; [cited 2025 Oct 15]. Available from: <https://www.ema.europa.eu/en/human-regulatory-overview/research-development/scientific-guidelines/multidisciplinary-guidelines/herbal-medicinal-products-scientific-guidelines>
15. Ministry of Ayush, Government of India. Ministry of Ayush [Internet]. New Delhi: Ministry of Ayush, Government of India; [cited 2025 Oct 15]. Available from: <https://ayush.gov.in/>
16. Alostad AH, Steinke DT, Schafheutle EI. Herbal Medicine Classification: Policy Recommendations. *Front Med (Lausanne)*. 2020 Feb 11; 7:31. doi: 10.3389/fmed.2020.00031. <https://pmc.ncbi.nlm.nih.gov/articles/PMC7026670/>
17. Jordan CR, Harris CM, Miranda MI, Kim DY, Hellberg RS. Labeling compliance and online claims for Ayurvedic herbal supplements on the U.S. market associated with the purported treatment of COVID-19. *Food Control*. 2023 Feb 6; 148:109673. doi: 10.1016/j.foodcont.2023.109673. <https://pmc.ncbi.nlm.nih.gov/articles/PMC9901855/>
18. Jeevanesh K, Manimaran V. Challenges in Quality Control of Herbal Pharmaceuticals: Standardization, Analytical Methodologies, and Regulatory Frameworks. *Bioscan (Special Issue)*. 2025;20(3):889–96. doi: 10.63001/tbs.2025.v20.i03.S.I(3).pp889-896.





WISELEAF SCIENTIFIC VENTURES

https://thebioscan.com/index.php/pub/article/download/4109/3256/7682?utm_source=perplexity

19.Kumar R. Combating Barriers in Herbal Medicine Regulation: A Study of India, United States, And European Union. *Eur Econ Lett.* 2025;15(1):1–9. doi: 10.63001/tbs.2025.v20.i03.S.I(3). pp889-896.

https://www.eelet.org.uk/index.php/journal/article/download/2358/2115/2606?utm_source=perplexity

20.Jain SD, Shrivastava SK, Agrawal A, Gupta AK. WHO guidelines for quality control of herbal medicines: From cultivation to consumption. *Int J Pharm Chem Anal.* 2024;11(3):212–25. doi: 10.18231/j.ijpca.2024.031.

<https://ijpca.org/archive/volume/11/issue/3/article/22100>

21.European Medicines Agency. Guideline on good agricultural and collection practice (GACP) for starting materials of herbal origin. Rev 1. London: European Medicines Agency; 2025 Aug 12. EMA/HMPC/246816/2005 Rev. 1.

<https://www.ema.europa.eu/en/good-agricultural-collection-practice-starting-materials-herbal-origin-scientific-guideline>

22.Wang H, Chen Y, Wang L, Liu Q, Yang S, Wang C. Advancing herbal medicine: enhancing product quality and safety through robust quality control practices. *Front Pharmacol.* 2023 Sep 24; 14:1265178. doi: 10.3389/fphar.2023.1265178.

<https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1265178/full>

23.Opuni KFM, Kretchy J-P, Agyabeng K, Boadu JA, Adanu T, Ankamah S, et al. Contamination of herbal medicinal products in low-and-middle-income countries: A systematic review. *Talanta Open.* 2021; 4:100070. doi: 10.1016/j.talo.2021.100070.

<https://www.sciencedirect.com/science/article/pii/S2666831921000400>

24.Daskalaki S, Poutos DG, Zimeras CA. A tool for automatic creation of biomedical ontology subsets: Development and evaluation. *J Biomed Inform.* 2011;44(5):844-50.

<https://www.sciencedirect.com/science/article/abs/pii/S0965229911001312>

25.Owusu G, Antwi-Adjei M, Ofori-Amoah J, Tuekpe RM, Mainoo AE, Kodua D, et al. Prevalence of herbal medicine consumption and regulatory compliance in some selected districts of the Bono region, Ghana. *BMC Complement Med Ther.* 2025; 25:202. doi: 10.1186/s12906-025-04953-4.

<https://pmc.ncbi.nlm.nih.gov/articles/PMC12142812/>

26.Sileshi D, Usure RE, Mekasha YT, Hasen G, Hafiz F, Kebebe D, et al. Traditional herbal medicine legislative and regulatory framework: a cross-sectional quantitative study and archival review perspectives. *Front Pharmacol.* 2025; 16:1475297. doi: 10.3389/fphar.2025.1475297.

<https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1475297/full>





WISELEAF SCIENTIFIC VENTURES

27. Press Information Bureau (PIB) Delhi. India to Host WHO - IRCH Workshop on Herbal Medicine Safety and Regulations from August 6 [Internet]. New Delhi: Ministry of Ayush, Government of India; 2025 Aug 5 [cited 2025 Oct 16]. Available from: <https://www.pib.gov.in/PressReleasePage.aspx?PRID=2152419>.
28. Lindenmaier MP, Bernart MW, Brinckmann JA. Advanced Methodologies for the Quality Control of Herbal Supplements and Regulatory Considerations. *Phytochem Anal.* 2025 Jun 24. Online ahead of print. doi: 10.1002/pca.70000. https://pubmed.ncbi.nlm.nih.gov/40555399/?utm_source=perplexity
29. Sustainability Directory. AI and the Future of Herbal Medicine Authentication. *Prism.* 2025 Sep 5 [cited 2025 Oct 17]. Available from: <https://prism.sustainability-directory.com/scenario/ai-and-the-future-of-herbal-medicine-authentication/>
30. Amin A, Park S. Comparative Phytochemistry and Chemotaxonomy. In: Dhyani P, Quispe C, Sharma E, Cho WC, editors. *Pharmacognosy and Phytochemistry: Principles, Techniques, and Clinical Applications.* Hoboken (NJ): Wiley; 2025. Chapter 9. Available from: <https://onlinelibrary.wiley.com/doi/10.1002/9781394203680.ch09>
31. Salman SS, Priyanka B, Sri GSL, Boddeda B. Emerging trends in advanced herbal pharmaceuticals: From bench to bedside. *GSC Biological and Pharmaceutical Sciences.* 2025;32(02):050-059. doi: 10.30574/gscbps.2025.32.2.0309. https://gsconlinepress.com/journals/gscbps/sites/default/files/GSCBPS-2025-0309.pdf?utm_source=perplexity
32. ECA Academy. Final Revised GACP Guideline Published. GMP Compliance website. 2025 Sep 10 [cited 2025 Oct 17]. Available from: <https://www.gmp-compliance.org/gmp-news/final-revised-gacp-guideline-published>
33. Indian Council of Agricultural Research. Good Agricultural and Collection Practices (GACP) for Medicinal Plants. ICAR website. 2025 Oct 15 [cited 2025 Oct 17]. Available from: <https://icar.org.in/en/good-agricultural-and-collection-practices-gacp-medicinal-plants>
34. Sethi SS, Bhardwaj T, Sethi SK, Kaur S, Rimpi, Baldi A. Advancing herbal medicine safety: the need for a global pharmacovigilance approach. *Naunyn Schmiedebergs Arch Pharmacol.* 2025 May 8. Online ahead of print. doi: 10.1007/s00210-025-04066-2. https://pubmed.ncbi.nlm.nih.gov/40338319/?utm_source=perplexity
35. Jaiganesh KP, Sivakumar P. A review on pharmacovigilance of herbal drugs. *Int J Herbal Med.* 2025;13(5):13-22. doi: 10.22271/flora.2025.v13.i5a.1026. https://www.florajournal.com/archives/2025/vol13issue5/PartA/13-4-25-505.pdf?utm_source=perplexity
36. Li J, Wu X, Feng HB, Zhang JG. Quality standards for traditional and complementary medicines: A review of current practice and future challenges. *J Tradit Complement Med.* 2025;15(1):1–10. doi: 10.1016/j.jtcme.2025.02.001





WISELEAF SCIENTIFIC VENTURES

<https://www.sciencedirect.com/science/article/abs/pii/S2214786125000257>

37. Salman SS, Priyanka B, Sri GSL, Boddeda B. Emerging trends in advanced herbal pharmaceuticals: From bench to bedside. *GSC Biol Pharm Sci.* 2025;32(02):050-059. doi: 10.30574/gscbps.2025.32.2.0309.

https://gsconlinepress.com/journals/gscbps/sites/default/files/GSCBPS-2025-0309.pdf?utm_source=perplexity

38. Wang H, Chen Y, Wang L, Liu Q, Yang S, Wang C. Advancing herbal medicine: enhancing product quality and safety through robust quality control practices. *Front Pharmacol.* 2023;14:1265178. doi: 10.3389/fphar.2023.1265178.

<https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1265178/full>

39. Balkrishna A, Sharma N, Srivastava D, Kukreti A, Srivastava S, Arya V. Exploring the Safety, Efficacy, and Bioactivity of Herbal Medicines: Bridging Traditional Wisdom Modern Science in Healthcare. *Future Integrative Medicine.* 2024;3(1):35-49. doi: 10.14218/FIM.2023.00086.

https://www.xiahepublishing.com/2835-6357/FIM-2023-00086?utm_source=perplexity

40. Vyshnavi N. Importance of Medicinal Plants in Medicine. *J Med Organic Chem.* 2021;1(1).

https://www.openaccessjournals.com/articles/importance-of-medicinal-plants-in-medicine-15240.html?utm_source=perplexity

41. Albia. Benefits of herbal medicine. *Albia BioCare Blog* [Internet]. 2025 Mar 12 [cited 2025 Oct 17]. Available from:

<https://albia.in/blog/benefits-herbal-medicine/>.





WISELEAF SCIENTIFIC VENTURES

**Thank you for your
contribution!**

